A COMPOSITION FOR IMPROVING GUT MICROBIOTA, BEHAVIOURAL PATTERN, ALPHA-SYNUCLEIN LEVELS, SLEEP PATTERN AND/OR SERUM MELATONIN

Abstract

Compositions for improving gut microbiota, improving behavioural pattern and alpha-synuclein levels, and improving sleep pattern and serum melatonin, especially in children with autism, are provided. Methods are also included for control of gut enterobacteria in children with autism, reconstitution of gut microbiota, and control of enterobacteria in autism and neurodegenerative diseases.

Description

BACKGROUND

Field of the Invention

The present invention relates to a composition for improving gut microbiota; control of gut enterobacteria in children with autism; reconstitution of gut microbiota and control of enterobacteria in autism and neurodegenerative diseases; a composition for improving behavioural pattern and alpha-synuclein levels, especially in autism; a composition for improving sleep pattern and serum melatonin, especially in children with autism.

Background Art

Gut Microbiota

Gut dysbiosis is one of the major pathologies in children with autism spectrum disorder (ASD). Evaluation of gut microbiota of the subjects in the present randomized pilot clinical study was undertaken and compared with an aim of gaining a mechanistic insight.

Behavioral Pattern and Alph-Synuclein Levels

Autism spectrum disorders (ASDs) are a group of developmental disabilities that can cause significant impairment in social, emotional, and communication skills (cdc.gov). Several causes and underlying mechanisms have been postulated for the pathogenesis of ASD, including genetic, environmental, immune dysregulation, neuroinflammation, and oxidative stress. Neuronal synaptic imbalance and mutation in synaptic proteins and receptors have also been reported to be associated with ASD (Al-Mazeedi et al., 2020). Synucleins are small soluble proteins that are present in presynaptic terminals, and they regulate synaptic plasticity and neurotransmitter release. Synucleins are important in the context of brains and neurons (Al-Mazeedi et al., 2020; Vargas et al., 2017).

Alpha-synuclein has already been reported to be associated with several neurodegenerative disorders, collectively called synucleinopathies such as Alzheimer's disease (AD), Parkinson's disease (PD), dementia with Lewy bodies (DLBs), and multiple system atrophy (Al-Mazeedi et al., 2020). Several studies have recently reported a strong association between lower levels of α-synuclein and ASD. At present, there is no definitive cure for ASD (Al-Mazeedi et al., 2020; Kadak et al., 2015; Sriwimol et al., 2018). Interventions involve speech and behavioural therapies to improve the symptoms. According to the research, the microbiota-gut-brain axis is significant because dysbiosis has been observed in gut-related diseases and other generalized disorders, especially of the nervous system, such as AD, multiple sclerosis, PD, and ASD (Srikantha et al., 2019). Therefore, nutritional supplements are considered potential interventions in alleviating gastrointestinal and behavioural symptoms in ASD (Karhu et al., 2020).

Beta-glucans, especially yeast-derived ones, have shown a considerable positive outcome as food supplements in modulating gut microbiota (Karhu et al., 2020; Xu et al., 2020). Nichi Glucan is a black yeast-derived AFO-202 (also referred to as FO-68 [(accession number) FERM BP-19327]) beta-glucan that has been in consumption for the past two decades (Ikewaki et al., 2007) and has been shown to have potential as a nutritional supplement to balance metabolic levels of glucose, lipids, and immunomodulators (Dedeepiya et al., 2012; Ganesh et al., 2014; Ikewaki et al., 2021). The present study was undertaken to investigate the effects of Nichi Glucan as a food supplement in children with ASD, especially with relevance to the childhood autism rating scale (CARS) score and alpha-synuclein levels.

Sleep and Melatonin

Inability to have a good quality of sleep is one of the major problems faced by people with autism spectrum disorders (ASD). This is attributed to lower melatonin levels and therefore melatonin supplementation is one of the treatments opted, reported with varying outcome. Beta Glucans having been earlier reported in animal studies to improve melatonin levels, we herein report the outcome of our pilot clinical study in which a Black yeast Aureobasidium pullulans derived Beta 1,3-1,6 Glucan food supplement was administered in children with ASD.

CITATION LIST

Non Patent Literature

• [NPL 1] Shi H, Yu Y, Lin D, et al. β-glucan attenuates cognitive impairment via the gut-brain axis in diet-induced obese mice. Microbiome. 2020; 8:143.
• [NPL 2] Sriwimol W, Limprasert P. Significant changes in plasma alpha-synuclein and beta-synuclein levels in male children with autism spectrum disorder. Biomed Res Int 2018; 2018:1-7.doi:10.1155/2018/4503871
• [NPL 3] Dutta S D, Patel D K, Ganguly K, Lim K T. Effects of GABA/β-glucan supplements on melatonin and serotonin content extracted from natural resources. PLoS One. 2021 Mar. 5; 16(3):e0247890. doi: 10.1371/journal.pone.0247890. PMID: 33667254; PMCID: PMC7935273.
• [NPL 4] Miller A L, Bessho S, Grando K, Tükel Ç. Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Front Immunol. 2021 Feb. 26; 12:638867.
• [NPL 5] Grimaldi R, Gibson G R, Vulevic J, Giallourou N, Castro-Mejia J L, Hansen L H, Leigh Gibson E, Nielsen D S, Costabile A. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 2018 Aug. 2; 6(1):133.

SUMMARY OF THE INVENTION

The present invention relates to the following:

• • 1. A composition for improving gut microbiota, comprising a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327).
  • 2. The composition according to 1, wherein the improvement of gut microbiota comprises a decrease of Akkermansia muciniphila with an increase of beneficial bacteria including Roseburia in a gut.
  • 3. The composition according to 1 or 2, wherein the composition is for prophylactic, ameliorating and/or curative treatment of autism spectrum disorders (ASD), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD) and/or epilepsy.
  • 4. The composition according to 1 or 2 for improving behavioural pattern and alpha-synuclein levels.
  • 5. The composition according to 1 or 2, wherein the composition is for improving sleep pattern and serum melatonin.
  • 6. The composition according to 5, wherein the improvement is in a child with autism spectrum disorder.
  • 7. The composition according to any one of 1 to 6, wherein the composition is a pharmaceutical composition.
  • 8. The composition according to any one of 1 to 6, wherein the composition is a food composition.

The present invention also relates to the following:

• • [1A] A composition for improving gut microbiota, comprising a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327).
  • [2A] The composition according to [1A], wherein the composition is a pharmaceutical composition.
  • [3A] The composition according to [1A], wherein the composition is a food composition.
  • [4A] The composition according to any one of [1A]-[3A], wherein the composition is for prophylactic, ameliorating and/or curative treatment of autism spectrum disorders (ASD), multiple sclerosis (MS), Alzheimer's disease (AD) and/or Parkinson's disease (PD).
  • [1B] A composition for improving behavioural pattern and alpha-synuclein levels, comprising a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327).
  • [2B] The composition according to [1B], wherein the composition is a pharmaceutical composition.
  • [3B] The composition according to [1B], wherein the composition is a food composition.
  • [1C] A composition for improving sleep pattern and serum melatonin, comprising a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327).
  • [2C] The composition according to [1C], wherein the composition is a pharmaceutical composition.
  • [3C] The composition according to [1C], wherein the composition is a food composition.

Effects of the Invention

Gut microbiota is improved and/or well-balanced by the present invention. Such a control in gut microbiota leads to an improvement of behavioural pattern, alpha-synuclein levels, sleep pattern and/or serum melatonin levels.

The present invention is effective in balancing the gut microbiota, especially, by a decrease in Bacteroides, Curli producing Enterobacteria Escherichia coli, Akkermansia muciniphila CAG:154, Blautia spp., Coprobacillus sp., and Clostridium bolteae with increase in Roseburia, Faecalibacterium prausnitzii and Prevotella copri. The other beta glucans don't produce such an effective and balanced modulation of gut bacteria with effects on diverse species (Shen R L, et al. 2012, Turunen K, et al. 2011, Zhen W, et al. 2021). While the enterobacteria may be decreased, a decrease in Akkermansia muciniphila has not been concomitantly reported. Further the concomitant increase in beneficial bacteria such as Roseburia, Faecalibacterium prausnitzii and Prevotella copri is an added advantage.

The present invention is effective for prophylactic, ameliorating and/or curative treatment of neurological disorders such as autism spectrum disorders (ASD), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD) and/or epilepsy. The present invention is effective for improving sleep pattern and serum melatonin, especially in children with autism spectrum disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Index of the most abundant taxa across species levels.

FIGS. 2A and 2B. Differences pre and post-intervention in the read count of selected bacteria between A. Enterobacteria; and, B. Firmicutes.

FIGS. 3A-3C. Most abundant taxa at the phyla (A), genus (B), and species (C) levels in the different groups of the study.

FIGS. 4A-4D. Principal component analysis (PCA) of: A, B. all the ten samples (five groups—pre- and post-intervention)—A, C. Score plot; B, D. Loading plot; Study groups (1) Control/Vehicle, 2—Baseline, 12—post-intervention, (2) AFO-202, 4—Baseline, 14—post-intervention, and (3) Telmisartan, 10—Baseline, 20—post-intervention.

FIGS. 5A-5C. Differential abundance analysis, log 2 fold change results for each group before and after intervention: A. Control, B. AFO-202, and C. Telmisartan.

FIGS. 6A-6F. Score plots of principal component analysis (PCA) and compounds with a VIP value of 1 or higher in the OPLS-DA of the different groups: A. Control; B. AFO-202; C. Telmisartan.

FIGS. 7A-7E. Peak height of the detected compounds after normalization. A. Succinic acid, B. Phosphoric acid, C. Fructose, D. Isoleucine, and E. Leucine (**significant;*not significant; p-value significance <0.05).

FIG. 8. Euclidean distance hierarchical clustering analysis demonstrating the different intensity levels of characteristic metabolites in AFO-202.

FIGS. 9A and 9B. Euclidean distance hierarchical clustering analysis demonstrating the different intensity levels of characteristic metabolites in A. Control; and, B. Telmisartan.

FIG. 10 shows decrease in abundance of Enterobacteria in AFO-202 compared to Control, post-intervention.

FIG. 11 shows decrease in abundance of Bacteroides in AFO-202 compared to Control, post-intervention.

FIG. 12 shows increase in abundance of Prevotella in AFO-202 compared to Control, post-intervention.

FIG. 13 shows decrease in Lactobacillus in AFO-202 and Control.

FIG. 14 shows CONSORT flow diagram of the trial.

FIG. 15. Data before and after adapter trimming.

FIG. 16. Average Read quality before and after adapter trimming.

FIG. 17. Average GC % before and after adapter trimming.

FIG. 18. Percentage of alignment to Bacteria, Fungi, Virus, Archae Bacteria and Human genomes.

FIG. 19. Post intervention control vs post intervention treatment SEED Average values.

FIG. 20. Distribution of Phyla: Phylum Proteobacteria was the most abundant followed by Phylum Firmicutes.

FIGS. 21A and 21B. Genus Abundance of major genera identified (A) Group (Gr.) 1 at baseline versus post-intervention and (B) Group (Gr.) 2 at baseline versus post-intervention.

FIGS. 22A-22D. FIG. 22A shows decrease in abundance of Enterobacteria in Group 2 compared to Group (Gr.) 1, post-intervention. FIG. 22B shows decrease in abundance of Bacteroides in Group (Gr.) 2, which had increased in Group 1 post-intervention. FIG. 22C shows increase in Prevotella in Group 1 and Group 2 post-intervention. FIG. 22D shows decrease in Lactobacillus in Group 1 and Group 2 post-intervention.

FIGS. 23A and 23B. Species Abundance of major species analysed; (A) Group (Gr.) 1 at baseline versus post-intervention and (B) Group (Gr.) 2 at baseline versus post-intervention.

FIGS. 24A and 24B. Distribution of Genera and Distribution of Species.

FIGS. 25A-25D. (A) Decrease in abundance of E. coli was significant in Group (Gr.) 2 compared to Group (Gr.) 1, post-intervention; (B) Significant increase in abundance of Faecalibacterium prausnitzii in Group 2 compared to Group 1 post-intervention; (C) Increase in Akkermansia muciniphila in Group 1 but decrease in Group 2 post-intervention; and, (D) Increase in Clostridium bolteae CAG:59 in Group 1 but decrease in Group 2 post-intervention.

FIGS. 26A-26C. A. The score on the childhood autism rating scale (CARS) in Gr. 1 (control), which was very mild and showed no improvement after the study, whereas the score decreased in all children by an average of 3 points for B. Gr. 2 (Nichi Glucan); and, C. Comparison between Gr. 1 and Gr. 2 showed a significant decrease in the CARS score, indicating improvement in autism's signs and symptoms in Gr. 2 (Nichi Glucan) compared to Gr. 1 (control) post-intervention (p-value=0.034517).

FIGS. 27A-27C. A. Plasma alpha-synuclein levels in Gr. 1 (control) pre- and post-intervention; B. Plasma alpha-synuclein in Gr. 2 (Nichi Glucan) pre- and post-intervention; and, C. Plasma alpha-synuclein levels in Nichi Glucan group Gr. 2 showed a significant increase compared to Gr. 1 (p-value=0.091701).

FIG. 28. The total sleep pattern score of the Children's Sleep Habits Questionnaire-Abbreviated (CSHQ-A) showing significant improvement by decrease in score in Nichi Glucan (Gr.2) compared to Gr.1 (Control) after the intervention.

FIGS. 29A-29C. Serum melatonin levels in Gr. 1 (Control group) pre- and post-intervention; serum melatonin levels in Gr. 2 (Nichi Glucan group) pre- and post-intervention; and fold increase in Nichi Glucan group Gr. 2 greater than in Gr.1

FIG. 30 explains, stepwise, the pathogenesis as well as the way beta glucan tackles each stage of the disease process: (A) & (B) Enterobacteria secretion of curli that causes misfolding of α-synuclein (αSyn); its aggregation in enteric neuronal cells is tackled by (1) control of enterobacteria, (2) scavenging of the accumulated amyloids by activated natural killer cells, and (3) reconstitution of beneficial microbiome; (C) The prion like propagation may not occur because the accumulation of curli proteins and amyloids is controlled at the level of production and aggregation (1) as well as clearing of already accumulated deposits (3); and, (D) Deposition of Lewy bodies, amyloid fibrils, and misfolded αSyn are tackled by (4) microglial-based scavenging.

FIG. 31. Increase in abundance of Roseburia hominis after AFO-202, whose increase may be attributed to the increase in melatonin.

FIG. 32. Increase in abundance of Roseburia inulinivorans after AFO-202, whose increase may be attributed to the increase in melatonin.

FIG. 33. Increase in abundance of Roseburia intestinalis after AFO-202, whose increase may be attributed to the increase in melatonin.

FIG. 34. Increase in abundance of Roseburia faecis after AFO-202, whose increase may be attributed to the increase in melatonin.

FIG. 35. Post Intervention Control vs Post Intervention Treatment Seed Average of the different functional properties and metabolic pathways beneficially modulated in AFO-202 (Treatment group).

FIGS. 36A and 36B. Expression of α-synuclein on the neuroblastoma cell line (SHSY-5Y Tet-On: SCC291) α-synuclein polyclonal antibody (Proteintech Co. 10842-1-AP), and expression of α-synuclein on the neuroblastoma cell line (SHSY-5Y Tet-On: SCC291) α-synuclein polyclonal antibody in a wider field of magnification (Proteintech Co. 10842-1-AP).

FIG. 37. Illustration of how AFO-202 prevents and treats neurological diseases by controlling production and propagation of Abnormal Alpha-Synuclein.

FIG. 38. Illustration of how AFO-202 prevents and treats neurological diseases by controlling production and propagation of Abnormal Alpha-Synuclein at the gut level by controlling the production of Alpha-Synuclein and scavenging of aggregates by Natural Killer (NK) cells and in the brain by microglia.

DETAILED DESCRIPTION OF INVENTION

The present invention relates to a composition for improving gut microbiota. The present invention also relates to an effective control of gut enterobacteria producing Alpha synuclein and Curli amyloids after consumption of Aureobasidium pullulans derived beta 1,3-1,6 glucans in children with autism spectrum disorder in a clinical pilot study. The present invention also relates to a beneficial reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism and potentials in neurodegenerative diseases. The present invention also relates to a gut microbiota reconstitution by Beta Glucans in autism.

Further, the present invention relates to a composition for improving behavioural pattern and alpha-synuclein levels, especially in autism spectrum disorder. The present invention also relates to an improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study.

Moreover, the present invention relates to a composition for improving sleep pattern and serum melatonin, especially in children with autism spectrum disorder. The present invention also relates to an improvement of sleep pattern and serum melatonin in children with autism spectrum disorder after consumption of Beta 1,3-1,6 Glucan in a pilot clinical study.

The glucan contained in the composition of the present invention can be a glucan derived from Aureobasidium pullulans strain FO-68 (Also referred to herein as “strain AFO 202”), and preferably β-1,3-1,6 glucan derived from FO-68 (Also referred to herein simply as “glucan”, “AFO 202 glucan” or “AF 202 beta glucan”). “Aureobasidium pullulans strain FO-68” has been deposited at the Patent Biological Depository Center, National Institute of Advanced Industrial Science and Technology, under the deposit number FERMP-19327.

While the domestic deposition was made on Apr. 23, 2003, Aureobasidium pullulans strain FO-68 has then been transferred to international deposition at the International Patent Organism Depositary, National Institute of Technology and Evaluation (Room. 120, 2-5-8, Kazusa Kamatari, Kisarazu-shi, Chiba, 292-0818 Japan) on Apr. 21, 2021 with the accession number: FERM BP-19327.

Aureobasidium pullulans strain FO-68 is also called as Aureobasidium strain FERM P-18099.

Scientific Properties of FO-68

This fungus produces high-molecular polysaccharide with high viscosity. This substance agglutinates easily with ethanol, making it possible to collect simply. This polysaccharide is of [beta] type, and is acidic polysaccharide having a main chain of 1,3 bond and branches from 3- and 6-positions. It contains carboxylic acids such as malic acid as organic acids and phosphoric acid. Moreover, it agglutinates easily with aluminum ions etc. This substance is also effective for the promotion of growth as a feed and the effluent treatment. It is effective as a food additive and functional food.

FO-68 forms blackish brown colonies on potato-dextrose-agar slant culturing for 7 days at 25 C. The fringe of colonies shows filamentous growth and becomes gradually light blackish brown. The cells are filamentous, and sometimes arthrospores, yeast-like budding conidiospores, oval yeast-like single cells, and, in some time, thick-walled spore cells are formed. The growth temperature is 25 C., and it decomposes hexoses such as glucose, fructose and galactose, sucrose, and starch. The medium becomes conspicuously viscous. Based on FO-68's mycological properties, it is a kind of Aureobasidium pullulans in the black fungus family of deuteromycetes.

Mycological Features of the Isolated Fungus

A colony of FO-68 has a smooth surface at first and grows into a grayish white, mucous and glossy oil drop-like (fat-like), yeast-like material. The filamentous fungus body grows radially from the fringe thereof, leading to crinkled, filamentous and just dendritic growth. This filamentous fungus body grows well not only on the surface of medium, but also in the medium. In a short time, light dark brown specks appear here and there on the surface of colony, which become black specks gradually, and overall surface becomes dark black eventually. On this filamentous fungus body, a lot of light brown, elliptic or oval conidiospores are produced laterally. This conidiospore falls easily in pieces. While the surface of oil drop-like colony puts on the conidiospores here and there.

As a method for culturing FO-68 and a method for producing β-1,3-1,6 glucan using FO-68, known methods can be used, for example, see JP 2004-329077A.

In some embodiment, the present invention relates to a composition comprising a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327) for improving gut microbiota, behavioural pattern, alpha-synuclein levels, sleep pattern and/or serum melatonin. In another aspect, the present invention also relates to use of Aureobasidium pullulans AFO-202 (FERM BP-19327) for improving gut microbiota, behavioural pattern, alpha-synuclein levels, sleep pattern and/or serum melatonin, and particularly relates to a method of improving gut microbiota, behavioural pattern, alpha-synuclein levels, sleep pattern and/or serum melatonin by administering Aureobasidium pullulans AFO-202 (FERM BP-19327) to a subject.

In the composition used in the present invention, a culture of FO-68 may be used as it is without purification, or glucan isolated from the culture or further purified as necessary may be used. In addition, for example, the culture product of the present invention was crushed into a concentrate, a paste, a spray-dried product, a freeze-dried product, a vacuum-dried product, a drum-dried product, a liquid product dispersed in a medium, a diluted product, and a dried product.

The composition of the present invention exerts its function when ingested by mammals including humans. The term “ingestion” as used herein is not limited to any administration route as long as it can enter the human body, and is realized by all known administration methods such as oral administration, tube administration, and enteral administration. Typically, oral ingestion and enteral ingestion via the digestive tract are preferable.

The dose of the present invention can be appropriately set in consideration of various factors such as administration route, age, body weight, and symptoms. The dose of the composition of the present invention is not particularly limited, but the amount of glucan is preferably 0.05 mg/kg/day or more, more preferably 0.5 mg/kg/day or more, particularly preferably 1.0 mg/kg/day. However, when ingested over a long period of time, the amount may be smaller than the preferable amount described above. In addition, the glucan used in the present invention has a sufficient dietary experience, and there is no problem in terms of safety. Therefore, an amount far exceeding the above amount (for example, 10 mg/kg/day or more) is possible.

The composition of the present invention can be used as a food or drink. The composition of the present invention, as a special-purpose food such as a food for specified health use and a nutritionally functional food, by administering to animals such as humans, can improve gut microbiota, behavioural pattern, alpha-synuclein levels, sleep pattern and/or serum melatonin.

When the composition of the present invention is used as food or drink, the type of food or drink is not particularly limited. Further, the shape of the food or drink is not particularly limited, and may be any shape of food or drink that is usually used. For example, it may be in any form such as solid form (including powder and granule form), paste form, liquid form and suspension form, and is not limited to these forms.

When used as a pharmaceutical, a dosage form that can be orally administered is preferable because the composition of the present invention reaches the intestine. Examples of preferable dosage forms of the drug according to the present invention include tablets, coated tablets, capsules, granules, powders, solutions, syrups, troches and the like. These various preparations are prepared according to a conventional method by using glucan, which is the active ingredient, an excipient, a binder, a disintegrating agent, a lubricant, a coloring agent, a flavoring agent, a solubilizing agent, a suspending agent, a coating agent, etc. It can be formulated by admixing the auxiliaries usually used in the technical field of pharmaceutical formulation.

In some embodiment, the present invention can be used in combination with other food, drink, drugs and any other substances in order to enhance the efficacy of the present invention.

Beneficial Regulation of Gut Microbiota Yielding an Advantageous Fecal Metabolome Profile by Administration of AFO-202 Biological Response Modifier Glucan in an Stam Animal Model of Non-Alcoholic Steatohepatitis, Paving Way for Effective Utilization in Human Health and Disease.

Introduction:

With approximately 100 trillion micro-organisms existing in the human gastrointestinal tract, the microbiome is now considered as a virtual organ of the body. The microbiome encodes over three million genes producing thousands of metabolites compared to 23,000 genes of the human genome and hence replaces many of the functions of the host influencing the host's fitness, phenotype, and health. Gut microbiota influences several aspects of human health including immune, metabolic and neurobehavioural traits [D1]. In regard to functions, the gut microbiota ferments non-digestible substrates like dietary fibres and endogenous intestinal mucus. The fermentation supports the growth of specialist microbes that produce short chain fatty acids (SCFAs) and gases. Major SCFAs produced are acetate, propionate, and butyrate.

Butryate is needed to maintain colon's cells, it helps in apoptosis of colon cancer cells, activation of intestinal gluconeogenesis, having beneficial effects on glucose and energy homeostasis and maintenance of oxygen balance in the gut, preventing gut microbiota dysbiosis. Propionate is transported to the liver, where it regulates gluconeogenesis and acetate is an essential metabolite for the growth of other bacteria, as well as playing a role in central appetite regulation [D1].

Gut dysbiosis or the altered state of the microbiota community has been associated with several diseases including but not limited to diabetes, metabolic disorders, obesity, cancers, rheumatoid arthritis, neurological disorders such as Parkinson's disease, Alzheimer's′, multiple sclerosis and autism spectrum disorders (ASD) [D2,3]. The fecal metabolome represents the functional readout of the gut microbial activity and can be considered to be an intermediate phenotype mediating host-microbiome interaction. An average 67.7% (±18.8%) of the fecal metabolome's variance represents the gut microbial composition.

Fecal metabolic profiling thus is a novel tool to explore links among microbiome composition, host phenotypes and disease states [D4]. Probiotics and pre-biotic nutritional supplements represent the major strategy other than fecal microbiota transplantation to restore the dsybiotic gut to a healthy state. Beta glucans are one of the most promising nutritional supplements with established efficacy in metabolic diseases, diabetes, cancer, cardiovascular diseases and neurological diseases. Beta glucans produced from two strains AFO-202 and N-163 of a black yeast Aureobasidium pullulans derived beta glucan has been reported with beneficial effects in diabetes [D5], dyslipidemia [D6], ASD [D7,8], Duchenne muscular dystrophy (DMD) [D9], Non-alcoholic steatohepatitis (NASH) [D10] and infectious diseases including COVID-19 [D11,12].

In a previous study, the AFO-202 beta 1,3-1,6 glucan was able to balance the gut microbiome in children with ASD [D13]. In the study on STAM™ murine model of NASH, the AFO-202 beta glucan significantly decreased inflammation-associated hepatic cell ballooning and steatosis while the N-163 beta glucan decreased fibrosis and inflammation. The combination of AFO-202 with N-163 significantly decreased the Non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) [D10]. The present study was undertaken as an extension of this NASH study to study the fecal microbiome and metabolome profile before and after administration of AFO-202 beta glucan.

Methods:

Mice

The study is reported in accordance with Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines. C57BL/6J mice were obtained from Japan SLC, Inc. (Japan). All animals used in this study were cared for under the following guidelines: Act on Welfare and Management of Animals (Ministry of the Environment, Japan, Act No. 105 of Oct. 1, 1973), standards relating to the care and management of laboratory animals and relief of pain (Notice No. 88 of the Ministry of the Environment, Japan, Apr. 28, 2006) and the guidelines for proper conduct of animal experiments (Science Council of Japan, Jun. 1, 2006). Protocol approvals were obtained from SMC Laboratories, Japan's IACUC (Study reference no: SP_SLMN128-2107-6_1). Mice were maintained in a specific pathogen-free (SPF) facility under controlled conditions of temperature (23±3° C.), humidity (50±20%), lighting (12-hour artificial light and dark cycles; light from 8:00 to 20:00) and air exchange.

The STAM model of NASH was induced as previously described [D10]. Mice were given a single subcutaneous injection of 200 μg streptozotocin (STZ, Sigma-Aldrich, USA) solution 2 days after birth and fed with a high-fat diet (HFD, 57 kcal % fat, Cat #HFD32, CLEA Japan, Inc., Japan) from 4-9 weeks of age. All mice develop liver steatosis and diabetes and at 3 weeks mice had established steatohepatitis, histologically.

Studygroups: There were five study groups, described below. Eight mice were included in each study group.

Group 1: Vehicle

Eight NASH mice were orally administered vehicle [RO water] in a volume of 5 mL/kg once daily from 6 to 9 weeks of age.

Group 2: AFO-202 Beta Glucan

Eight NASH mice were orally administered vehicle supplemented with AFO-202 Beta Glucan at a dose of 1 mg/kg in a volume of 5 mL/kg once daily from 6 to 9 weeks of age.

Group 3: Telmisartan

Eight NASH mice were orally administered vehicle supplemented with Telmisartan at a dose of 10 mg/kg once daily from 6 to 9 weeks of age.

TABLE 1
Study design and treatment schedule
	No.	Test	Dose	Volume
Group	mice	substance	(mg/kg)	(mL/kg)	Regimen	Sacrifice
1	8	Vehicle	—	5	PO, QD,	9 wks
					6-9 wks
2	8	AFO-202	1	5	PO, QD,	9 wks
		Beta			6-9 wks
		Glucan
3	8	Telmisartan	10	5	PO, QD,	9 wks
					6-9 wks

Test Substances

AFO-202 Beta Glucan was provided by GN Corporation Co Ltd., Japan. Telmisartan (Micardis(R)) was purchased from Boehringer Ingelheim GmbH (Germany).

Randomization

NASH model mice were randomized into 3 groups of 8 mice at 6 weeks of age based on their body weight the day before the start of treatment. The randomization was performed by body weight-stratified random sampling using Excel software. NASH model mice were stratified by their body weight to get SD and the difference in the mean weights among groups as small as possible.

Animal Monitoring and Sacrifice

The viability, clinical signs (lethargy, twitching, labored breathing) and behavior were monitored daily. Body weight was recorded daily before the treatment. Mice were observed for significant clinical signs of toxicity, moribundity and mortality before administration and after administration. The animals were sacrificed at 9 weeks of age by exsanguination through direct cardiac puncture under isoflurane anesthesia (Pfizer Inc.).

Collection of Fecal Pellets Samples:

Frequency: Fecal samples were collected at the 6 weeks of age (before administration) and 9 weeks of age (before sacrifice).

Procedure: At 6 weeks of age, fecal samples were collected from each mouse by clean catch method. Handle animals with clean gloves sterilized with 70% ethanol. A sterile petri dish was placed on the bench. Gently massage the abdomen, position the bottom of mouse over a fresh petri dish, and collect 1-2 fecal pellets. At sacrifice, fecal samples were aseptically collected from cecum. The tubes with feces were placed on ice immediately. These tubes were snap frozen in liquid nitrogen and stored at −80° C. for shipping.

Microbiome Analysis:

In this analysis, the 16S rRNA sequence data acquired by the next-generation sequencer from the fecal RNA was used to perform community analysis using the QIIME2 program for microbial community analysis. The raw read data in FASTQ format output from the next-generation sequencer was trimmed to remove adapter sequences and low QV regions that may be included in the data. Cutadapt was used to remove adapter sequences from DNA sequencing reads. Trimmomatic was used as read trimming tool for Illumina NGS data. The adapter sequence was trimmed using the adapter trimming program “cutadapt” if the Trimming of the region at the end of the read sequence overlapped the corresponding sequence by at least one base (mismatch tolerance: 20%). When reads containing N were present in at least one of Read1 and Read2, both Read1 and Read2 were removed.

Illumina Adapter Sequence Information

Read1 3′ End Side

• • CTGTCTTCTATACACATCTCCGAGCCCACGAGAC

Read2 3′ End Side

• • CTGTCTTCTATACACATCTGACGCTGCCGACGA

Trimming of low QV regions was performed on the read data after processing using the QV trimming program “Trimmomatic” under the following conditions.

<QV Trimming Conditions>

The window of 20 bases is slid from the 5′ side, and the area where the average QV is less than 20 is trimmed.

After trimming, only the reads with more than 50 bases remaining in both Read1 and Read2 were taken as output.

Population Analysis

The microbial community analysis based on 16S rRNA sequence was performed on the sequence data trimmed in the previous section using the microbial community analysis program “QIIME2”. The annotation program “sklearn” included in QIIME2 is used to annotate the ASV (OTU) sequences.

Using “sklearn”, an annotation program included in QIIME2, the ASV (OTU) sequences obtained were annotated with taxonomy information [Kingdom (kingdom)/Phylum (phylum)/Class (class)/Order (order)/Family (family)/Genus/Species] based on the 16S rDNA database.

The data set of 16S rDNA database “greengenes” provided on the QIIME2 Resources site was used for the analysis. The ASVs (OTUs) obtained above were aggregated and graphed based on the taxonomy information a and the read counts of each specimen. Based on the composition of bacterial flora for each specimen compiled above, various index values for α-diversity were calculated.

Metabolome Analysis:

After lyophilization of the fecal sample, about 10 mg of the sample was separated, extracted by the Bligh-Dyer method, and the resulting aqueous layer1 was collected and lyophilized. The residue was derivatized using 2-methoxyamine hydrochloride and MSTFA, and submitted to gas chromatography-mass spectrometry (GC-MS) as an analytical sample. 2-Isopropylmalic acid was used as an internal standard. In addition, an operational blank test was also conducted.

Analytical equipment used was GCMS-TQ8030 (Shimadzu Corporation); Column BPX-5 (film thickness 0.25 μm, length 30 m, inner diameter 0.25 mm, Shimadzu GC).

Peak Detection and Analysis:

MS-DIAL ver.4.7 (http://prime.psc.riken.jp/compms/index.html) was used to analyze and prepare the peak list (peak height) under the conditions given in Table 2. In doing so, peaks that were detected in the QC samples and whose C.V. was less than 20% and whose intensity was more than twice that of the operating blank were treated as detected peaks.

TABLE 2
Abundance of all the bacteria analysed at baseline and post-intervention
				F18S_3			F18S_13-
			F18S_1	AFO-	F18S_9-	F18S_11-	AFO-	F18S_19-
			Control-	202 -	Telmisartan-	Control-	202-	Telmisartan-
Family	Genus	Species	pre	pre	pre	post	post	post
Erysipelotrichaceae	Allobaculum	—	12083	15713	6375	8007	6542	622
Turicibacteraceae	Turicibacter	—	12538	6159	9408	3346	2749	786
Desulfovibrionaceae	—	—	306	1398	3882	8016	10096	6012
Clostridiaceae	Other	Other	7455	3689	7143	3479	2806	723
Lactobacillaceae	Lactobacillus	—	8	3433	416	11554	5804	254
Streptococcaceae	Lactococeus	—	5038	2755	2239	1081	2146	1948
Bacteroidaceae	Bacteroides	—	1091	1 07	1596	1562	2831	8412
[Paraprevotellaceae]	[Prevotella]	—	962	1777	1674	540	1865	7582
—	—	—	17	680	1552	526	5964	6029
Deferribacteraceae	Mucispirillum	schaedleri	36	1486	4795	2087	1644	1921
Bacteroidaceae	Bacteroides	acidifaciens	322	781	983	2633	2161	2571
—	—	—	497	760	853	1386	1478	2764
Verrucomicrobiaceae	Akkermansia	muciniphila	21 1	1963	2305	0	746	320
Rikenellaceae	—	—	475	849	696	616	769	117
Enterobacteriaceae	Other	Other	0	5	17	100	0	40
Lactobacillaceae	Lactobacillus	—	1729	1119	883	594	459	513
S24-7	—	—	592	953	623	494	796	411
Lachnospiraceae	—	—	149	914	752	826	1194	1545
Peptostreptocpccaceae	—	—	1705	7	1121	1344	6 1	181
Lachnospiraceae	[Ruminococcus]	gnavus	1015	1118	2041	582	398	898
Lachnospiraceae	Coprococeus	—	90	955	444	708	1191	1468
Bifidobacteriaceae	Bifidobacterium	pseudolongum	711	1236	1317	180	324	111
Enterobacteriaceae	Proteus	—	14	42	0	1432	520	1153
Lactobacillaceae	Lactobacillus	Other	1456	362	64	2494	844	111
S24-7	—	—	442	804	740	819	555	329
Porphyromonadaceae	Parabacteroides	distasonis	111	194	320	699	700	1437
Clostridiaceae	—	—	389	384	1242	387	572	79
—	—	—	41	289	420	998	1118	536
Desulfovibrionaceae	Desulfovibrio	—	0	8	65	734	739	503
S24-7	—	—	331	629	708	155	495	271
Coriobacteriaceae	Adlercreutzia	—	1261	411	625	399	280	135
S24-7	—	—	216	457	480	471	163	527
Erysipelotrichaceae	Clostridium	cocleatum	0	95	319	519	1185	696
Ruminococcaceae	Ruminococcus	—	532	1331	1164	50	257	266
—	—	—	250	302	319	522	564	995
Lachnospiraceae	Other	Other	35	267	481	611	832	436
Lachnospiraceae	[Ruminococcus]	gnavus	238	1211	311	0	25	87
Turicibacteraceae	Turicibacter	—	822	472	586	269	206	0
Lachnospiraceae	—	—	119	46	611	119	119	253
Bacteroidaceae	Bacteroides	—	18	73	460	180	283	2042
Ruminococcaceae	Oscillospira	—	82	400	293	267	804	621
Clostridiaceae	Other	Other	923	362	17	314	132	70
Lachnospiraceae	Roseburia	—	88	466	488	408	878	927
Lachnospiraceae	—	—	66	386	338	461	658	698
S24-7	—	—	389	291	305	98	129	104
Lachnospiraceae	[Ruminococcus]	gnavus	44	522	123	466	0	126
—	—	—	224	692	418	104	49	236
—	—	—	82	358	357	323	299	267
Lachnospiraceae	Coprococcus	—	38	349	126	297	454	562
S24-7	—	—	146	230	322	199	549	144
S24-7	—	—	153	3 8	237	340	131	410
—	—	—	7	199	116	283	2 5	590
Lachnospiraceae	Other	Other	263	65	562	169	100	245
Lachnospiraceae	[Ruminococcus]	gnavus	386	162	375	62	433	686
Erysipelotrichaceae	Allobaculum	—	512	415	286	501	301	0
Desulfovibrionaceae	Desulfovibrio	C21_c20	47	333	604	98	294	43
S24-7	—	—	212	366	383	120	271	152
—	—	—	53	228	524	177	178	345
Streptococcaceae	Lactococcus	garvieae	167	0	11	0	0	8
—	—	—	0	227	0	0	0	0
Enterobacteriaceae	Proteus	—	0	0	0	507	184	386
Lachnospiraceae	—	—	76	760	44	103	0	786
S24-7	—	—	162	376	399	120	103	74
Lachnospiraceae	[Ruminococcus]	gnavus	38	471	278	31	179	331
—	—	—	273	690	371	0	38	44
Clostridiaceae	Clostridium	Other	145	179	707	196	284	0
Lachnospiraceae	—	—	37	867	0	179	356	15
Clostridiaceae	Other	Other	542	252	215	233	97	49
—	—	—	403	25	313	21	0	54
Clostridiaceae	Other	Other	7 6	307	255	281	127	5
S24-7	—	—	163	408	196	20	199	101
Lachnospiraceae	[Ruminococcus]	gnavus	301	295	601	151	118	260
Bacteroidaceae	Bacteroides	—	11	74	170	20	66	1596
S24-7	—	—	165	318	327	67	220	125
—	—	—	264	754	323	0	39	3
Lachnospiraceae	[Ruminococcus]	gnavus	310	363	120	177	58	281
Ruminococcaceae	Oscillospira	—	69	329	284	164	288	393
Ruminococcaceae	Anaerotruncus	—	38	189	638	112	113	12
Alcaligenaceae	Sutterella	—	257	217	191	399	107	63
S24-7	—	—	169	368	394	83	85	54
F16	—	—	10	0	329	117	0	22
—	—	—	305	37	320	0	0	0
Other	Other	Other	456	0	276	360	170	0
Lachnospiraceae	[Ruminococcus]	gnavus	146	175	168	173	91	325
S24-7	—	—	206	230	476	0	0	153
Rikenellaceae	—	—	0	162	259	135	264	134
Lachnospiraceae	[Ruminococcus]	gnavus	656	0	62	492	0	30
Lachnospiraceae	—	—	0	118	250	126	244	359
Clostridiaceae	Other	Other	0	164	693	119	235	39
Lachnospiraceae	—	—	46	111	78	160	205	239
Ruminococcaceae	Oscillospira	—	117	97	160	249	220	138
Enterococcaceae	Enterococcus	—	45	42	32	822	61	0
Rikenellaceae	—	—	39	147	239	119	230	96
S24-7	—	—	188	153	208	40	59	79
Lactobacillaceae	Lactobacillus	reuteri	517	157	0	428	340	0
Bacteroidaceae	Bacteroides	acidifaciens	0	90	161	124	202	127
Ruminococcaceae	Oscillospira	—	75	162	202	51	2 4	451
Enterobacteriaceae	Escherichia	coli	0	0	0	0	0	0
Ruminococcaceae	Oscillospira	—	16	262	152	135	137	280
—	—	—	117	2 6	228	29	17	254
S24-7	—	—	84	173	157	2 0	62	92
—	—	—	1 9	0	988	0	0	0
Other	Other	Other	11	149	463	230	27	251
Lachnospiraceae	—	—	51	67	46	287	224	163
Lachnospiraceae	[Ruminococcus]	gnavus	88	185	148	190	272	63
Lachnospiraceae	—	—	28	54	390	17	62	117
Enterobacteriaceae	Klebsiella	Other	0	0	0	225	0	33
Lachnospiraceae	—	—	11	105	76	51	99	187
Enterobacteriaceae	Klebsiella	—	0	0	0	210	0	7
—	—	—	11	491	0	32	61	261
Lactobacillaceae	Lactobacillus	—	167	26	4	857	183	0
Other	Other	Other	27	23	57	102	117	248
—	—	—	0	114	209	176	243	0
Erysipclotrichaceae	Allobaculum	—	0	0	203	0	0	59
—	—	—	72	267	131	0	0	84
Lachnospiraceae	—	—	34	188	207	15	165	271
—	—	—	4	4	362	263	8	173
Other	Other	Other	18	70	58	149	183	269
Lactobacillaceae	Lactobacillus	reuteri	339	55	0	470	93	0
Ruminococcaceae	Oscillospira	—	40	88	158	77	244	273
Lachnospiraceae	—	—	27	93	50	122	193	139
S24-7	—	—	90	0	1 8	0	103	125
S24-7	—	—	91	97	64	55	8	111
Lachnospiraceae	—	—	22	69	315	31	45	119
S24-7	—	—	40	75	104	60	198	8
S24-7	—	—	123	161	60	36	39	74
Lachnospiraceae	—	—	22	16	19	229	192	98
—	—	—	22	18	28	40	109	376
Coriobacteriaceae	Adlercreutzia	—	121	196	110	63	33	30
—	—	—	43	83	200	53	95	118
Clostidiaceae	Other	Other	100	0	0	0	0	0
Turicibacteraceae	Turicibacter	—	521	0	125	0	0	0
Ruminococcaceae	Ruminococcus	—	49	105	193	0	81	143
Ruminococcaceae	Oscillospira	—	13	10	215	36	75	119
Dehalobacteriaceae	Dehalobacterium	—	20	38	43	100	256	268
Staphylococcaceae	Staphylococcus	Other	177	72	110	88	81	34
Rikenellaceae	—	—	13	62	61	139	140	97
Lachnospiraceae	—	—	155	109	87	63	114	98
—	—	—	53	188	60	0	0	68
Staphylococcaceae	Staphylococcus	sciuri	184	66	34	139	63	41
—	—	—	356	0	103	25	0	0
Ruminococcaceae	Ruminococcus	—	72	98	157	16	119	124
Coriobacteriaceae	Adlercreutzia	—	176	96	101	34	46	0
Ruminococcaceae	Oscillospira	—	34	67	61	103	101	120
Lachnospiraceae	Clostridium	Other	0	32	85	15	15	40
Lachnospiraceae	Coprococcus	—	56	92	151	69	61	85
Desulfovibrionaceae	—	—	4	41	50	90	18	148
—	—	—	32	162	94	28	23	103
Lachnospiraceae	—	—	22	2 5	0	53	0	272
Dehalobacteriaceae	Dehalobacterium	—	0	34	41	9	203	239
Coriobacteriaceae	Adlercreutzia	—	108	127	90	52	63	0
Lachnospiraceae	—	—	14	39	37	3	108	119
Lachnospiraceae	—	—	87	193	168	48	17	14
Ruminococcaceae	Oscillospira	—	0	0	0	0	101	4 3
S24-7	—	—	56	158	5	33	47	51
Streptococcaceae	Streptococcus	—	0	0	0	112	106	44
Lachnospiraceae	[Ruminococcus]	gnavus	0	107	83	126	165	37
Lachnospiraceae	—	—	0	144	102	0	102	173
Lachnospiraceae	—	—	50	158	231	11	17	10
Coriobacteriaceae	Adlercreutzia	—	142	9	74	26	19	8
Lachnospiraceae	—	—	220	7	2	55	52	57
Erysipelotrichaceae	Clostridium	cocleatum	0	0	0	106	222	119
S24-7	—	—	15	36	53	93	160	0
Lachnospiraceae	—	—	7	40	27	64	61	81
Bacteroidaceae	Bacteroides	—	0	0	55	0	0	468
Ruminococcaceae	Oscillospira	—	0	46	59	87	97	53
Ruminococcaceae	—	—	21	41	41	81	139	72
Lachnospiraceae	Other	Other	42	11	52	53	86	90
Lachnospiraceae	Dorea	—	23	46	28	50	63	154
Lachnospiraceae	—	—	0	0	0	70	78	94
S24-7	—	—	34	130	168	0	29	0
Lachnospiraceae	—	—	0	87	92	0	96	138
Lactobacillaceae	Lactobaccilus	Other	107	148	0	83	189	0
—	—	—	0	39	34	29	73	48
Ruminococcaceae	Oscillospira	—	24	95	99	0	52	101
S24-7	—	—	0	43	55	64	52	9
S24-7	—	—	55	52	67	0	53	71
[Mogibacteriaceae]	—	—	55	76	36	44	53	28
Peptococcaceae	—	—	18	80	43	36	152	42
—	—	—	42	42	13	0	0	40
—	—	—	0	36	0	83	0	213
S24-7	—	—	31	99	76	33	36	19
Ruminococcaceae	Oscillospira	—	17	25	5	26	88	135
Ruminococcaceae	Oscillospira	—	15	110	97	4	14	53
Lachnospiraceae	[Ruminococcus]	gnavus	43	135	33	0	0	87
Ruminococcaceae	Oscillospira	—	15	35	57	33	100	42
Lactobacillaceae	Lactobaccilus	reuteri	80	103	0	76	178	0
Coriobacteriaceae	Adlercreutzia	—	112	73	58	0	0	0
Lachnospiraceae	—	—	12	0	0	36	0	0
S24-7	—	—	0	0	64	48	113	49
Turicibacteraceae	Turicibacter	—	0	0	0	134	0	0
S24-7	—	—	0	0	45	128	53	41
Rikenellaceae	—	—	11	14	25	84	84	86
Enterobacteriaceae	Other	Other	0	0	0	99	0	0
Rikenellaceae	Other	Other	5	40	47	37	43	53
Porphy ceae	Parabacteroides	—	0	2	16	63	72	79
Lactobacillaceae	Lactobaccilus	Other	87	86	0	81	146	0
—	—	—	0	47	60	0	38	0
S24-7	—	—	13	53	27	22	73	45
S24-7	—	—	15	30	35	0	83	109
—	—	—	8	50	85	43	14	19
Enterobacteriaceae	Klebsiella	Other	0	0	0	82	0	0
—	—	—	32	73	63	0	5	3
Lachnospiraceae	Other	Other	8	6	48	24	67	137
Ruminococcaceae	Oscillospira	—	0	0	0	102	134	0
Ruminococcaceae	Oscillospira	—	0	67	71	0	30	65
Bacteroidaceae	Bacteroides	acidifaciens	0	0	27	31	35	35
Erysipelotrichaceae	—	—	85	29	51	7	14	0
Lachnospiraceae	Dorea	—	18	0	98	6	15	74
Enterobacteriaceae	Enterobacter	Other	125	0	0	30		41
Ruminococcaceae	Oscillospira	—	0	0	42	0	82	45
Ruminococcaceae	Other	Other	1	3	61	0	44	12
Ruminococcaceae	Oscillospira	—	0	0	0	0	68	184
Rikenellaceae	—	—	0	0	31	61	55	43
—	—	—	0	63	9	12	45	79
Lachnospiraceae	Other	Other	0	0	98	0	0	273
Other	Other	Other	0	0	18	39	65	87
Ruminococcaceae	Oscillospira	—	0	47	79	0	37	72
S24-7	—	—	0	23	38	28	78	85
Lachnospiraceae	—	—	6	15	3	111	127	0
Streptococcaceae	Staphylococcus	—	53	0	0	168	30	27
—	—	—	0	77	96	0	0	0
—	—	—	0	0	87	60	0	0
—	—	—	0	0	0	0	219	101
Other	Other	Other	0	0	10	15	29	71
Aerococcaceae	Aerococcus	—	7	0	0	22	85	187
Ruminococcaceae	—	—	0	0	0	0	0	0
—	—	—	0	0	61	0	111	108
Streptococcaceae	Staphylococcus	—	40	18	0	120	0	3
Ruminococcaceae	Oscillospira	—	19	31	0	14	71	26
—	—	—	11	36	0	7	11	51
Ruminococcaceae	Ruminococcus	—	6	15	0	13	110	43
—	—	—	0	0	6	0	0	266
Other	Other	Other	0	19	0	0	64	48
Ruminococcaceae	Oscillospira	—	12	86	30	0	63	0
Lachnospiraceae	[Ruminococcus]	gnavus	51	0	27	18	26	95
Lachnospiraceae	—	—	0	0	0	65	48	0
Other	Other	Other	0	0	0	0	81	45
Ruminococcaceae	Oscillospira	—	11	25	37	23	16	23
—	—	—	0	0	69	0	99	90
Other	Other	Other	38	0	0	46	67	11
Other	Other	Other	0	0	0	0	56	53
Other	Other	Other	0	40	68	0	0	57
Lachnospiraceae	Clostridium	Other	0	0	0	18	0	101
Lachnospiraceae	—	—	0	0	0	16	0	23
Other	Other	Other	0	42	13	18	62	0
Other	Other	Other	9	0	23	40	0	51
Ruminococcaceae	Oscillospira	—	0	20	25	0	62	38
Desulfovibrionaceae	—	—	0	0	23	0	54	42
Dehalobacteriaceae	Dehalobacterium	—	11	31	24	0	0	0
Porphy	Parabacteroides	—	0	9	3	29	19	115
Ruminococcaceae	Ruminococcus	—	0	21	44	15	38	22
Lachnospiraceae	Coprococcus	—	10	39	23	6	12	46
Ruminococcaceae	Oscillospira	—	0	8	0	0	0	77
Other	Other	Other	0	0	0	0	70	38
Lachnospiraceae	Coprococcus	—	0	16	34	25	0	49
Ruminococcaceae	Oscillospira	—	0	0	87	0	67	0
Christensenellaceae	—	—	49	0	37	8	15	9
S24-7	—	—	0	11	44	8	19	8
Ruminococcaceae	Oscillospira	—	0	0	95	0	54	0
Lachnospiraceae	Coprococcus	—	0	0	11	19	54	29
Lachnospiraceae	Other	Other	0	0	0	0	0	0
Enterococcaceae	Va coccus	—	11	0	0	0	14	20
Erysipelotrichaceae	Clostridium	cocleatum	0	0	16	28	61	34
—	—	—	9	25	92	0	0	0
Desulfovibrionaceae	Bilophila	—	0	8	11	13	46	17
—	—	—	0	22	107	0	0	0
Corynebacteriaceae	Corynebacterium	stationis	72	0	0	18	23	0
Lachnospiraceae	Other	Other	0	43	0	41	0	34
Lachnospiraceae	Other	Other	0	0	0	27	26	82
Lachnospiraceae	—	—	22	9	14	7	0	10
Lachnospiraceae	—	—	0	6	31	26	0	0
—	—	—	0	22	108	0	0	0
—	—	—	0	0	0	0	67	84
—	—	—	0	30	0	0	0	0
Ruminococcaceae	—	—	5	52	27	0	0	0
—	—	—	0	24	96	0	0	0
Lachnospiraceae	—	—	0	54	90	0	0	0
Dehalobacteriaceae	Dehalobacterium	—	3	8	3	19	23	43
Other	Other	Other	0	71	0	0	0	68
Streptococcaceae	Streptococcus	luteciae	25	19	12	0	15	0
—	—	—	0	55	0	0	82	0
S24-7	—	—	9	0	0	38	0	36
Ruminococcaceae	A otruncus	—	0	7	6	13	23	11
Ruminococcaceae	Ruminococcus	—	0	63	10	0	0	0
Lachnospiraceae	Clostridium	Other	0	0	26	0	0	0
—	—	—	0	31	10	0	0	10
Ruminococcaceae	Oscillospira	—	0	13	11	6	18	22
Lachnospiraceae	Coprococcus	—	0	13	20	19	25	30
—	—	—	20	39	12	12	0	0
S24-7	—	—	0	0	0	0	113	0
A ceae		—	21	25	16	0	2	0
Lachnospiraceae	—	—	0	0	0	0	0	60
Ruminococcaceae	Oscillospira	—	0	0	54	0	0	30
S24-7	—	—	0	0	47	0	6	0
—	—	—	0	0	0	0	0	107
Ruminococcaceae	Oscillospira	—	0	0	35	0	27	9
Bacteroidaceae	Bacteroides	acidifaciens	0	0	0	105	0	0
Bacteroidaceae	Bacteroides	acidifaciens	0	6	0	3	32	11
Lachnospiraceae	Dorea	—	11	21	25	3	0	8
Ruminococcaceae	Other	Other	4	14	10	0	8	11
Lachnospiraceae	—	—	0	80	7	0	0	13
Lachnospiraceae	—	—	11	0	20	0	0	0
S24-7	—	—	20	0	1	0	0	1
Lachnospiraceae	Other	Other	0	19	14	0	0	0
—	—	—	4	42	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	13	0	9	15	9
Ruminococcaceae	Oscillospira	—	0	0	42	0	0	0
Lachnospiraceae	—	—	0	0	14	13	20	19
Erysipelotrichaceae	—	—	38	0	0	0	0	0
S24-7	—	—	0	0	6	0	0	0
Lachnospiraceae	—	—	0	11	13	0	17	9
Ruminococcaceae	Oscillospira	—	15	76	0	0	0	0
Lachnospiraceae	—	—	0	21	22	0	0	14
Other	Other	Other	0	0	49	0	0	0
F16	—	—	0	66	0	0	18	0
Christensenellaceae	—	—	6	17	19	0	5	5
Lachnospiraceae	Other	Other	0	0	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	9	12	0	0	0
—	—	—	0	0	80	0	0	0
Ruminococcaceae	Other	Other	8	12	14	4	0	0
—	—	—	0	19	0	0	0	0
Lachnospiraceae	Other	Other	15	0	0	0	18	0
Other	Other	Other	0	0	0	0	0	0
Enterococcaceae	Vagococcus	—	29	0	0	0	0	26
Ruminococcaceae	Ruminococcus	—	14	9	23	0	0	0
Erysipelotrichaceae	Coprabacillus	—	11	2	11	0	0	0
Other	Other	Other	0	22	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	9	11	0	0	9
Ruminococcaceae	Oscillospira	—	0	38	0	0	0	0
—	—	—	0	14	0	0	0	0
Lachnospiraceae	—	—	0		0	15	14	0
Ruminococcaceae	Oscillospira	—	0	0	0	0	0	31
Lachnospiraceae	Coprococcus	—	0	0	0	0	0	0
Ruminococcaceae	Other	Other	0	0	8	10	9	5
—	—	—	0	0	0	0	0	0
Erysipelotrichaceae	—	—	0	9	6	0	14	2
Rikenellaceae	—	—	0	7	0	8	4	11
—	—	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	40
—	—	—	15	11	8	0	0	0
Lachnospiraceae	—	—	0	0	0	0	0	0
—	—	—	0	10	15	0	0	0
Lachnospiraceae	Clostridium	Other	0	0	0	0	0	28
Erysipelotrichaceae	—	—	7	18	9	0	9	0
Streptococcaceae	Streptococcus	minor	0	9	9	0	0	0
Ruminococcaceae	Oscillospira	—	0	0	0	0	0	0
—	—	—	0	0	27	0	8	0
Lachnospiraceae	Other	Other	13	7	7	0	0	0
Other	Other	Other	0	0	36	0	0	0
—	—	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	0
—	—	—	14	0	0	0	0	0
—	—	—	0	13	8	0	0	0
Lachnospiraceae	—	—	0	0	7	11	0	12
Streptococcaceae	Streptococcus	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	0
S24-7	—	—	0	0	0	0	0	0
—	—	—	0	0	42	0	0	0
Other	Other	Other	0	0	0	0	0	42
[Mogibacteriaceae]	—	—	7	4	0	0	12	0
Enterobacteriaceae	Enterobacter	Other	13	0	0	0	0	0
Eubacteriaceae	A tis	—	0	13	5	2	0	0
Erysipelotrichaceae	—	—	0	0	0	0	0	19
Aerococcaceae	Aerococcus	—	0	0	0	0	0	39
Ruminococcaceae	Oscillospira	—	0	21	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	0	0	0	10	12
Other	Other	Other	0	16	5	0	0	0
—	—	—	0	0	5	9	10	8
Lachnospiraceae	Coprococcus	—	0	17	0	0	0	0
Other	Other	Other	0	0	35	0	0	0
—	—	—	0	33	0	0	0	0
Lachnospiraceae	Other	Other	0	12	11	0	0	0
Ruminococcaceae	Oscillospira	—	0	8	0	0	14	0
S24-7	—	—	0	0	0	32	0	0
Ruminococcaceae	Ruminococcus	—	0	15	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	0	31	0	0	0
—	—	—	0	30	0	0	0	0
—	—	—	0	14	0	0	0	0
—	—	—	0	0	0	0	0	0
—	—	—	0	0	16	0	8	0
Ruminococcaceae	Ruminococcus	—	0	0	0	12	8	0
Lachnospiraceae	—	—	6	7	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	14	0	0	0	0
—	—	—	0	0	14	0	0	0
—	—	—	0	0	20	0	0	0
Corynebacteriaceae	Corynebacterium	stationis	26	0	0	0	0	0
Ruminococcaceae	Other	Other	0	4	5	0	0	0
S24-7	—	—	0	0	0	0	0	13
Ruminococcaceae	Oscillospira	—	0	0	0	0	0	26
Ruminococcaceae	Oscillospira	—	0	0	0	0	0	0
Ruminococcaceae	Ruminococcus	—	13	11	0	0	0	0
[Mogibacteriaceae]	—	—	11	0	0	0	4	0
Erysipelotrichaceae	Coprobacillus	—	0	0	0	0	0	0
Erysipelotrichaceae	Clostridium	cocleatum	0	0	0	2	0	1
S24-7	—	—	0	0	0	0	0	0
Coriobacteriaceae	—	—	0	7	0	0	0	0
Coriobacteriaceae	Adlercreutzia	—	4	0	0	0	0	0
Leucon ceae	Weissella	parame enteroides	2	0	0	0	3	12
Enterococcaceae	Vagococcus	—	0	0	0	0	0	0
Ruminococcaceae	Buty coccus	pullic um	0	0	6	0	0	0
[Mogibacteriaceae]	—	—	0	0	0	0	12	6
—	—	—	0	0	8	0	0	0
—	—	—	0	0	20	0	0	0
—	—	—	0	0	20	0	0	0
S24-7	—	—	0	0	0	0	9	11
Ruminococcaceae	Oscillospira	—	0	9	0	0	0	0
Planococcaceae	Sporosarcina	—	0	0	0	8	0	0
Lachnospiraceae	Bl	producta	0	7	0	0	6	0
Erysipelotrichaceae	Other	Other	0	0	7	0	0	0
—	—	—	0	0	0	0	0	0
Ruminococcaceae	Ruminococcus	—	0	15	0	0	0	0
—	—	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	0
—	—	—	0	0	0	15	0	0
Coriobacteriaceae	Adlercreutzia	—	10	0	0	4	0	0
Other	Other	Other	0	0	0	0	0	0
Ruminococcaceae	Other	Other	0	0	0		9	0
Erysipelotrichaceae	—	—	0	0	0	0	14	0
Deferribacteraceae	Mucispirillum	schaedleri	0	0	0	0	0	0
Methylobacteriaceae	Methylobacterium	Other	0	0	0	0	0	0
Methanobacteriaceae	Methanobrevibacter	—	0	0	0	0	0	0
—	—	—	0		0	2	0	0
Lachnospiraceae	Other	Other	0	0	12	0	0	0
Lachnospiraceae	Dorea	—	11	0	0	0	0	0
Lachnospiraceae	Dorea	—	0	4	7	0	0	0
Lachnospiraceae	—	—	0	0	11	0	0	0
Erysipelotrichaceae	—	—	0	0	0	11	0	0
—	—	—	0	0	0	11	0	0
Other	Other	Other	0	0	0	0	0	0
Ruminococcaceae	Ruminococcus	—	0	0	0	0	0	11
Lachnospiraceae	Other	Other	0	10	0	0	0	0
Erysipelotrichaceae	Clostridum	cocleatum	0	0	0	0	0	0
Clostridiaceae	—	—	0	0	10	0	0	0
S24-7	—	—	0	0	0	0	6	0
Ruminococcaceae	Oscillospira	—	0	0	0	0	0	10
—	—	—	9	0	0	0	0	0
—	—	—	0	0	0	0	0	0
Erysipelotrichaceae	—	—	0	0	0	0	0	9
Streptococcaceae	—	—	0	0	0	0	0	0
Erysipelotrichaceae	—	—	0	0	0	0	0	0
Turicibacteraceae	Turicibacter	—	7	0	0	0	0	0
S24-7	—	—	0	7	0	0	0	0
Ruminococcaceae	Oscillospira	—	0	7	0	0	0	0
Lachnospiraceae	—	—	0	7	0	0	0	0
—	—	—	0	0	0	3	0	4
Erysipelotrichaceae	—	—	0	0	0	0	0	0
Ruminococcaceae	Ruminococcus	—	0	0	0	0	0	7
Moraxellaceae	Psychrobacter	Other	3	0	0	0	0	0
Paenibacillaceae	Other	Other	0	6	0	0	0	0
Lachnospiraceae	Coprococcus	—	0	6	0	0	0	0
Bacillaceae	Bacillus	—	0	0	0	0	0	0
Enterococcaceae	Vagococcus	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	0
Lachnospiraceae	—	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	6
—	—	—	5	0	0	0	0	0
—	—	—	0	0	5	0	0	0
Ruminococcaceae	Oscillospira	—	0	4	0	0	0	0
—	—	—	0	0	0	0	0	0
Erysipelotrichaceae	—	—	0	0	4	0	0	0
Other	Other	Other	0	0	0	0	0	4
Clostridiaceae	Clostridium	Other	3	0	0	0	0	0
—	—	—	0	0	0	0	0	0
Ruminococcaceae	Buty coccus	pulli um	0	0	0	0	0	0
Ruminococcaceae	—	—	0	0	3	0	0	0
Deferribacteraceae	Mucispirillum	schaedleri	0	0	0	0	3	0
Turicibacteraceae	Turicibacter	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	3
Verrucomicrobiaceae	Akkermansia	phil	2	0	0	0	0	0
[Mogibacteriaceae]	—	—	0	2	0	0	0	0
Alcaligenaceae	S ella	—	0	0	0	0	0	0
Lachnospiraceae	Dorea	longicateria	0	0	2	0	0	0
Ruminococcaceae	—	—	0	0	0	0	2	0
Lachnospiraceae	—	—	0	0	0	0	0	0
—	—	—	0	0	0	0	0	2
indicates data missing or illegible when filed

Differential Abundance Analysis, PCA and PCA, OPLS-DA and Clustering Analysis:

Principal component analysis (PCA) and orthogonal partial least squares-discriminant analysis (OPLS-DA) were performed to visualize the metabolic differences among the experimental groups. For principal component analysis, SIMCA-P+ ver.17 (Umetrics) was used. The normalized peak heights of the sample-derived peaks were used to perform principal component analysis using all samples and five points (F18S-12, F18S-14, F18S-16, F18S-18, and F18S-20). Transform was set to none, and Scaling was set to Pareto scaling. Differential metabolites were selected according to the statistically significant variable importance in the projection (VIP) values obtained from the OPLS-DA model. Hierarchical Cluster Analysis (HCA) and heat maps were performed using R (https://www.r-project.org/).

Statistical Analysis:

Statistical data were analysed using Microsoft Excel statistics package analysis software. Graphs were prepared using Origin Lab's Originb 2021 software. For normally distributed variables, t-test or ANOVA with Tukey HSD was used and P values<0.05 were considered significant. For OPLS-DA, values from two-tailed Student's t-tests were applied on the normalized peak areas; metabolites with VIP values>1 and P values<0.05 were included. The Euclidean distance and Ward's method were used to analyze the heat map. The mean and variance were normalized so that the mean is 0 and the variance is 1.

Results:

There were no significant differences in mean body weights at any day during the treatment period between the control group and the other treatment groups. There were no significant differences in mean body weights on the day of sacrifice between the treatment groups.

Gut Microbiome Analysis:

With regard to the taxonomic profiling, firmicutes represented the most abundant phyla followed by Bacteroidetes (FIG. 1)

When individual taxa were analysed in each of the beta glucan groups comparing it to Telmisartan (standard), decrease in enterobacteria was highest in AFO-202 group (FIG. 2A). Decrease in Decrease in Firmicutes was highest in AFO-202 group (FIG. 2B).

Fecal Metabolome Analysis:

The resulting score plot of the principal component analysis using the normalized peak heights of the 10 samples (Pre- and post intervention of five groups), is shown in FIG. 3. The contribution of the first principal component was 55%, and that of the second principal component was 20%. Principal component analysis of post-intervention samples using the peak heights after normalization and the obtained score plot is shown in FIGS. 4A and 4C and the loading plot in FIGS. 4B and 4D. The contribution of the first principal component was 49% and that of the second principal component was 34%.

Peak height of all the detected metabolite compounds after normalization is available in Table 3. The values which showed decrease post-intervention are highlighted in bold in the different groups. The number of peaks detected in the QC samples was 108, of which 53 peaks were qualitatively determined and 55 peaks were unknown.

Differential abundance analysis, log 2 fold change results are shown in FIG. 5.

TABLE 3
Peak height of all the detected metabolite compounds after normalization
	Name	Gr. 1 Control	Gr. 2-AFO-202	Telmisartan
S.	of the			Differ-			Differ-			Differ-
No	Compound	Pre	Post	ence	Pre	Post	ence	Pre	Post	ence
1	2-Aminobutyric	16544.74	40209.97	23665.23	23704.19	27627.27	3 23.08	2 46.06	43700.57	17954.52
	acid-2TMS
2	2-Hydroxyisobutyric	36888.72	145407.17	108518.45	38444.81	146808.33	108363.52	2.36	170732.7	133880.36
	acid-2TMS
3	3-Aminoglutaric	2064.63	11599.10	9534.47	2674.96	8297.81	5622.84	3808.51	12436.04	8627.53
	acid-3TMS
4	3-Hydroxybutyric	78693.42	32663.28	−46030.14	49425.90	15869.18	−33556.73	15499.52	10891.34	−4608.17
	acid-2TMS
5	3-Methyl-	2494.33	15765.26	13270.93	5771.05	12154.53	6383.48	7152.49	12393.37	5240.87
	2-oxo leric
	acid- -TMS
6	4-Hydroxyphenyl	71212.24	90389.17	1 176.93	38406.22	61406.93	23000.73	36067.25	4	3815.29
	acid-2TMS
7	5-Aminovaleric	359981.32	177455.86	−182525.46	28606.18	220398.9	191792	28517.91	2 2458.93	26394.02
	acid-3TMS
8	5-Oxoproline-	86202.33	183221.07	97018.7	101052.25	142117.70	41065.45	113169.35	.94	.59
	2TMS
9	Acetylglycine-	622 .84	.14	16600.30	62217.0	75225.0	13007.93	.14	.2	2
	TMS
10	Alanine-2TMS	462486.71	9 2281.83	469795.13	575514.07	709299.17	133785.10	544032.	1268525.27	724492. 0
11	Asparag -	50264.14	47387.02	−2877.12	52065.54	39742.05	−12323.49	.79	68357.	10864.48
	3TMS
12	Aspartic	122316.67	309390.39	187073.73	168305.85	250489.61	82183.75	183416.60	4 .75	2 17.15
	acid-3TMS
13	Fructose- -		999935.86	−726073.07	323320.36	936708.26	613387.90	325202.45	111093 .22	7857 .77
	5TMS
14		36824.30	44185.98	7361.68	57488.33	33927.51	−23560. 3	.59	24027.13	−65 28.4
	4TMS
15	Galactose- -	92513.44	457335.67	822.23	177745.54	661315.76	48 .22	359608.12	.00	−170827.12
	5TMS
16	Glucose- -	299911.54	17403 .37	1440487.83	842456.89	996893.55	154436.66	400546.16	55701.34
	5TMS
17	Glutamic	197256.75	658386.79	461130.05	264245.78	515323.80	251078.03	61041.65	74375 .06	382709.41
	acid-3TMS
18	Glutamine-	60900.94	73851.25	12950.31	45289.87	46071.10	781.23	4 99.14	7 644.26	30745.13
	3TMS
19	Glycerol-	100045.16	5 2115.32	412070.17	193048.44	332266.23	139217.82	283873.86	324467.91	405
	3TMS
20	Glycine-	17 941.04	19 667.24	14726.20	182268.66	182802.22	533.56	179124. 5	288456.14	109331.29
	3TMS
21	Hypoxanthine-	1820 .77	73610.39	554 0.63	25970.42	54650.62	28680.21	33144.25	5 .97	23680.72
	2TMS
22	I -	20341.44	29963.22	9621.79	27134.0	52940.46	25806.38	24548.88	37226.82	12677.9
	4TMS
23	Isoleucine-	240751.6	255 .87	14928.19	213617.13	18 .81	−28538.33	175687.57	381173.16	205
	2TMS
24	Lactic acid-	126966.77	174366.10	43399.33	161320.99	112769.78	−48551.21	71969.33	36363.66	−35605.88
	2TMS
25	Leucine-	405177.22	48496	79792.64	381285.89	366743.37	−14542.52	364222. 0	631954.96	267732.46
	2TMS
26	Lysine-	453167.29	1042910.27	589742.	578069.33	771280.17	193210.94	592034.86	952876.14	360841.28
	4TMS
27	Malic acid-	15431.92	50833.82	35401.90	18557.13	136072.04	117514.91	54899.38	38544.73	−16354.66
	3TMS
28	Mannose- -	46604.74	101647.05	55042.30	58090.57	125118.62	67028.06	79951.11	65364.10	−14587.00
	3TMS
29	Methionine-	72809.85	128516. 4	55706.	84612.94	90620.	6007.93	103825.98	168797.44	6 1.46
	2TMS
30	N-Acetyl -	51349.02	194543.7	143194.68	95958.86	210636.96	114678.10	207515.87	90678.54	−116837.33
	4TMS
31	Nicot	8270.	31967.10	23696.54	12163.20	23936.48	11773.28	1835 .32	23826.50	5467.18
	acid-TMS
32	Norvaline-	4923.32	100191.34	5268.03	82912.31	73583.61	−9328.70	72621.50	110365.67	37744.18
	TMS
33	thine-	45698.47	101711.56	56013.10	40654.29	52324.86	11670.57	44496.80	62226.84	17730.04
	4TMS
34	Phenylalamine-	173673.02	290028.18	116355.17	186230.03	228284.46	42048.43	208441.78	342996.16	134 4.38
	2TMS
35	Phosphoric	13703.35	692470.05	678766.	467.68	765279.47	709811.79	107073.44	122301.92	15228.48
	acid-3TMS
36	Proline-	57195.44	92021.21	34825.77	77037.72	103324.97	26287.25	6.02	151136.53	52750.51
	2TMS
37	P -	90940.03	4806.17	−86133.86	30410.15	5030.93	−25379.22	21749.	6122.	−15626.91
	4TMS
38	Pyruvic	31557.87	108630.32	77072.65	40255.26	105996.98	65741.72	41703.69	116493.60	74789.91
	acid- -TMS
39	Ribo	90115.51	64726.74	−25388.76	85151.16	66560.71	−18390.46	95701.95	64707.65	−30994.30
	acid-5TMS
40	Rib -	199285.35	806414.91	607129.56	321848.24	706173.47	384325.23	510635.39	6996 0.70	189015.32
	4TMS
41	#Sz,899;-	134100.10	150072.29	15972. 9	134521.62	135009.56	487.94	124526.34	206603. 4	820 .40
	3TMS
42	Spe -	11571. 9	14335.92	2 64.13	8257.93	7462.86	−795.07	9612. 4	8122.10	−1490.65
	3TMS
43	Succinic	200720.47	75253.68	−125466.79	32921.32	139 291.07	1365369.7	263097.91	13904.61	50806.69
	acid-2TMS
44	Taurine-	15049.13	66033.11	50983.98	14685.18	46705.91	32020.73	14857.44	24726.77	9869.33
	3TMS
45	T nine-	137361.71	175385.78	38024.08	137475.15	135608.93	−1866.22	122185.79	240869.77	118683.98
	3TMS
46	Thy -	5319.57	16561.64	11242.07	6636.79	13272.69	6635.90	12893.64	7133.20	−5760.44
	2TMS
47	Tryptophan-	21044.89	2089 .79	−149.10	17365.35	18254.73	889.38	16169.30	28678.00	12 08.70
	3TMS
48	Tyrosine-	273469.68	438287.99	164818.32	293828.48	51487.07	576 8.59	309190.46	42582 .94	116635.49
	3TMS
49	Uracil-	25078.62	92837.69	67759.07	44546.07	84845.85	40299.79	74843.38	71567.16	−3276.22
	2TMS
50	Valine-	353165.15	405846.51	52681.36	290698.34	255449.25	−35249. 8	254032.97	521841.20	267808.23
	2TMS
51	Xanthine-	53777.98	130586.54	76808.56	79540.73	113793.80	34253.08	101684.60	103194.40	1 09.80
	3TMS
52	Xylose- -	174559.36	290187.08	115627.72	186404.46	228374.90	41970.44	208 74.29	343176.94	134602.65
	4TMS
indicates data missing or illegible when filed

Score plots of PCA and compounds with a VIP value of 1 or higher in the OPLS-DA are shown in FIG. 6 and Table 4 shows the compounds with a VIP value of 1 or higher and their Coefficients in OPLS-DA. The results of the principal component analysis of the control group showed that the contribution of the first principal component axis (PC1) was 96.7% and that of the second principal component axis (PC2) was 1.5%. In AFO-202 group, PCA showed that PC1 and PC2 contributed 90.4% and 4.9%, respectively. In the Telmisartan group, PC1 and PC2 contributed 95.1% and 1.9%, respectively.

TABLE 4
Coefficients of Metabolite compounds with a VIP value
of 1 or higher in OPLS-DA in the different groups
	Coefficients
No.	Metabolites	Control	AFO-202	Telmisartan
1	Glucose-meto-5TMS	−0.000108	−0.000091	−0.000139
2	Fructose-meto-5TMS	0.000133	−0.000173	−0.000209
3	Phosphoric acid-3TMS	−0.000125
4	Ribose-meto-4TMS	−0.000116	−0.000132	−0.000083
5	Lysine-4TMS	−0.000116	−0.000083	−0.000120
6	Alamine-2TMS	−0.000109	−0.000003	−0.000171
7	Glutamic acid-3TMS	−0.000100	−0.000101	−0.000149
8	Glycero-3TMS	−0.000102	−0.000080
9	Galactose-meto-5TMS	−0.000092	−0.000144	0.000094
10	Aspartic acid-3TMS	−0.000063	−0.000061	−0.000113
11	5-Aminovaleric acid-3TMS	0.000069	−0.000103	−0.000123
12	Tyrosine-3TMS	−0.000064		−0.000043
13	N-Acetylmannosamine-meto-4TMS	−0.000055	−0.000068
14	Succinic acid-2TMS	0.000059	−0.000259
15	Phenylalanine-2TMS	−0.000049		−0.000087
16	Xylose-meto-4TMS	−0.000048		−0.000087
17	2-Hydroxyisobutyric acid-2TMS	−0.000054	−0.000072	−0.000072
18	5-Oxoproline-2TMS	−0.000043
19	Phosphoric acid-3TMS		−0.000197
20	Malic acid-3TMS		−0.000077
21	Mannose-meto-5TMS		−0.000057
22	Pyruvic acid-meto-TMS		−0.000065	−0.000046
23	Lactic acid-2TMS
24	Valine-2TMS			−0.000075
25	Leucine-2TMS			−0.000087
26	Isoleucine-2TMS			−0.000083
27	Threonine-3TMS			−0.000080
28	Glycine-3TMS			−0.000058
29	5-Oxoproline-2TMS			−0.000064
30	Serine-3TMS			−0.000065

In all the groups except telmisartan, phosphoric acid shoed the highest log 2 fold change in terms of increase. Putrescine showed the highest decrease. In regard to specific compounds, increase in succinic acid was highest in AFO-202 (P-value=0.06) with statistical significance (FIG. 7A). Increase in phosphoric acid was also high in AFO-202 (FIG. 7B), though not significant (p-value=0.21). Decrease in fructose was highest in AFO-202 (FIG. 7C) (p-value=0.0007). Euclidean distance hierarchical clustering analysis demonstrating the different intensity levels of characteristic metabolites also matched the above observations (FIG. 8 and FIG. 9)

Discussion:

This is the first study to investigate profiles of fecal gut microbiome and metabolome in a NASH model of mice with relevance to beta glucans specially so for two different beta glucans produced by different strains of same species of black yeast A. pullulans. Beta glucans are obtained from different sources and the functionality depends on the source and extraction/purification processes [D14]. The beta glucans described in the study from AFO-202 strain of the A. pullulans black yeast are unique as they are produced as an exopolysaccharide without the need for extraction/purification and hence the biological actions are superior [D15].

The AFO-202 beta glucan has been reported to have superior metabolic benefits by regularization of blood glucose levels [D5] apart from immune enhancement in immune-infectious illnesses such as COVID-19 [D11,12] and has been reported to produce positive effects on melatonin and alpha-synuclein neurotransmitters apart from improving sleep and behaviour in neurodevelopmental disorders such as ASD [D7,8]. In the NASH animal study, AFO-202 beta glucan has been able to significantly decrease inflammation-associated hepatic cell ballooning and steatosis [D10].

The N-163 beta glucan has been able to produce immune-modulatory benefits in terms of regulating dyslipidaemia evident from balance of the levels of non-esterified fatty acids [D16] and decrease in fibrosis and inflammation in NASH [D10]. The combination of AFO-202 and N-163 beta glucans has been able to decrease in pro-inflammatory markers and increase in anti-inflammatory markers in an advantageous manner in healthy human volunteers [D17], decrease the NAFLD Activity Score (NAS) in the NASH model [D10] and significantly control of immune-mediated dysregulated levels of IL-6, CRP and Ferritin in Covid-19 patients [D11,12]. In the study done on gut microbiome analysis in ASD subjects, there was efficient control of enterobacteria apart from beneficial reconstitution of the gut microbiome favourable for producing benefits in ASD by AFO-202 beta glucan [D13]. In the current study, we sought to evaluate the benefits of AFO-202 and N-163 individually and in combination in the NASH animal model.

The STAM model of NASH used in the study is a disease model, the Stelic Animal model [D10,18,19], in which mice are allowed to develop liver steatosis by injection streptozotocin solution 2 days after birth and fed with a high-fat diet. This model recapitulates most of the features of metabolic syndrome which occurs in humans wherein obesity and a high fat diet gives rise to diabetes, dyslipidaemia and liver steatosis.

Therefore, the gut microbiome profiles and fecal metabolite profiles that are present at baseline can be considered to recapitulate that which is present in metabolic syndrome [D20,21] which over time will produce pathophysiological problems in different organ systems of the body including the heart, liver, kidney apart from immune-metabolic interactions leading to a declined immune system with aging and its associated complications.

Therefore, the present study will serve as a forerunner to study the effects of the beta glucans on different aspects of metabolic syndrome associated pathologies as well as conditions associated with immune-metabolic interactions including neurological disorders in which such immune-metabolic interactions have profound implications [D20].

Relevance of Metabolome and Microbiome to NASH:

An abundance of bacterial species, such as Proteobacteria, Enterobacteria, and Escherichia coli has been reported in humans with NAFLD[D21, 22]. In the current study, a decrease in Enterobacteria with AFO-202 was reported.

Potentials in Neurological Illnesses:

Neurodevelopmental and Neurodegenerative:

We have earlier reported the decrease in Enterobacteria, Escherichia coli, Akkermansia muciniphila CAG:154, Blautia spp., Coprobacillus sp., and Clostridium bolteae CAG:59, with an increase of Faecalibacterium prausnitzii and Prevotella copri after AFO-202 consumption in children with ASD [D13]. In the present study as well, the decrease in enterobacteria was highest in AFO-202 group (FIG. 5A). Succinic acid which has been reported to be lower in ASD individuals [D23] was found to increase the highest in AFO-202 group (FIGS. 7A-C). In regard to neurodegenerative diseases such as Parkinson's disease, amino acids such as isoleucine, and leucine have been found to be higher in the fecal metabolome [D24]. In the present study, decrease in these amino acids were highest in the AFO-202 group (FIGS. 7D-E).

Other Implications:

Use of Steroids has been reported to cause increase in E-Coli, enterococcus while decrease in Bacteroides [D25]. In the current study, the control of enterobacteria with increase in Bacteroides by AFO-202 make it worthy adjuncts for medications such as steroids as well.

Conclusion:

In summary, black yeast A. pullulans' strain AFO-202 produced beta glucans increase the gut microbial diversity, control the harmful bacteria, promote healthy ones apart from producing beneficial differences in fecal metabolites, all indicative of a healthy profile both individually and in combination in this NASH animal model. AFO-202 will serve as a worthy treatment adjunct for neurodevelopmental conditions such as ASD and neurodegenerative conditions such as PD. With further validation on the correlation between gut microbiome and fecal metabolites in specific conditions, these safety proven prebiotics have potential applications in promoting a healthy life.

Increasing Gut Microbiota

There is increasing evidence that gut dysbiosis plays a critical role in the development and progression of several neurodevelopmental conditions such as autism spectrum disorders (ASD), neuroinflammatory conditions such as multiple sclerosis (MS) and neurodegenerative diseases such as Alzheimers (AD) and Parkinson's disease (PD). The biofilms and byproducts of the bacteria especially the Gram-negative enteric bacteria mediate the effects of the altered gut microbiome in these disease conditions. Amyloid proteins constitute the major part of the biofilms especially the Curli amyloid whose characteristics have been reported to be similar to pathological and immunomodulatory human amyloids such as Alzheimer's disease associated amyloid-β, ASD and PD associated α-synuclein [A1].

Though these reports discuss on the correlation of the levels of these amyloids, enteric bacteria and the neural diseases, there has been no simple and safe intervention with subjective and objective correlation to a clinical benefit associated by altering the gut microbiota to a beneficial advantage. We herein report the outcome of beneficial reconstitution of gut microbiota especially those of the bacteria which are associated with Alpha synuclein and Curli amyloids after consumption of Beta 1,3-1,6 Glucans in children with autism spectrum disorder in a clinical pilot study.

The emerging evidence of constant communication and interaction between the gut and the brain through the gut-brain axis has begun to unravel its significance associated with the health of the central nervous system. Any dysbiosis of the gut microbiota has been shown to influence the development and progression of neurological pathologies of developmental (autism spectrum disorder [ASD]), inflammatory (multiple sclerosis [MS]), and degenerative (Alzheimer's disease [AD] and Parkinson's disease [PD]) disorders (Kang et al., 2019). The mechanisms involve activation of the immune system; production of inflammatory cytokines and chemokines (e.g., IL-6 and TNF-α); and alteration of the gut barrier permeability, which in turn is due to the increased levels of circulating lipopolysaccharide in these neurological disorders. These mechanisms modulate the neurotrophic factors, activity of the central and peripheral nervous system, and the endocrine pathways, all of which contribute to the onset or the phenotypic expression of neuropsychiatric and neurodevelopmental disorders (Santocchi et al., 2020).

Another important player is the amyloid protein, which has self-aggregation properties. Even non-identical amyloid proteins can accelerate reciprocal amyloid aggregation in a prion-like fashion. Nearly 30 amyloidogenic proteins are encoded by humans, whereas some functional amyloids are produced by the gut microbiome (Werner et al., 2020). Of importance are cell-surface amyloid proteins called curli, which are produced by certain enterobacteria that in turn accelerate formation of α-synuclein (αSyn), which is a presynaptic neurotransmitter that is crucial in the initiation and pathogenesis of neurological disorders such as ASD, PD, AD, and MS (Sampson et al., 2020). Though these reports (Sampson et al., 2020; Werner et al., 2020; Santocchi et al., 2020) discuss the correlation of the levels of these amyloids, enteric bacteria, and neural diseases, there has been no simple and safe intervention with subjective and objective correlation to a clinical benefit that can be derived based on an associated balancing of the gut microbiota.

We herein report the outcome of beneficial reconstitution of gut microbiota, especially those of the bacteria associated with αSyn and curli amyloids after consumption of beta 1,3-1,6 glucans in children with ASD in a clinical pilot study. The beta-glucan studied (Nichi Glucan) was obtained from the AFO-202 strain of a black yeast called Aureobasidium pullulans that has beneficial advantages in metabolic disorders by alleviating glucotoxicity (Dedeepiya et al., 2012), lipotoxicity (Ganesh et al., 2014; Ikewaki et al., 2021^a), lipidemia-induced hepatic fibrosis (Ikewaki et al., 2021^b), inflammation (Ikewaki et al., 2021^b) apart from immune-enhancement (Ikewaki et al., 2021^c), and modulation in COVID-19 (Raghavan et al., 2022), which have been reported in translational and clinical studies.

The effects of this AFO-202 beta glucan in terms of behavioural (Raghavan et al., 2021a) and sleep pattern improvement (Raghavan et al., 2021^b), increase in levels of plasma αSyn (Raghavan et al., 2021^a), and serum melatonin (Raghavan et al., 2021^b) levels in children with ASD has been reported. We report the effects of AFO-202 beta glucan on the gut microbiome in children with ASD who participated in our pilot study.

The beta-glucan studied (Nichi Glucan) was obtained from the AFO-202 strain of a black yeast called Aureobasidium pullulans that has beneficial advantages in metabolic disorders by alleviating glucotoxicity [B5], lipotoxicity [B6, B7], lipidemia-induced hepatic fibrosis [B8], inflammation [B8] apart from immune-enhancement [B9], and modulation in COVID-19 [B10], which have been reported in translational and clinical studies. The effects of this AFO-202 beta glucan in terms of behavioural [E11] and sleep pattern improvement [B12], increase in levels of plasma αSyn [E11], and serum melatonin [B12] levels in children with ASD has been reported. We report the effects of AFO-202 beta glucan on the gut microbiome in children with ASD who participated in our pilot study.

In this randomized pilot clinical study, we have evaluated the gut microbiota of subjects with autism spectrum disorder (ASD) after consumption of Aureobasidium pullulans (black yeast) AFO-202 strain-produced beta glucan, Nichi Glucan.

Example 1

Methods:

The study was conducted in 18 subjects who were randomly allocated; six subjects (n=6) to the control group (Gr.1) who underwent conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day, and twelve subjects (n=12) Gr. 2 underwent supplementation with an Aureobasidium black yeast AFO-202 (Aureobasidium pullulans strain AFO-202 (also referred to as FO-68 [accession number: FERM BP-19327])) derived beta glucan, Nichi Glucan 0.5 g twice daily along with the conventional treatment. Stool samples from the subjects was collected at baseline and after the intervention. The samples were sequenced using Novaseq 6000 with a read length of 151 bp and taken for whole genome metagenome analysis.

Thirteen subjects (four in control (Gr.1) and nine in Nichi Glucan (Gr.2) completed the study. The sample reads were filtered for human DNA contamination. The alignment to the human genome was around 18.98%. The filtered reads were then aligned to bacterial, fungal, viral and archea genomes. The overall alignment to the bacterial genome was around 40%. However, the alignment to the viral, fungi and archea genomes was around 0.05-0.2%. De novo assembly was carried out using the pre-processed reads to obtain the scaffolds. These scaffolds were then used for gene prediction. Bacterial abundance was analysed.

Results:

The abundance of Enterobacter was decreased almost to nil in the Nichi Glucan (Gr.2) group after intervention while it increased from 0.36% to 0.85% in the control group (FIG. 10). The abundance of Bacteroides increased from 16.84 to 19.09% in the control while it decreased from 11.60 to 11.43% in the Gr. 2 (FIG. 11) after intervention. The abundance of Prevotella increased in both Gr.1 and Gr.2 (FIG. 12). The decrease in abundance of Lactobacillus was significant in Gr.2 compared to Gr. 1 (FIG. 13).

Conclusion:

Earlier reports have indicated a lower abundance of Prevotella, higher abundance of Lactobacillus and Bacteroides in children with autism spectrum disorders [A2]. MS patients also have been reported to have a lower abundance of Prevotella [A4]. Enterobacter produce functional amyloid proteins termed curli which promotes human amyloid α-synuclein (αSyn) pathology and the aggregation of curli and αSyn stimulates pathological and immunological processes that lead to the neurodevelopmental and neurodegenerative diseases such as ASD, MS, PD and AD [A1]. The results of this study which have produced favorable results after Nichi Glucan consumption in the gut microbiota by alleviate the pathological processes behind such neurodevelopmental and neurodegenerative diseases involving amyloid accumulations warrant larger clinical studies to recommend this as a routine food supplement in patients with neurodegenerative and neuroinflammatory conditions apart from research to explore their mechanisms and further potentials.

Example 2

Methods:

Eighteen subjects with ASD were randomly allocated: six subjects in the control group (Group 1): conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day, and 12 subjects (Group 2) underwent supplementation with Nichi Glucan 0.5 g twice daily along with the conventional treatment for 90 days.

Results:

Whole genome metagenome (WGM) sequencing of the stool samples at baseline and after intervention, showed that among genera of relevance, the abundance of Enterobacteria was decreased almost to zero in Group 2 after intervention, whereas it increased from 0.36% to 0.85% in Group 1. The abundance of Bacteroides increased in Group 1, whereas it decreased % in Group 2. The abundance of Prevotella increased in both Group 1 and Group 2. The decrease in abundance of Lactobacillus was significant in Group 2 compared to Group 1. Among species, a decrease was seen in Escherichia coli, Akkermansia muciniphila CAG:154, Blautia spp., Coprobacillus sp., and Clostridium bolteae CAG:59, with an increase of Faecalibacterium prausnitzii and Prevotella copri, which are both beneficial.

Conclusion:

AFO-202 beta 1,3-1,6 glucan apart from balancing the gut microbiome in children with ASD, its role in effective control of curli-producing enterobacteria that leads to α-synuclein (αSyn) misfolding and accumulation, may have a prophylactic role in Parkinson's and Alzheimer's diseases as well.

Trial Registration:

The study was registered in India's clinical trial registry CTRI, Ref no:

• • CTRI/2020/10/028322. URL:
  • http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=47623&EncHid=&userName=ken max.

Example 3

Methods:

This study was approved by the institutional ethics committee of the hospital in which the study took place and was registered as a clinical trial in the national clinical trial registry. The caregivers of each subject gave their informed consent for inclusion before participation in the study. The study was conducted in accordance with the Declaration of Helsinki.

Patient Involvement:

Patients were involved in the design and conduct of this research. During the feasibility stage, priority of the research question, choice of outcome measures, and methods of recruitment were informed by discussions with patients through a focus group session and structured interviews. Once the trial has been published, participants will be informed of the results through a study newsletter suitable for a non-specialist audience.

Study Design

The subjects enrolled in the study had received a diagnosis of ASD from a developmental pediatrician, which was verified by a psychologist using a clinical interview for a behavioural pattern that incorporated the Childhood Autism Rating Scale score.

Eighteen subjects with ASD were enrolled in this prospective, open-label, pilot clinical trial comprised of two arms. The CONSORT flow diagram is presented in FIG. 14.

Study Groups

Arm 1 or Group 1 (control group): Six subjects with ASD underwent conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day.

Arm 2 or Group 2 (Nichi Glucan group): 12 subjects underwent supplementation with Nichi Glucan food supplement along with conventional treatment (remedial behavioural therapies and L-carnosine 500 mg per day). Each subject consumed two sachets (0.5 g each) of Nichi Glucan daily—one sachet with a meal twice daily—for 90 days.

The inclusion and exclusion criteria along with the assessment of behavioural and sleep pattern apart from evaluation of levels of αSyn and melatonin are available in the results of the clinical trial reported earlier (Raghavan et al., 2021^a,b)

Faecal Sample Collection and Preparation

Faecal samples were collected at baseline and 90 days after the intervention using a sterile faecal collection kit and the samples were kept at −20° C. until they were transferred to the laboratory and processed. Samples for DNA extraction were stored at −80° C. until needed for analysis.

DNA Extraction

Total microbial DNA was extracted from faeces of each specimen using the QIAAmp DNA Mini Kit (Qiagen) according to manufacturer's instructions. Each batch of specimens were extracted with negative buffer control (extraction control).

Library Preparation

Whole-genome metagenome sequencing libraries were prepared. In brief, the DNA was sheared using a Covaris ultrasonicator. Sheared DNA was subjected to a sequence of enzymatic steps for repairing the ends and tailing with dA by ligation of indexed adapter sequences. These adapter-ligated fragments were then cleaned up using SPRI beads. Next, the clean fragments are indexed using limited cycle PCR to enrich the adapter-ligated molecules. Finally, the amplified products were purified and checked before sequencing.

Metagenome Sequencing

Prepared libraries were sequenced using Novaseq 6000 with a read length of 151 bp. The samples were taken for whole genome metagenome analysis. Initially, the reads were filtered for human DNA contamination (FIGS. 15-17). The alignment to the human genome was around 18.98%. The filtered reads were then aligned to bacterial, fungal, viral, and archea genomes (FIG. 18). The overall alignment to the bacterial genome was around 40%. However, the alignment to the viral, fungi, and archaea genomes was around 0.05-0.2%. De novo assembly was carried out using the preprocessed reads to obtain the scaffolds, which were then used for gene prediction. The abundances at the phylum, genus, and species level were evaluated.

Microbiome Bioinformatics

The following bioinformatics pipeline was used to perform whole-genome-sequencing metagenomic analysis. The quality of the raw data was analysed and the adapters were trimmed. The low-processed reads were first aligned to human genome to remove unaligned reads that were then assembled using METASPADES de novo assembler for metagenomics. After assembly, the gene prediction was performed using PRODIGAL. The predicted genes were then searched against existing genes in the NCBI database using the DIAMOND MEGAN5 program. The occurrence of dominant microbial population was studied at various levels (phylum, class, order, family, and genus) based on the taxonomic abundance in the given samples. The dominance was calculated based on the amount of sequence obtained from samples, community composition, and the contig size distribution. Chimeric sequences were identified and filtered from the analysis.

Statistical Analysis

Statistical data were analysed using Microsoft Excel statistics package analysis software. Paired t tests were also calculated using this package, and P values<0.05 were considered significant.

Results

Eighteen patients who fulfilled all the selection criteria and none of the exclusion criteria were selected to begin the study. During enrolment, one participant in the treatment group (Group 2) dropped out before the study began. During the study, four subjects were lost to follow-up: two in Group 1 (one dropped out due to social problems in the family, and the other relocated to another city) and two in Group 2 (one dropped out due to social problems in the family, and the other relocated to another city). After excluding these four subjects, 13 subjects were included in the analysis.

The pre-processed reads were first aligned with the human genome (hg19) using BWA-MEM aligner to remove human genome contamination from the samples. The uncontaminated sequences were then taken for further alignment with known bacteria, fungi, virus, and archaea bacteria genomes using BWA MEM aligner. Around 7-12% of the reads mapped to the human genome, and the bacterial genome with 30-60% mapped reads.

Regarding the SEED average, there was several fold decrease in all the gene annotations (metabolites and metabolic functions) in the AFO-202 Nichi Glucan treatment group including Carbohydrates, Fatty acids, lipids, virulence, metabolite damage and nitrogen metabolism (FIG. 19 and Table 5).

Bacterial kingdom was the most abundant organism type one. In both Group 1 (control) and Group 2 (Nichi Glucan), both before and after intervention, phylum Firmicutes was the most abundant followed by Bacteroidetes (FIG. 20). Although in Group 1 Proteobacteria was the next most abundant followed by Actinobacteria, this relationship was reversed in Group 2 (FIG. 21).

Among the genera of relevance, the abundance of Enterobacter was decreased to almost zero in Group 2 after intervention, while it increased from 0.36% to 0.85% in Group 1 (FIG. 22A). The abundance of Bacteroides increased from 16.84% to 19.09% (p-value=0.42) in Group 1, while it showed little significant difference (11.60% and 11.43%) (p value=0.46) (FIG. 22B) after intervention. The abundance of Prevotella increased in both Group 1 and Group 2 (FIG. 22C). The decrease in abundance of Lactobacillus was significant in Group 2 compared to Group 1 (FIG. 22D). Desulfovibrio decreased from 0.40% to 0.28% in Gr.2. Species abundance increased in Group 2 after intervention. Faecalibacterium prausnitzii, Bifidobacterium longum, and Firmicutes bacterium CAG:124 represented the most abundant species (FIG. 23 and FIG. 24). Escherichia coli decreased in both Group 1 and Group 2 but the difference was significant in Group 2 (p-value=0.02) (FIG. 25A). Faecalibacterium prausnitzii increased in both Group 1 and Group 2 but the difference was significant in Group 2 (p-value=0.041) (FIG. 25B). Akkermansia muciniphila CAG:154 (FIG. 25C) and Clostridium bolteae CAG:59 increased in the Group 1, whereas it decreased in Group 2 (FIG. 25D). Prevotella copri increased in both the groups. Blautia spp., Coprobacillus sp., and several Clostridium spp. decreased in both the groups.

The data of the genus and species level abundance in Gr. 1 and Gr. 2 are presented in Tables 5-9.

TABLE 5
Genus level: Mean and percentage abundance as baseline
and post-intervention in Gr. 1 (Control)
		Percentage
	Mean abundance	of abundance
			Post-		Post-
S.			Inter-		Inter-
No	Genus	Baseline	vention	Baseline	vention
1	Bacteroides	16395	16956	16.84	19.09
2	Prevotella	2019	7252	2.07	8.16
3	Clostridium	6277	5792	6.45	6.52
4	Faecalibacterium	4646	5398	4.77	6.08
5	Bifidobacterium	7375	4809	7.58	5.41
6	Blautia	6123	4175	6.29	4.70
7	Roseburia	3257	3564	3.35	4.01
8	Eubacterium	2268	3016	2.33	3.40
9	Ruminococcus	3484	2066	3.58	2.33
10	Lachnoclostridium	1289	1682	1.32	1.89
11	Hungatella	66	1381	0.07	1.55
12	Dialister	983	1380	1.01	1.55
13	Klebsiella	1121	1357	1.15	1.53
14	Alistipes	3487	1352	2.55	1.52
15	Enterococcus	4721	1270	4.85	1.43
16	Veillonella	0	1244	0.00	1.40
17	Akkermansia	827	1126	0.85	1.27
18	Streptococcus	384	1093	0.39	1.23
19	Megasphaera	64	1084	0.07	1.22
20	Anaerostipes	393	1020	0.40	1.15
21	Parabacteroides	1686	971	1.73	1.09
22	Lactobacillus	1857	956	1.91	1.08
23	Coprococcus	897	915	0.92	1.03
24	Dorea	1352	862	1.39	0.97
25	Butyricicoccus	1339	815	1.38	0.94
26	Flavonifractor	669	823	0.69	0.93
27	Escherichia	1062	822	1.09	0.92
28	Odoribacter	1036	803	1.06	0.90
29	Enterobacter	355	757	0.36	0.85
30	Subdoligranulum	802	597	0.82	0.67
31	Oscillibacter	699	569	0.72	0.64
32	Bilophila	0	552	0.00	0.62
33	Eggerthella	829	548	0.85	0.62
34	Collinsella	1617	541	1.66	0.61
35	Turicibacter	0	415	0.00	0.47
36	Mitsuokella	0	409	0.00	0.46
37	Catenibacterium	540	403	0.55	0.45
38	Fusicatenibacter	434	392	0.45	0.44
39	Romboutsia	206	357	0.21	0.40
40	Haemophilus	88	346	0.09	0.39
41	Gemmiger	524	343	0.54	0.39
42	Sutterella	139	301	0.14	0.34
43	Lachnospira	0	294	0.00	0.33
44	Mycoplasma	292	251	0.30	0.28
45	Holdemanella	585	199	0.60	0.22
46	Parasutterella	0	197	0.00	0.22
47	Weissella	173	177	0.18	0.20
48	Ruminiclostridium	174	148	0.18	0.17
49	Chlamydia	133	147	0.14	0.16
50	Dakarella	97	147	0.10	0.16
51	Lactococcus	144	144	0.15	0.16
52	Clostridioides	107	126	0.11	0.14
53	Terrisporobacter	0	123	0.00	0.14
54	Coprobacillus	224	114	0.23	0.13
55	Adlercreutzia	405	101	0.42	0.11
56	Butyrivibrio	121	90	0.12	0.10
57	Anaerotruncus	135	81	0.14	0.09
58	Bacillus	262	69	0.27	0.08
59	Agathobaculum	54	67	0.05	0.08
60	Shigella	53	60	0.05	0.07
61	Tyzzerella	13	59	0.01	0.07
62	Oribacterium	145	52	0.15	0.06
63	Intestinimonas	91	50	0.09	0.06
64	Citrobacter	0	49	0.00	0.06
65	Fusobacterium	0	46	0.00	0.05
66	Acholeplasma	0	41	0.00	0.05
67	Pseudoflavonifractor	68	40	0.07	0.05
68	Raoultella	0	32	0.00	0.04
69	Muribaculum	0	31	0.00	0.03
70	Acidiphilium	27	29	0.03	0.03
71	Paenibacillus	110	28	0.11	0.03
72	Acidaminococcus	0	25	0.00	0.03
73	Salmonella	0	22	0.00	0.03
74	Anaeromassilibacillus	179	22	0.18	0.02
75	Pantoea	0	21	0.00	0.02
76	Intestinibacter	0	21	0.00	0.02
77	Eisenbergiella	85	20	0.09	0.02
78	Prevotellamassilia	0	20	0.00	0.02
79	Anaerotignum	0	17	0.00	0.02
80	Selenomonas	0	16	0.00	0.02
81	Actinomyces	0	16	0.00	0.02
82	Paraprevotella	26	10	0.03	0.01
83	Porphyromonas	0	9	0.00	0.01
84	Barnesiella	129	0	0.13	0.00
85	Anaerococcus	141	0	0.14	0.00
86	Stenotrophomonas	13	0	0.01	0.00
87	Finegoldia	82	0	0.08	0.00
88	Pediococcus	10	0	0.01	0.00
89	Solobacterium	27	0	0.03	0.00
90	Peptoniphilus	929	0	0.95	0.00
91	Urinacoccus	144	0	0.15	0.00
92	Enterorhabdus	46	0	0.05	0.00
93	Slackia	69	0	0.07	0.00
94	Achromobacter	59	0	0.06	0.00
95	Lysinibacillus	1130	0	1.16	0.00
96	Olsenella	192	0	0.20	0.00
97	Comamonas	131	0	0.13	0.00
98	Ruthenibacterium	63	0	0.06	0.00
99	Viridibacillus	40	0	0.04	0.00
100	Rummeliibacillus	603	0	0.62	0.00
101	Gordonibacter	735	0	0.75	0.00
102	Drancourtella	19	0	0.02	0.00
103	Monoglobus	24	0	0.02	0.00
104	Lagierella	39	0	0.04	0.00
105	Peptococcus	27	0	0.03	0.00
106	Senegalimassilia	122	0	0.13	0.00
107	Libanicoccus	25	0	0.03	0.00
108	Urmitella	24	0	0.02	0.00
109	Paraclostridium	19	0	0.02	0.00
110	Acinetobacter	1273	0	1.31	0.00
111	Anaerocolumna	9	0	0.01	0.00
112	Marvinbryantia	22	0	0.02	0.00
113	Robinsoniella	50	0	0.05	0.00
114	Neglecta	33	0	0.03	0.00
115	Butyricimonas	180	0	0.19	0.00
116	unknown	6947	5101	7.14	5.74

TABLE 6
Genus level: Mean and percentage abundance as baseline
and post-intervention in Gr. 2 (Nichi Glucan)
	Mean abundance	Percentage of abundance
S.			Post-		Post-
No	Genus	Baseline	Intervention	Baseline	Intervention
1	Bacteroides	13463	14088	11.60	11.43
2	Clostridium	8728	12105	7.52	9.83
3	Bifidobacterium	6771	5625	5.84	4.57
4	Faecalibacterium	5291	9278	4.56	7.53
5	Enterococcus	4583	40	3.95	0.03
6	Eubacterium	4380	5007	3.78	4.06
7	Ruminococcus	4265	6143	3.68	4.99
8	Blautia	4196	3973	3.62	3.22
9	Alistipes	3187	2268	2.75	1.84
10	Collinsella	2542	1590	2.19	1.29
11	Parabacteroides	2419	1307	2.08	1.06
12	Oscillibacter	1956	2542	1.69	2.06
13	Prevotella	1887	5979	1.63	4.85
14	Lactobacillus	1860	1093	1.60	0.89
15	Roseburia	1756	7932	1.51	6.44
16	Trichosporon	1683	0	1.45	0.00
17	Dorea	1592	1585	1.37	1.29
18	Lachnoclostridium	1360	1056	1.17	0.86
19	Olsenella	1354	246	1.17	0.20
20	Escherichia	1346	505	1.16	0.41
21	Klebsiella	1067	80	0.92	0.06
22	Gemmiger	970	1161	0.84	0.94
23	Streptococcus	925	521	0.80	0.42
24	Coprococcus	910	1228	0.78	1.00
25	Subdoligranulum	904	1112	0.78	0.90
26	Eggerthella	871	190	0.75	0.15
27	Dialister	765	1062	0.66	0.86
28	Hungatella	732	175	0.63	0.14
29	Lysinibacillus	709	0	0.61	0.00
30	Acinetobacter	677	0	0.58	0.00
31	Pediococcus	662	0	0.57	0.00
32	Holdemanella	649	546	0.56	0.44
33	Butyricicoccus	623	1257	0.54	1.02
34	Catenibacterium	620	470	0.53	0.38
35	Cloacibacillus	602	265	0.52	0.21
36	Pichia	588	0	0.51	0.00
37	Odoribacter	577	271	0.50	0.22
38	Rummeliibacillus	555	0	0.48	0.00
39	Weissella	555	24	0.48	0.02
40	Flavonifractor	545	729	0.47	0.59
41	Senegalimassilia	505	56	0.43	0.05
42	Megasphaera	464	1203	0.40	0.98
43	Romboutsia	463	130	0.40	0.11
44	Desulfovibrio	461	344	0.40	0.28
45	Fusicatenibacter	452	641	0.39	0.52
46	Sutterella	436	780	0.38	0.63
47	Mycoplasma	424	265	0.37	0.21
48	Peptoniphilus	413	0	0.36	0.00
49	Ruminiclostridium	411	387	0.35	0.31
50	Anaerotruncus	410	485	0.35	0.39
51	Butyrivibrio	404	315	0.35	0.26
52	Methanobrevibacter	395	368	0.34	0.30
53	Megamonas	392	501	0.34	0.41
54	Bacillus	326	150	0.28	0.12
55	Butyricimonas	319	39	0.28	0.03
56	Anaerostipes	318	485	0.27	0.39
57	Phascolarctobacterium	317	464	0.27	0.38
58	Akkermansia	305	498	0.26	0.40
59	Gordonibacter	304	0	0.26	0.00
60	Coprobacillus	295	438	0.25	0.36
61	Coraliomargarita	294	339	0.25	0.28
62	Methanosphaera	282	0	0.24	0.00
63	Enterobacter	257	17	0.22	0.01
64	Pyramidobacter	231	15	0.20	0.01
65	Acidaminococcus	230	269	0.20	0.22
66	Paenibacillus	229	184	0.20	0.15
67	Acidiphilium	219	555	0.19	0.45
68	Adlercreutzia	210	334	0.18	0.27
69	Actinomyces	191	4	0.16	0.00
70	Succinatimonas	190	383	0.16	0.31
71	Libanicoccus	188	119	0.16	0.10
72	Angelakisella	184	79	0.16	0.06
73	Pseudoflavonifractor	183	173	0.16	0.14
74	Chlamydia	176	130	0.15	0.11
75	Anaeromassilibacillus	175	135	0.15	0.11
76	Intestinimonas	157	174	0.14	0.14
77	Duodenibacillus	150	181	0.13	0.15
78	Oribacterium	145	103	0.33	0.08
79	Clostridioides	129	64	0.11	0.05
80	Barnesiella	118	84	0.10	0.07
81	Slackia	109	0	0.09	0.00
82	Eisenbergiella	95	112	0.08	0.09
83	Acidovorax	93	0	0.08	0.00
84	Lactococcus	92	0	0.08	0.00
85	Paraprevotella	91	16	0.08	0.01
86	Shigella	90	90	0.08	0.07
87	Oxalobacter	87	0	0.08	0.00
88	Selenomonas	84	231	0.07	0.19
89	Turicibacter	74	36	0.06	0.03
90	Haemophilus	74	196	0.06	0.16
91	Pygmaiobacter	69	0	0.06	0.00
92	Urinacoccus	64	0	0.06	0.00
93	Bilophila	63	613	0.05	0.50
94	Allisonella	62	54	0.05	0.04
95	Ruthenibacterium	51	69	0.04	0.06
96	Raoultibacter	50	0	0.04	0.00
97	Comamonas	44	0	0.04	0.00
98	Neglecta	42	37	0.04	0.03
99	Atopabium	40	11	0.03	0.01
100	Christensenella	38	41	0.03	0.03
101	Massilimaliae	37	32	0.03	0.03
102	Finegoldia	36	0	0.03	0.00
103	Treponema	36	48	0.03	0.04
104	Robinsoniella	36	0	0.03	0.00
105	Enterorhabdus	36	40	0.03	0.03
106	Viridibacillus	36	0	0.03	0.00
107	Peptococcus	35	0	0.03	0.00
108	Fusobacterium	34	30	0.03	0.02
109	Terrisporobacter	34	7	0.03	0.01
110	Tyzzerella	33	171	0.03	0.14
111	Erysipelatoclostridium	32	0	0.03	0.00
112	Sporobacter	32	36	0.03	0.03
113	Mitsuokella	31	432	0.03	0.35
114	Cutaneotrichosporon	31	0	0.03	0.00
115	Marvinbryantia	31	28	0.03	0.02
116	Corallococcus	30	143	0.03	0.12
117	Anaerotignum	28	18	0.02	0.01
118	Prevotellamassilia	24	158	0.02	0.13
119	Anaerofilum	24	35	0.02	0.03
120	Synergistes	22	0	0.02	0.00
121	Alloprevotella	22	22	0.02	0.02
122	Isoptericola	22	0	0.02	0.00
123	Anaerococcus	21	0	0.02	0.00
124	Propionibacterium	20	0	0.02	0.00
125	Leuconostoc	20	0	0.02	0.00
126	Brachyspira	19	95	0.02	0.08
127	Lachnospira	18	386	0.02	0.31
128	Lagierella	17	0	0.02	0.00
129	Mogibacterium	16	0	0.01	0.00
130	Agathobaculum	15	61	0.01	0.05
131	Pseudobutyrivibrio	15	35	0.01	0.03
132	Hydrogenoanaerobacterium	14	14	0.01	0.01
133	Holdemania	14	0	0.01	0.00
134	Desulfotomaculum	14	0	0.01	0.00
135	Veillonella	14	324	0.01	0.26
136	Succinivibrio	14	32	0.01	0.03
137	Anaerocolumna	14	14	0.01	0.01
138	Mobilibacterium	12	0	0.01	0.00
139	Arabia	12	0	0.01	0.00
140	Enorma	11	0	0.01	0.00
141	Candida <Debaryomycetaceae>	11	0	0.01	0.00
142	Intestinibacter	11	13	0.01	0.01
143	Kurthia	10	0	0.01	0.00
144	Paeniclostridium	9	0	0.01	0.00
145	Paraclostridium	8	0	0.01	0.00
146	Listeria	8	0	0.01	0.00
147	Kwoniella	8	0	0.01	0.00
148	Cryptococcus	7	0	0.01	0.00
149	Fournierella	0	23	0.00	0.02
150	Sellimonas	0	23	0.00	0.02
151	Blastocystis	0	34	0.00	0.03
152	Acholeplasma	0	126	0.00	0.10
153	Azospirillum	0	162	0.00	0.13
154	Porphyromonas	0	7	0.00	0.01
155	Emergencia	0	14	0.00	0.01
156	Acetobacter	0	13	0.00	0.01
157	Dakarella	0	64	0.00	0.05
158	Parasutterella	0	133	0.00	0.11
159	Elusimicrobium	0	128	0.00	0.10
160	Drancourtella	0	32	0.00	0.03
161	Anaerovorax	0	15	0.00	0.01
162	Caldicoprobacter	0	15	0.00	0.01
163	unknown	12707	16408	10.93	13.32

TABLE 7
Species level: Mean abundance at baseline
and post-intervention in Gr. 1 (Control)
	Mean abundance
			Post-
S.		Base-	Inter-
No	Species	line	vention
1	Prevotella copri	530	2058
2	uncultured Clostridium sp.	2459	1860
3	Bifidobacterium longum	2150	1433
4	Hungatella hathewayi	65	1287
5	Bacteroides fragilis	2052	1189
6	Bacteroides thetaiotaomicron	1432	1172
7	Blautia producta	25	985
8	Bifidobacterium bifidum	941	946
9	Roseboria intestinalis	144	930
10	Bacteroides vulgatus	364	866
11	Bacteroides ovatus	1186	846
12	Clostridium neonatale	0	770
13	Escherichia coli	998	267
14	Akkermansia muciniphila	464	760
15	uncultured Butyricicoccus Sp.	948	751
16	Prevotella copri CAG: 164	362	700
17	Flavonifractor plautii	445	640
18	[Eubacterium] rectale	380	594
19	Anaerostipes sp. BG01	0	584
20	Dialister sp. CAG: 357	0	540
21	Lactobacillus ruminis	628	536
22	Bacteroides uniformis	265	519
23	Roseburia faecis	625	507
24	Prevotella sp. CAG: 386	61	481
25	Eubacterium sp. CAG: 252	0	472
26	[Clostridium] bolteae	0	471
27	[Eubacterium] eligens	0	470
28	Bifidobacterium adolescentis	574	466
29	Klebsiella pneumoniae	397	461
30	Prevotella sp. CAG: 1092	0	457
31	Dialister succinatiphilus	412	454
32	Clostridium sp. AT4	12	450
33	Prevotella sp. CAG: 604	154	445
34	Firmicutes bacterium CAG: 124	806	439
35	uncultured Blautia sp.	1136	435
36	Bacteroides xylanisolvens	402	414
37	Bilophila wadsworthia	0	412
38	Blautia obeum	1024	410
39	Prevotella sp. 885	48	406
40	Fusicatenibacter saccharivorans	432	391
41	[Clostridium] clostridioforme	76	379
42	Megasphaera elsdenii	0	376
43	Bacteroides nordii	56	369
44	Faecalibacterium sp. CAG: 82	296	362
45	[Ruminocossus] gnavus	367	361
46	Ruminococcus sp. CAG: 177	427	359
47	Dorea longicatena	402	358
48	Mitsuokella multacida	0	356
49	Blautia wexlerae	738	355
50	Eubacterium sp. CAG: 251	0	351
51	[Ruminococcus] torques	790	342
52	Prevotella multisaccharivorax	72	334
53	Odoribacter splanchnicus	417	330
54	Firmicutes bacterium CAG: 176	653	329
55	Dialister sp. CAG: 486	143	328
56	Gemmiger formicilis	481	320
57	Firmicutes bacterium CAG: 41	334	311
58	Streptococcus thermophilus	0	305
59	Romboutsia timonensis	171	299
60	Subdoligranulum sp. 60_17	438	296
61	Bacteroides oleiciplenus	0	286
62	Subdoligranulum variabile	275	281
63	Bacteroides plebeius	0	280
64	uncultured Faccalibacterium sp.	168	280
65	Roseburia hominis	94	273
66	Anaerostipes hadrus	350	266
67	Alistipes putredinis	568	266
68	butyrate-producing bacterium SS3/4	0	259
69	Firmicutes bacterium CAG: 103	872	255
70	Eggerthella lenta	392	254
71	Catenibacterium sp. CAG: 290	324	240
72	Mycoplasma sp. CAG: 956	229	238
73	Veillonella dispar	0	238
74	Oscillibacter sp. ER4	283	238
75	Clostridium sp. CAG: 81	0	236
76	Collinsella aerofaciens	715	236
77	Bacteroides timonenasis	0	235
78	Turicibacter sanguinis	0	233
79	Bifidobacterium sp. N5G01	530	230
80	Bacteroides caccae	548	224
81	Clostridiales bacterium KLE1615	0	216
82	uncultured Ruminococcus sp.	760	213
83	Bacteroides cellulosilyticus	0	213
84	Clostridium sp. CAG: 7	55	213
85	Parabacteroides merdae	40	211
86	Clostridium sp. CAG: 389	291	208
87	Blautia sp. CAG: 37	162	208
88	Coprococcus eutactus	158	200
89	Veillonella atypica	0	200
90	Ruminococcus callidus	32	200
91	Holdemanella biformis	585	199
92	Lachnospiraceae bacterium TF01-11	0	199
93	uncultured Lachnospira sp.	0	190
94	Bacteroides stercoris	0	187
95	Bifidobacterium catenulatum	142	183
96	[Eubacterium] hallii	346	174
97	Prevotella sp. CAG: 520	0	173
98	Roseburia sp. CAG: 18	283	173
99	Alistipes sp. HGB5	27	172
100	Haemophilus parainfluenzae	52	172
101	Streptococcus salvarius	71	169
102	Coprococcus catus	49	167
103	Firmicutes bacterium CAG: 65	89	164
104	Bacteroides plebeius CAG: 211	0	163
105	Ruminococcus bromii	158	163
106	Megasphaera massiliensis	12	161
107	Enterobacter hormaechei	47	158
108	Roseburia intestinalis CAG: 13	0	153
109	Catenibacterium mitsuokai	198	149
110	Dakarella massiliensis	97	147
111	Chlamydia trachomatis	132	146
112	Enterobacter cloacae	70	145
113	Bifidobacterium pseudocatenulatum	251	145
114	Clostridiales bacterium VE202-06	0	144
115	Firmicutes bacterium CAG: 65_45_313	0	142
116	[Clostridium] symbiosum	0	140
117	Veillenella parvula	0	139
118	Clostridiales bacterium 1_7_47FAA	0	336
119	Burkholderiales bacterium 1_1_47	0	135
120	Roseburia sp. CAG: 18_43_25	158	134
121	Bacteroides sp. HPS0048	64	132
122	Weissella confusa	124	132
123	Clostridium sp. CAG: 122	0	131
124	Firmicutes bacterium CAG: 424	146	131
125	Prevotella stercorea	0	127
126	Ruminococcus sp. CAG: 254	445	127
127	Bacteroides sp. 2_2_4	64	127
128	Enterococcus asini	0	126
129	Blautia sp. KLE 1732	185	126
130	Clostridioides difficile	107	125
131	Firmicutes bacterium CAG: 129_59_24	164	124
132	[Eubacterium] siraeum	50	124
133	Clostridiales bacterium 42_27	184	120
134	Bifidobacteriam kashiwanohense	125	117
135	Roseburia inulinivorans	482	117
136	Prevotella sp. CAG: 732	28	114
137	Firmicutes bacterium CAG: 170	235	113
138	Clostridium sp. CAG: 12237_41	0	113
139	Clostridium bolteae CAG: 59	0	113
140	Clostridium sp. ATCC BAA-442	67	113
141	Laetobacillus ruminis CAG: 367	87	113
142	Firmicutes bacterium CAG: 102	0	111
143	Ruminococcus sp.5_1_39BFAA	166	105
144	Firmicutes bacterium CAG: 114	480	103
145	Alistipes senegalensis	628	102
146	Alistipes finegoldii	41	101
147	Adlercreutzia equolifaciens	405	101
148	Sutterella sp. CAG: 351	132	100
149	Parabacteroides distasonis	67	100
150	Parasutterella excrementihominis	0	98
151	uncultured Eubacterium sp.	294	98
152	Enterococcus avium	292	97
153	Bacteroides dorei	235	97
154	Bacteroides stercorirosoris	0	97
155	Collinsella sp. CAG: 66	156	96
156	uncultured bacterium	89	95
157	Lactococcus garvieae	0	95
158	Prevotella sp. CAG: 474	21	95
159	Terrisporobacter glycolicus	0	94
160	Osdillibacter sp. 57_20	66	94
161	Veillonella sp. DORA_A_3_16_22	0	94
162	Ruminococcus sp. CAG: 90	118	92
163	Prevotella sp. CAG: 592	0	92
164	Lachnospira pactinoschiza	0	92
165	Bacteroides intestinalis	0	89
166	Bacteroides caccae CAG: 21	231	88
167	Bacteroides sp. 3_1_23	12	87
168	Clostridiales bacterium 41_21_two_genomes	21	87
169	Faecalibacterium sp. CAG: 82-related_59_9	24	85
170	Klebsiella michiganensis	0	85
171	Bifidobacterium sp. N4G05	217	83
172	Proteobacteria bacterium CAG: 139	0	81
173	Clostridiales bacterium 41_12_two_minus	83	81
174	Eubacterium sp. CAG: 248	0	80
175	Dorea formicigenerans	292	80
176	Megasphaera sp. D1SK 18	0	79
177	Coprobacillus sp. CAG: 235	197	79
178	Prevotella stercorea CAG: 629	0	79
179	Clostridiales bacterium 52_15	218	79
180	Clostridiales bacterium 59_14	133	77
181	Blautia sp. CAG: 37	163	77
182	uncultured Bacteroides sp.	0	76
183	Alistipes finegoldii CAG: 68	0	75
184	Dorea sp. CAG: 105	39	74
185	Ruminococcus obeum CAG: 39	163	73
186	Bacteroides cellulosilyticus CAG: 158	0	70
187	Ruminococcus sp. CAG: 17	170	69
188	Eubacterium sp. CAG: 38	0	69
189	Clostridium sp. CAG: 91	0	69
190	Klebsiella oxytoca	0	68
191	Bacteroides sp. 43_46	134	68
192	Prevotella sp. P3-122	0	68
193	Roseburia sp. CAG: 471	101	68
194	Agathobaculum desmolans	54	67
195	Sutterella parvirubra	0	66
196	Eubacterium rectale CAG: 36	35	66
197	Collinsella sp. 4_8_47FAA	144	65
198	Blantia sp. Marseille-P3201T	68	65
199	Bacteroide sp. 4_1_36	75	63
200	Odoribacter sp. 43_10	61	62
201	Parasutterella excrementihominis CAG: 233	0	60
202	Bilophila sp. 4_1_30	0	60
203	Eubacterium elugens CAG: 72	0	60
204	Parabacteroides merdae CAG: 48	0	59
205	Blautia sp. CAG: 37_48_57	87	59
206	Bifidobacterium breve	485	58
207	Ruminococcus sp. CAG: 108	45	58
208	Firmicutes bacterium CAG: 83	430	57
200	Bacteroides sp. 41_26	0	57
210	Anaerostipes caccae	0	56
211	uncultured Flavonifractor sp.	65	56
212	Enterococcus sp. HMSC05C03	31	56
213	Butyricicoccus sp. BB10	347	56
214	Alistipes putredinis CAG: 67	57	55
215	Bacteroides sp. D20	18	54
216	Lachnoclostridium sp. An196	34	54
217	Dorea longicatena CAG: 42	29	53
218	Klebsiella variicola	0	53
219	Akkermansia muciniphila CAG: 154	21	48
220	Streptococcus pneumoniae	36	48
221	Firmicutes bacterium CAG: 129	73	48
222	Eubacterium sp. 45_250	0	48
223	Bacteroides sp. D22	51	47
224	Eubacterium sp. CAG: 76	0	47
225	Clostridiales bacterium VE202-28	0	47
226	Oscillibacter sp. CAG: 241	69	46
227	Blautia massiliensis	69	46
228	Blautia sp. SF-50	77	46
229	Parabacteroides sp. D13	39	45
230	Enterococcus faecium	844	45
231	Mitsuokella jalaludinii	0	45
232	Sutterella wadsworthensis	0	44
233	Clostridiales baterium 36_14	48	44
234	Coprococcus sp. CAG: 131	66	44
235	Lachnoclostridium sp. An14	0	43
236	Lachnospiracaea bacterium 7_1_58FAA	18	43
237	Blautia sp. Marseille-P2398	86	43
238	Eubacterium ballii CAG: 12	85	42
239	Bacteroides sp. 1_1_30	49	42
240	Clostridiales bacterium VE202-03	25	41
241	Acholeplasma sp. CAG: 878	0	40
242	Blautia sp. CAG: 52	175	40
243	Veillonella sp. HPA0037	0	40
244	Alistipes indistinctus	91	39
245	Ruminococcus sp. SR1/5	57	39
246	Roseburia sp. CAG: 50	0	38
247	Erwinia phage vB_EamM_V3	0	38
248	Bacteroides sp. D2	0	38
249	Eubacterium ramulus	34	37
250	Veillonella sp. oral taxon 158	0	37
251	Clostridia bacterium UC5, 1-2H11	22	36
252	Turicibacter sp. H121	0	36
253	Fusobacterium sp. CAG: 815	0	36
254	Alistipes sp. 58_9_plus	0	35
255	Prevotella sp. CAG: 873	0	34
256	Clostridium sp. CAG: 448	0	34
257	Clostridium sp. CAG: 492	0	34
258	Firmicutes bacterium CAG: 822	0	34
259	Veillonella sp. ACP1	0	34
260	Bacteroides sp. 14(A)	0	33
261	Clostridiales bacterium NK3B98	0	33
262	Ruminococcus sp. CAG: 108_related_41_35	25	33
263	Bacteroides intestinalis CAG: 315	0	32
264	Lactobacillus rogosae	0	32
265	Alistipes timonensis	27	32
266	Anaerotruncus sp. CAG: 390	26	31
267	Prevotella sp. P4-65	0	31
268	Blautia sp. An81	27	31
269	Bacteroides fragilis CAG: 558	57	31
270	Tyzzerella nexilis	0	30
271	Romboutsia ilealis	0	30
272	[Clostridium] citroniae	0	29
273	Prevotella sp. P5-108	0	29
274	Prevotella sp. P4-76	0	29
275	Acidiphilium sp. CAG: 727	27	29
276	Muribaculum intestinale	0	29
277	Eubacterium sp. 41_20	27	29
278	Shigella sonnei	0	28
279	Terrisporobacter othiniensis	0	28
280	Bifidobacterium adolescentis CAG: 119	0	28
281	Veillonella sp. ICM51a	0	28
282	Prevotella sp. AGR2160	0	27
283	Bacteroides sp. 3_1_13	11	27
284	Prevotella sp. CAG: 279	320	27
285	Intestinimonas butyriciproducens	72	27
286	Prevotella bryantii	0	27
287	Streptococcus parasanguinis	12	27
288	Clostridium sp. CAG: 43	0	27
289	Klebsiella aerogenes	503	27
290	Ruminococcus sp. CAG: 330	37	26
291	Clostridium sp. SS2/1	43	26
292	uncultured Oscillibacter sp.	53	26
293	Prevotella sp. P5-64	0	26
294	Firmicutes bacterium CAG: 341	281	25
295	Oscillibacter sp. CAG: 241_62_21	32	25
296	Megashaera sp. MJR8396C	0	25
297	Coprococcus sp. CAG: 131-related_45_246	0	25
298	Ruminococcus sp. CAG: 9	61	25
299	Prevotella sp. P5-60	0	25
300	Bacteroides sp. CAG: 927	0	24
301	Megashaera sp. BL7	0	24
302	Bacteroidales bacterium 52_46	0	24
303	Odoribacter splanchnicus CAG: 14	50	24
304	Bacteroides sp. 43_108	0	24
305	Citrobacter koseri	0	24
306	Clostridium sp. CAG: 221	0	23
307	Veillonella tobetsuensis	0	23
308	Collinsella sp. TF06-26	144	23
309	Prevotella sp. P2-180	0	23
310	Bacteroides intestinalis CAG: 564	0	23
311	Lachnoclostridium edouardi	0	23
312	Eggerthella sp. 1_3_56FAA	25	22
313	Klebsiella sp. MS 92-3	24	22
314	Ruminococcus faecis	39	22
315	Bacteroides sp. 3_1_19	0	22
316	Bacteroides stercoris CAG: 120	0	22
317	Bacteroides sp. 1_1_14	170	21
318	Parabacteroides johnsonii	0	21
319	Weissella cibaria	0	21
320	Prevotella sp. P4-67	0	21
321	Intestinibacter bartlettii	0	21
322	Lachnospiraeceae bacterium 6_1_63FAA	21	21
323	Eubacterium siraeum CAG: 80	0	21
324	Salmonella enterica	0	21
325	Prevotella sp. P4-51	0	21
326	Clostridium botulinum	0	20
327	Clostridium nexile CAG: 348	0	20
328	Prevotellamassilia timonensis	0	20
329	Prevotella sp. P5-125	0	20
330	Clostridiales bacterium VE202-09	0	20
331	Shigella flexneri	0	20
332	Eubacterium sp. CAG76_36_125	0	20
333	Prevotella sp. P5-119	0	20
334	Prevotella ruminicola	0	19
335	Prevotella lascolanii	0	19
336	Prevotella buccae	0	19
337	Clostridium butyricum	0	19
338	Blautia sp. An46	20	19
339	Eggerthella sp. HGA1	19	19
340	Coprococcus comes	85	18
341	Prevotella sp. CAG: 1185	0	18
342	Lachnospiraeceae bacterium 5_1_63FAA	35	18
343	Bifidobacterium ruminantium	263	18
344	Bacteroides finegoldii	0	18
345	Bacteroides sp. 4_3_47FAA	0	17
346	Bacteroides sp. 3_1_40A	0	17
347	Bacteroides sp. CAG: 530	0	17
348	Lachnospiraeceae bacterium CAG: 364	15	16
349	Prevotella sp. CAG: 1124	0	16
350	Bacteroides vulgatus CAG: 6	0	16
351	Prevotella baroniae	0	16
352	Anaerotignum lactatifermentans	0	16
353	Blautia hansenii	14	15
354	Prevotella sp. CAG: 487	0	15
355	Prevotella timonensis	0	15
356	Ruminococcus gnavus CAG: 126	17	15
357	Megasphaera sp. NM10	0	15
358	Prevotella buccalis	0	14
359	Prevotella sp. P5-92	0	14
360	Streptococcus infantarius	0	14
361	Bacteroides sp. AR20	0	14
362	Enterobacter sp. BIDMC 29	0	14
363	Lachnospiraceae bacterium 2_1_58FAA	13	14
364	Bacteroides uniformis CAG: 3	18	14
365	Prevotella sp. CAG: 5226	0	14
366	Bacteroides sartorii	0	14
367	Blautia schinkii	0	14
368	[Clostridium] lavalense	0	13
369	Prevotella intermedia	0	13
370	Bacteroides mediterraneensis	0	13
371	Veillonella sp. 6_1_27	0	13
372	Lactoccoccus lactis	140	13
373	Bacteroides faecis	0	12
374	Lachnospiraceae bacterium JC7	37	12
375	Prevotella histicola	0	11
376	Sutterella sp. KLE1602	0	11
377	Prevotella oralis	0	11
378	Bifidobacterium bifidum CAG: 234	0	10
379	Prevotella sp. P4-119	0	10
380	Prevotella paludivivens	0	10
381	Prevotella sp. tc2-28	0	10
382	Prevotella sp. P5-126	0	10
383	Prevotella sp. 109	0	10
384	Prevotella brevis	0	10
385	Prevotella oris	0	9
386	Prevotella sp. DNF00663	0	9
387	Prevotella oryzae	0	9
388	Prevotella sp. CAG: 255	0	9
389	Prevotella sp. S7-1-8	0	9
390	Prevotella dentalis	0	9
391	Prevotella sp. KH2C16	0	9
392	Prevotella sp. CAG: 1058	0	9
393	Prevotella maculosa	0	9
394	Prevotella bergensic	0	9
395	Ruminococcaceae bacterium D16	14	8
396	Dorea formicigenerans CAG:28	31	0
397	Rummeliibacillus stabekisii	41	0
398	Bifidobacterium pseudolongum	30	0
399	Clostridium sp. CAG: 138	415	0
400	Blautia sp. CAG: 257	39	0
401	Enterococcus sp. HMSC072H05	14	0
402	Bacteroides dorei CAG: 222	22	0
403	Bacteroides sp. CAG: 189	67	0
404	[Desulfotomaculum] guttoideum	17	0
405	Tissierellia bacterium S5-A11	21	0
406	Ruminococcus sp. CAG: 382	21	0
407	Peptococcus niger	27	0
408	Oribacterium sp. C9	24	0
409	Olsenella provencensis	22	0
410	Collinsella sp. CAG: 289	85	0
411	Ruthenibacterium lactatiformans	63	0
412	Acinetobacter sp. NIPH 899	71	0
413	Oribacterium sp. WCC10	33	0
414	Clostridium sp. CAG: 609	259	0
415	Clostridium sp. CAG: 571	33	0
416	Butyricimonas virosa	146	0
417	Slackia piriformis	52	0
418	Firmicutes bacterium CAG: 110	278	0
419	Achromobacter xylosoxidans	12	0
420	Lactobacillus mucosae	321	0
421	Clostridium sp. CAG: 433	54	0
422	Clostridium sp. CAG: 226	155	0
423	Solobacterium moorei	27	0
424	bacterium LF-3	22	0
425	Anaerococcus prevotii	17	0
426	Olsenella sp. An188	24	0
427	Clostridium minihomine	16	0
428	Acinetobacter sp. NIPH 2171	133	0
429	Anaeromassilibacillus senegalensis	19	0
430	Dialister invisus	60	0
431	Firmicutes bacterium CAG: 646	12	0
432	bacterium MS4	32	0
433	Gordonibacter pamelaeae	82	0
434	Parabacteroides sp. HGS0025	18	0
435	Anaeromassilibacillus sp. Marseille-P3371	12	0
436	Peptoniphilus senegalensis	37	0
437	Clostridium sp. 7_2_43FAA	17	0
438	Peptoniphilus duerdenii	16	0
439	Comamonas testosteroni	90	0
440	Anaeromassilibacillus sp. An200	9	0
441	Lysinibacillus sp. ZYM-1	44	0
442	Mycoplasma sp. CAG: 472	53	0
443	Clostridium sp. L2-50	37	0
444	Collinsella sp. MS5	44	0
445	Firmicutes bacterium CAG: 555	26	0
446	Bacillus kochii	12	0
447	Faecalibacterium sp. CAG: 74_58_120	295	0
448	Clostridium sp. CAG: 793	270	0
449	Neglecta timonensis	26	0
450	[Clostridium] celerecrescens	750	0
451	Clostridium sp. ASB-410	20	0
452	Enterococcus cassaliflavus	251	0
453	Eggerthella timonensis	23	0
454	Faecalibacterium sp. CAG: 74	439	0
455	Clostridiales bacterium Marseille-P2846	187	0
456	Anaerocococcus vaginalis	30	0
457	Anaeromassilibacillus sp. An250	39	0
458	Acinetobacter sp. CIP 101934	13	0
459	Firmicutes bacterium CAG: 24	145	0
460	Firmicutes bacterium HGW-Firmicutes-16	22	0
461	Barnesiella intestinihominis	121	0
462	Enterococcus gallinarum	214	0
463	Lysinibacillus sp. FJAT-14222	245	0
464	Alistipes shahii	40	0
465	Peptoniphilus timonensis	41	0
466	Akkermansia sp. CAG: 344	85	0
467	Lagierella massiliensis	39	0
468	Acinetobacter sp. LCT-H3	26	0
469	Drancourtella massiliensis	12	0
470	Subdoligranulum sp. 4_3_54A2FAA	88	0
471	Peptoniphilus harei	30	0
472	Ruminococcus sp. CAG:9-related_41_34	11	0
473	Ruminococcus lactaris	22	0
474	Firmicutes bacterium CAG: 24053_14	48	0
475	Enterorhabdus caecimuris	28	0
476	Alistipes sp. Marseille-P2431	21	0
477	Bacteroides thetaiotaomicron CAG: 40	42	0
478	Ruminococcus flavefaciens	30	0
479	Blantis sp. Marseille-P3087	46	0
480	Oribacterium sp. P6A1	25	0
481	Clostridium sp. C105KSO15	124	0
482	Achromobacter sp. Root170	21	0
483	Clostridium sp. CAG: 264	101	0
484	Lysinibacillus sphaerieus	108	0
485	Clostridium sp. CAG: 1024	39	0
486	Urinacoccus sp. Marseille-P3926	136	0
487	Enterococcus sp. FDAARGOS_375	30	0
488	Clostridiales bacterium	81	0
489	Lysinibacillus boronitolerans	27	0
490	Collinsella bouchesdurhonensis	32	0
491	Rummeliibacillus pyenus	562	0
492	Erysipelotrichaceae bacterium NK3D112	33	0
493	Collinsella sp. 60_9	26	0
494	Alistipes obesi	352	0
495	Dialister invisus CAG: 218	290	0
496	Eubacterium sp. CAG: 161	21	0
497	Bacteroides sp. 3_1_33FAA	22	0
498	Firmicutes bacterium CAG: 110_56_8	45	0
499	uncultured Coprococcus sp.	83	0
500	Paraclostridium bifermentans	17	0
501	Monoglobus pectinilyticus	24	0
502	Oribacterium sp. NK2B42	20	0
503	Lactobacillus brevis	32	0
504	Senegalimassilia anaerobia	122	0
505	Acinetobacter baumannii	228	0
506	Clostidium sp. CAG: 567	236	0
507	Coprococcus sp. ART55/1	22	0
508	Peptoniphilus sp. HMSC075B08	105	0
509	Enterococcus pallens	17	0
510	Finegoldia magna	82	0
511	Lysinibacillus sp. FJAT-14745	97	0
512	Coprobacillus sp. 8_1_38FAA	10	0
513	Peptoniphilus sp. oral taxon 375	118	0
514	uncultured crAssphage	31	0
515	Gordonibacter massiliensis	20	0
516	Olsenella sp. An290	19	0
517	Peptoniphilus grossensis	71	0
518	Bacteroides sp. 9_1_42FAA	31	0
519	Firmicutes bacterium CAG: 176_63_11	30	0
520	Enterococcus faecalis	238	0
521	Lactobacillus plantarum	259	0
522	Lysinibacillus fusiformis	42	0
523	Eubacterium sp. 38_16	21	0
524	Peptoniphilus sp. HMSC062D09	42	0
525	Alistipes sp. AG:53	39	0
526	Bacteroidales bacterium 43_8	22	0
527	Peptoniphilus phoceensis	55	0
528	Peptoniphilus sp. BV3AC2	12	0
529	Clostridium sp. CAG: 302	267	0
530	Gordonibacter urolithinfaciens	567	0
531	Acinetobacter sp. YZS-X1-1	115	0
532	Lysinibacillus xylanilyticus	242	0
533	Acinetobacter schindleri	91	0
534	Bacteroides sp. CAG: 20	60	0
535	Clostridium sp. CAG: 269	67	0
536	Alistipes sp. cv1	20	0
537	Roseburia inulinivorans CAG: 15	111	0
538	Urmitella timonensis	24	0
539	Olsenella sp. An293	20	0
540	Eisenbergiella tayi	73	0
541	Enterococcus saccharolyticus	16	0
542	Parabacteroides goldsteinii	602	0
543	Marvinbryantia formatexigens	22	0
544	Lysinibacillus macroides	49	0
545	Bacteroides salyersiae	248	0
546	Eubacterium sp. CAG: 146	52	0
547	Peptoniphilus coxii	318	0
548	Libanicoccus massiliensis	25	0
549	Roseburia sp. CAG: 182	36	0
550	Clostridium sp. CAG: 413	26	0
555	Dorea sp. AGR2135	24	0
552	Acinetobacter lwoffii	12	0

TABLE 8
Species level: Mean abundance at baseline and
post-intervention in Gr. 2 (Nichi Glucan)
	Mean abundance
			Post-
S. No	Species	Baseline	Intervention
1	Faecalibacterium prausnitzii	3613	6596
2	Bifidobacterium longum	2012	1446
3	Firmicutes bacterium CAG: 124	1684	1308
4	Trichosporon asahii	1683	0
5	Bifidobacterium adolescentis	1376	931
6	Escherichia coli	1264	471
7	uncultured Clostridium sp.	1062	2726
8	Collinsella aerofaciens	1048	729
9	uncultured Blautia sp.	981	879
10	Ruminococcus sp. CAG: 177	977	565
11	Firmicutes bacterium CAG: 103	972	925
12	Bacteroides fragilis	960	1186
13	Blautia obeum	877	777
14	Gemmiger formicilis	865	1022
15	Firmicutes bacterium CAG: 170	847	989
16	Dorea longicatena	819	785
17	Firmicutes bacterium CAG: 110	787	604
18	Clostridium sp. CAG: 226	779	321
19	Clostridium sp. CAG: 138	743	528
20	uncultured Ruminococcus sp.	726	913
21	Bacteroides uniformis	707	512
22	Alistipes sp. CAG: 435	690	721
23	Hungatella hathewayi	681	171
24	Holdemanella biformis	649	546
25	Oscillibacter sp. CAG: 241	634	419
26	Firmicutes bacterium CAG: 176	617	945
27	Firmicutes bacterium CAG: 83	612	400
28	Subdoligranulum sp. 60_17	588	734
29	Pichia kudriavzevii	582	0
30	Bacteroides thetaiotaomicron	581	562
31	Prevotella copri	568	1458
32	Eubacterium sp. CAG: 202	536	0
33	Enterococcus faecium	528	0
34	Klebsiella pneumoniae	524	44
35	Rummeliibacillus pycnus	516	0
36	Senegalimassilia anaerobia	505	56
37	[Eubacterium] rectale	499	1165
38	Firmicutes bacterium CAG: 114	489	386
39	Bifidobacterium bifidum	476	418
40	Bacteroides ovatus	472	448
41	Bacteroides vulgatus	467	375
42	Blautia wexlerae	464	486
43	Lactobacillus ruminis	464	634
44	[Ruminococcus] torques	452	347
45	Fusicatenibacter saccharivorans	450	624
46	[Eubacterium] hallii	442	218
47	Olsenella umbonata	441	37
48	Desulfovibrio piger	434	303
49	Dialister sp. CAG: 486	433	447
50	uncultured Eubacterium sp.	429	294
51	Enterococcus avium	425	0
52	Faecalibacterium sp. CAG: 74	415	485
53	Bacteroides caccae	398	152
54	Oscillibacter sp. CAG: 241_62_21	392	469
55	Romboutsia timonensis	388	112
56	Eubacterium sp. CAG: 180	379	338
57	Parabacteroides merdae	377	101
58	Pediococcus pentosaceus	371	0
59	Enterococcus faecalis	362	0
60	Clostridiales bacterium Marseille-P2846	358	355
61	Clostridium sp. CAG: 221	355	326
62	Butyricicoccus sp. BB10	334	177
63	[Clostridium] celerecrescens	333	0
64	Lentisphaerae bacterium GWF2_44_16	332	307
65	[Clostridium] bolteae	331	43
66	Clostridiales bacterium 42_27	329	463
67	Prevotella sp. CAG: 279	326	754
68	Bifidobacterium sp. N5G01	325	383
69	Firmicutes bacterium CAG: 129	324	380
70	Cloacibacillus porcorum	322	248
71	Clostridium sp. CAG: 1024	319	488
72	Prevotella copri CAG: 164	318	771
73	Catenibacterium mitsuokai	312	274
74	Eggerthella lenta	309	60
75	Mycoplasma sp. CAG: 956	306	117
76	Oscillibacter sp. ER4	302	587
77	Roseburia faecis	301	662
78	Coraliomargarita sp. CAG: 312	292	338
79	Clostridiales bacterium 52_15	290	332
80	Catenibacterium sp. CAG: 290	287	180
81	Pediococcus acidilactici	282	0
82	Bacteroides dorei	281	357
83	Clostridiales bacterium 59_14	280	386
84	Firmicutes bacterium CAG: 176_63_11	280	400
85	Alistipes putredinis	278	201
86	Odoribacter splanchnicus	277	129
87	bacterium OL-1	275	15
88	Parabacteroides sp. SN4	274	249
89	[Eubacterium] eligens	273	552
90	Alistipes indistinctus	272	13
91	Alistipes obesi	272	0
92	Clostridium sp. CAG: 510	270	449
93	Dialister sp. CAG: 357	270	360
94	Faecalibacterium sp. CAG: 74_58_120	264	368
95	Lactobacillus brevis	262	0
96	Bifidobacterium ruminantium	261	257
97	Anaerostipes hadrus	260	422
98	Enterococcus casseliflavus	259	0
99	Cloacibacillus sp. An23	257	0
100	Bacteroides plebeius	250	250
101	Weissella confusa	249	12
102	Lactobacillus plantarum	249	0
103	Bacteroides sp. CAG: 545	246	379
104	Clostridium sp. CAG: 452	245	120
105	uncultured Faecalibacterium sp.	243	437
106	Collinsella sp. 4_8_47FAA	239	166
107	Firmicutes bacterium CAG: 555	237	281
108	Ruminococcus sp. CAG: 724	236	367
109	Roseburia inulinivorans	233	1197
110	Lentisphaerae bacterium GWF2_45_14	232	228
111	Bacteroides xylanisolvens	232	285
112	uncultured Butyricicoccus sp.	230	995
113	Butyricimonas virosa	230	0
114	Bacteroides intestinalis	230	135
115	Collinsella sp. CAG: 166	228	187
116	Ruminococcus sp. CAG: 488	225	211
117	Coprococcus catus	225	412
118	Klebsiella aerogenes	224	0
119	Phascolarctobacterium sp. CAG: 207	220	21
120	Acidiphilium sp. CAG: 727	219	555
121	Parabacteroides gordonii	217	0
122	[Eubacterium] siraeum	212	189
123	Adlercreutzia equolifaciens	210	334
124	Butyrivibrio sp. CAG: 318	208	0
125	Blautia sp. CAG: 37	207	203
126	Clostridium sp. CAG: 448	203	192
127	Bacteroides salyersiae	203	193
128	Coprobacillus sp. CAG: 235	197	145
129	Clostridiales bacterium	194	147
130	Bifidobacterium pseudocatenulatum	194	174
131	Collinsella sp. TF06-26	189	155
132	Alistipes sp. CAG: 53	189	180
133	Clostridium sp. CAG: 571	189	14
134	Sutterella sp. CAG: 397	188	193
135	Libanicoccus massiliensis	188	119
136	Succinatimonas sp. CAG: 777	187	376
137	Subdoligranulum variabile	187	244
138	Anaerotruncus sp. CAG: 390	185	275
139	Bifidobacterium angulatum	185	332
140	Angelakisella massiliensis	184	79
141	Alistipes senegalensis	183	57
142	Megamonas funiformis	182	175
143	Ruminococcus obeum CAG: 39	180	137
144	Acidaminococcus fermentans	180	199
145	Lactobacillus mucosae	178	0
146	Firmicutes bacterium CAG: 129_59_24	174	400
147	Chlamydia trachomatis	174	127
148	Lentisphaerae bacterium GWF2_52_8	172	173
149	Ruminococcus bromii	172	301
150	Eubacterium sp. CAG: 581	171	148
151	Clostridium sp. CAG: 433	170	8
152	Weissella cibaria	170	0
153	Methanobrevibacter smithii	161	159
154	Enterococcus gallinarum	161	0
155	Firmicutes bacterium CAG: 240	159	135
156	Clostridium sp. CAG: 302	159	20
157	Bacteroides plebeius CAG: 211	158	160
158	Firmicutes bacterium CAG: 24053_14	158	158
159	Eubacterium limosum	157	0
160	Clostridium sp. CAG: 349	157	143
161	Clostridium sp. CAG: 43	156	162
162	Parabacteroides sp. HGS0025	155	0
163	Akkermansia muciniphila	153	218
164	Clostridium sp. CAG: 245	152	15
165	Enterococcus hirae	151	0
166	Duodenibacillus massiliensis	150	181
167	Firmicutes bacterium CAG: 272	149	254
168	Coprococcus eutactus	148	100
169	Verrucomicrobia bacterium CAG: 312_58_20	148	273
170	Faecalibacterium sp. CAG: 82	147	398
171	Lysinibacillus xylanilyticus	147	0
172	Firmicutes bacterium CAG: 460	144	166
173	Peptoniphilus coxii	141	0
174	uncultured bacterium	141	176
175	Lysinibacillus sp. FJAT-14222	141	0
176	Bifidobacterium breve	139	132
177	Clostridium sp. CAG: 245_30_32	138	9
178	Clostridium sp. CAG: 451	136	30
179	Sutterella wadsworthensis	136	279
180	Parabacteroides goldsteinii	135	13
181	Streptococcus mutans	133	0
182	Roseburia hominis	132	630
183	Streptococcus salivarius	131	110
184	Alistipes sp. CAG: 514	131	147
185	Firmicutes bacterium CAG: 137	131	72
186	Roseburia sp. CAG: 18	130	229
187	Ruminococcus sp. 5_1_39BFAA	129	152
188	Clostridioides difficile	127	64
189	Flavonifractor plautii	125	221
190	Gordonibacter urolithinfaciens	125	0
191	Firmicutes bacterium CAG: 110_56_8	123	87
192	Pyramidobacter sp. C12-8	122	0
193	Ruminococcus sp. CAG: 17	122	151
194	Bifidobacterium sp. N4G05	119	125
195	Streptococcus thermophilus	118	0
196	Clostridium sp. CAG: 568	117	204
197	Blautia sp. KLE 1732	115	51
198	Parabacteroides merdae CAG: 48	114	30
199	Dorea formicigenerans	114	119
200	Barnesiella intestinihominis	112	77
201	[Clostridium] clostridioforme	111	124
202	Intestinimonas butyriciproducens	110	124
203	Olsenella scatoligenes	107	13
204	Clostridium sp. CAG: 413	107	472
205	uncultured Flavonifractor sp.	105	138
206	Clostridium sp. CAG: 343	104	0
207	Alistipes shahii	104	102
208	Pyramidobacter piscolens	103	0
209	Firmicutes bacterium CAG: 238	103	75
210	Collinsella sp. CAG: 289	102	0
211	Bacteroides caccae CAG: 21	102	107
212	Acinetobacter baumannii	101	0
213	Lentisphaerae bacterium GWF2_50_93	100	109
214	Bacteroides sp. 2_2 4	97	83
215	Eubacterium sp. CAG: 841	93	105
216	Ruminococcus sp. CAG: 382	93	170
217	Firmicutes bacterium CAG: 270	92	45
218	Olsenella sp. kh2p3	90	13
219	Phascolarctobacterium succinatutens	90	420
220	Lactobacillus fermentum	90	0
221	Mycoplasma sp. CAG: 877	89	41
222	Bacteroides intestinalis CAG: 564	87	60
223	Oxalobacter formigenes	87	0
224	Eisenbergiella tayi	86	99
225	Parabacteroides distasonis	86	157
226	Lentisphaerae bacterium GWF2_49_21	84	96
227	Dorea longicatena CAG: 42	84	83
228	Ruminococcus sp. CAG: 563	83	191
229	Olsenella sp. KH3B4	83	16
230	Lactobacillus ruminis CAG: 367	82	106
231	Blautia sp. CAG: 37_48_57	82	140
232	Alistipes sp. 56_sp_Nov_56_25	82	62
233	Enterococcus thailandicus	80	0
234	Alistipes sp. HGB5	80	0
235	Blautia sp. CAG: 237	78	207
236	Bacteroides stercoris	77	19
237	Firmicutes bacterium HGW-Firmicutes-9	75	94
238	Clostridium sp. CAG: 1193	75	125
239	Roseburia sp. CAG: 18_43_25	75	173
240	Firmicutes bacterium HGW-Firmicutes-16	74	73
241	Oscillibacter sp. 57_20	74	403
242	Olsenella provencensis	74	7
243	Olsenella sp. An188	74	0
244	Anaerotruncus colihominis	73	71
245	Clostridium sp. CAG: 524	73	71
246	Bacteroides coprocola CAG: 162	72	79
247	Firmicutes bacterium CAG: 41	72	310
248	Coprococcus comes	71	125
249	Ruminococcus sp. CAG: 90	71	9
250	Clostridium sp. CAG: 492	70	0
251	Pygmaiobacter massiliensis	69	0
252	Lysinibacillus sphaericus	69	0
253	Roseburia intestinalis	69	1218
254	Ruminococcus flavefaciens	69	267
255	uncultured Coprococcus sp.	68	22
256	Lactococcus lactis	68	0
257	uncultured Oscillibacter sp.	66	87
258	Gordonibacter pamelaeae	65	0
259	Bacteroides eggerthii	64	0
260	Bifidobacterium kashiwanohense	64	82
261	Clostridiales bacterium 41_12_two_minus	63	195
262	Collinsella sp. 60_9	63	17
263	Allisonella histaminiformans	62	54
264	Megasphaera elsdenii	61	262
265	Lysinibacillus sp. FJAT-14745	61	0
266	Ruminococcus sp. CAG: 9	60	59
267	Urinacoccus sp. Marseille-P3926	60	0
268	Bacteroides coprocola	60	99
269	Olsenella sp. An285	59	0
270	Acinetobacter sp. NIPH 2171	59	0
271	Clostridium sp. CAG: 7	59	396
272	Bifidobacterium catenulatum	58	75
273	Olsenella sp. An290	58	0
274	Eubacterium hallii CAG: 12	57	41
275	Streptococcus pneumoniae	57	8
276	Collinsella sp. MSS	56	0
277	Eggerthella sp. CAG: 209	56	0
278	Bacteroides sp. CAG: 20	56	37
279	Clostridium sp. C105KSO15	55	0
280	Bacteroides sp. CAG: 189	55	36
281	Clostridium sp. CAG: 594	55	0
282	Bacteroides sp. AR29	55	0
283	Subdoligranulum sp. 4_3_54A2FAA	54	65
284	Ruminococcus bicirculans	54	172
285	Oscillibacter sp. 1-3	53	70
286	Blautia sp. Marseille-P3087	53	39
287	Turicibacter sanguinis	52	26
288	Peptoniphilus sp. oral taxon 375	52	0
289	Olsenella sp. An293	52	0
290	Bacteroides intestinalis CAG: 315	51	32
291	Acinetobacter sp. YZS-X1-1	51	0
292	Ruthenibacterium lactatiformans	51	69
293	Coprococcus eutactus CAG: 665	51	0
294	Firmicutes bacterium CAG: 321	51	69
295	Bacteroides sp. D20	50	32
296	Clostridium sp. CAG: 264	50	38
297	Blautia producta	49	0
298	Firmicutes bacterium CAG: 176_59_8	49	90
299	Bacteroides sp. 1_1_14	48	18
300	Erysipelotrichaceae bacterium 6_1_45	48	0
301	Peptoniphilus sp. HMSC075B08	47	0
302	Selenomonas bovis	47	168
303	Bacteroides sp. 4_1_36	45	27
304	Slackia piriformis	44	0
305	Enterobacter cloacae	44	0
306	[Clostridium] citroniae	43	0
307	Ruminococcus sp. CAG: 254	43	486
308	Alistipes finegoldii	43	143
309	Haemophilus parainfluenzae	43	87
310	Alistipes onderdonkii	42	14
311	Actinomyces sp. HPA0247	42	0
312	Roseburia sp. CAG: 182	42	317
313	Parabacteroides sp. merdae-related_45_40	41	10
314	butyrate-producing bacterium SS3/4	41	248
315	Collinsella vaginalis	41	8
316	Faecalibacterium sp. CAG: 82-related_59_9	41	99
317	Acinetobacter schindleri	40	0
318	Bacteroides oleiciplenus	40	55
319	Megamonas rupellensis	40	35
320	Blautia sp. Marseille-P2398	40	44
321	Clostridium sp. CAG: 81	40	238
322	Comamonas kerstersii	40	0
323	Eggerthella sp. 1_3_56FAA	39	0
324	Enterobacter hormaechei	39	0
325	Rummeliibacillus stabekisii	39	0
326	Acinetobacter bereziniae	39	0
327	Lactobacillus pentosus	39	0
328	Eubacterium eligens CAG: 72	39	102
329	Oscillibacter valericigenes	38	58
330	Bacteroides nordii	38	0
331	Clostridium sp. CAG: 127	37	628
332	Eggerthella sp. HGA1	37	0
333	[Ruminococcus] gnavus	37	96
334	Ruminococcus sp. CAG: 108	37	100
335	Olsenella mediterranea	37	0
336	Oscillibacter sp. PC13	37	56
337	Subdoligranulum sp. CAG: 314	37	36
338	Oscillibacter ruminantium	37	68
339	Roseburia inulinivorans CAG: 15	37	161
340	Finegoldia magna	36	0
341	Bacteroides sp. 3_1_23	36	42
342	Peptococcus niger	35	0
343	Bacteroides sp. HPS0048	35	0
344	Oribacterium sp. WCC10	35	15
345	Firmicutes bacterium CAG: 552_39_19	34	68
346	Paraprevotella clara CAG: 116	34	0
347	Clostridiales bacterium 41_21_two_genomes	34	338
348	Prevotella sp. CAG: 604	34	247
349	Intestinimonas massiliensis	34	34
350	Clostridium sp. L2-50	34	123
351	Clostridium sp. CAG: 1000	34	0
352	Firmicutes bacterium CAG: 24	33	9
353	Enterococcus sp. FDAARGOS_375	33	0
354	Prevotella sp. CAG: 891	33	34
355	Parabacteroides sp. D13	33	60
356	Enterococcus sp. HMSC05C03	33	0
357	Eubacterium siraeum CAG: 80	33	39
358	Megasphaera sp. BL7	33	74
359	Bacteroides sp. D22	33	41
360	Lysinibacillus macroides	32	0
361	Klebsiella sp. MS 92-3	32	0
362	Sporobacter termitidis	32	36
363	Acinetobacter sp. NIPH 899	32	0
364	Pseudoflavonifractor capillosus	31	31
365	Lysinibacillus fusiformis	31	0
366	Peptoniphilus grossensis	31	0
367	Firmicutes bacterium CAG: 102	31	206
368	Ruminococcus albus	31	33
369	Cutaneotrichosporon oleaginosum	31	0
370	Firmicutes bacterium HGW-Firmicutes-21	31	0
371	Marvinbryantia formatexigens	31	28
372	Collinsella bouchesdurhonensis	31	0
373	Acidovorax sp. 12322-1	31	0
374	Firmicutes bacterium CAG: 321_26_22	31	51
375	Corallococcus sp. CAG: 1435	30	143
376	Bacteroides sp. 3_1_40A	30	17
377	Ruminococcaceae bacterium D5	30	31
378	Bacteroidales bacterium 43_8	30	0
379	Anaerotruncus rubiinfantis	30	14
380	Ruminococcus champanellensis	30	57
381	Clostridium sp. CAG: 349_48_7	30	25
382	Eubacterium rectale CAG: 36	29	95
383	Clostridium sp. CAG: 91	29	107
384	Butyricimonas sp. An62	29	0
385	Clostridiales bacterium GWF2_36_10	29	0
386	Alistipes finegoldii CAG: 68	29	0
387	Flavonifractor sp. An10	28	30
388	Lactobacillus salivarius	28	0
389	Butyricimonas synergistica	28	0
390	Firmicutes bacterium CAG: 65	28	160
391	Prevotella sp. CAG: 5226	28	188
392	Romboutsia ilealis	27	8
393	Eubacterium sp. CAG: 146	27	27
394	Clostridium sp. CAG: 609	27	19
395	Blautia schinkii	27	0
396	Methanosphaera stadtmanae	27	0
397	Alistipes timonensis	26	0
398	Lysinibacillus sp. ZYM-1	26	0
399	Lachnospiraceae bacterium JC7	26	17
400	Bacteroides sp. CAG: 709	26	140
401	Terrisporobacter glycolicus	26	0
402	Bacteroides sp. 3_1_19	25	22
403	bacterium LF-3	25	20
404	Bacteroides stercorirosoris	24	31
405	Peptoniphilus phoceensis	24	0
406	Oribacterium sp. P6A1	24	0
407	Prevotellamassilia timonensis	24	158
408	Ruminococcus faecis	24	10
409	Anaerofilum sp. An201	24	35
410	Dorea sp. 42_8	24	17
411	Eubacterium sp. CAG: 251	24	290
412	Clostridium sp. CAG: 389	23	45
413	Blautia sp. SF-50	23	9
414	Eubacterium sp. CAG: 76	23	76
415	Clostridiales bacterium NK3B98	23	33
416	Firmicutes bacterium ASF500	23	46
417	Bacteroides bouchesdurhonensis	23	0
418	Eubacterium sp. 38_16	22	22
419	Clostridium sp. HGF2	22	0
420	Bacteroides sp. 9_1_42FAA	22	16
421	Mitsuokella jalaludinii	22	280
422	Paraprevotella clara	22	0
423	Blautia massiliensis	22	7
424	Coriobacteriaceae bacterium 68-1-3	22	0
425	Bacteroides sp. 43_108	22	22
426	Olsenella sp. An270	22	0
427	Isoptericola variabilis	22	0
428	Clostridium sp. KNHs209	21	13
429	Streptococcus parasanguinis	21	61
430	Gordonibacter massiliensis	21	0
431	Bilophila wadsworthia	21	436
432	uncultured Bacteroides sp.	21	46
433	Firmicutes bacterium CAG: 552	21	31
434	Clostridium sp. SS2/1	21	60
435	Parabacteroides johnsonii	21	8
436	Flavonifractor sp. An100	20	50
437	Propionibacterium acidifaciens	20	0
438	Clostridium sp. CAG: 914	20	29
439	Clostridium sp. 26_22	20	0
440	Bacteroides cellulosilyticus	20	82
441	Ruminococcaceae bacterium D16	20	163
442	Butyricicoccus pullicaecorum	20	30
443	Actinomyces sp. ICM47	20	0
444	Olsenella sp. Marseille-P2300	20	0
445	Collinsella tanakaei	20	15
446	Gemmiger sp. An120	19	39
447	Pseudoflavonifractor sp. An184	19	35
448	Peptoniphilus sp. HMSC062D09	19	0
449	Bacteroides sp. 3_1_13	19	36
450	Flavonifractor sp. An306	19	32
451	Firmicutes bacterium CAG: 145	19	15
452	Peptoniphilus timonensis	18	0
453	Eubacterium ventriosum	18	70
454	Clostridiales bacterium 43-6	18	0
455	Cloacibacillus evryensis	18	0
456	Akkermansia muciniphila CAG: 154	18	13
457	Oribacterium sp. C9	18	0
458	Olsenella uli	18	11
459	Prevotella sp. CAG: 1092	17	299
460	Slackia heliotrinireducens	17	0
461	Lagierella massiliensis	17	0
462	Firmicutes bacterium CAG: 194	17	14
463	Lachnospiraceae bacterium 28-4	17	0
464	Oribacterium sp. NK2B42	17	0
465	Bacteroides eggerthii CAG: 109	17	0
466	Eggerthella timonensis	17	0
467	Clostridium sp. CAG: 762	17	79
468	Brachyspira sp. CAG: 484	17	91
469	methanogenic archaeon mixed culture ISO4-G1	17	38
470	Eggerthella sp. 51_9	17	0
471	Ruminococcus sp. CAG: 379	17	27
472	Bacteroides timonensis	17	98
473	Oscillibacter sp. CAG: 155	17	36
474	Peptoniphilus senegalensis	17	0
475	Lachnospira pectinoschiza	16	117
476	Firmicutes bacterium CAG: 95	16	197
477	Megamonas sp. Calf98-2	16	10
478	Massilimaliae massiliensis	16	14
479	Anaeromassilibacillus sp. An200	16	17
480	Odoribacter sp. 43_10	16	0
481	Bacteroides mediterraneensis	16	11
482	Bacteroides dorei CAG: 222	16	7
483	Bacteroides sp. 4_3_47FAA	16	13
484	Firmicutes bacterium CAG: 534	16	314
485	Ruminococcaceae bacterium FB2012	16	0
486	Clostridium disporicum	16	0
487	Neglecta timonensis	16	13
488	Bacteroides uniformis CAG: 3	15	9
489	Clostridium bolteae CAG: 59	15	0
490	Agathobaculum desmolans	15	61
491	Bacteroides sartorii	15	5
492	Bacteroides sp. D2	15	63
493	Lachnoclostridium sp. An196	15	151
494	Acidaminococcus massiliensis	15	0
495	Raoultibacter massiliensis	15	0
496	Clostridium sp. SN20	15	0
497	Eggerthella sp. YY7918	15	0
498	Bacteroides sp. 43_46	15	0
499	Lachnospiraceae bacterium 7_1_58FAA	15	25
500	Eggerthellaceae bacterium AT8	15	0
501	Alistipes sp. AL-1	15	10
502	Ruminococcus sp. SR1/5	15	0
503	Bacteroides fragilis CAG: 558	15	0
504	[Clostridium] thermosuccinogenes	14	0
505	Hydrogenoanaerobacterium saccharovorans	14	14
506	Alistipes sp. 58_9_plus	14	0
507	Eubacterium sp. CAG: 86	14	92
508	Faecalibacterium sp. CAG: 1138	14	29
509	Actinomyces oris	14	0
510	Dorea sp. CAG: 105	14	0
511	Eubacteriaceae bacterium CHKC1005	14	17
512	Succinivibrio dextrinosolvens	14	32
513	Lactococcus garvieae	14	0
514	Bacteroides sp. 1_1_30	14	33
515	[Clostridium] asparagiforme	14	9
516	Ruminococcus sp. CAG: 9-related 41_34	14	13
517	Enterococcus sp. HMSC072H05	14	0
518	Firmicutes bacterium CAG: 475	14	39
519	Clostridium sp. CAG: 440	14	0
520	Coprobacillus sp. 8_1_38FAA	14	35
521	Alloprevotella rava	14	14
522	Collinsella ihuae	13	0
523	Coprobacillus sp. CAG: 235_29_27	13	0
524	Megasphaera sp. NM10	13	39
525	Enterorhabdus caecimuris	13	21
526	Peptoniphilus harei	13	0
527	Prevotella sp. CAG: 755	13	13
528	Ruminococcus sp. CAG: 579	13	0
529	Paraprevotella xylaniphila	13	0
530	Enterococcus sp. 5B7_DIV0075	12	0
531	Tyzzerella nexilis	12	81
532	Ruminococcus sp. CAG: 57	12	36
533	Parabacteroides sp. Marseille-P3763	12	0
534	Raoultibacter timonensis	12	0
535	Bacteroides thetaiotaomicron CAG: 40	12	0
536	Clostridiales bacterium SK-Y3	12	0
537	Eubacterium sp. 41_20	12	62
538	Mobilibacterium timonense	12	0
539	Arabia massiliensis	12	0
540	Bacteroides vulgatus CAG: 6	12	7
541	Lysinibacillus boronitolerans	12	0
542	Ruminococcus sp. CAG: 108-related_41_35	11	50
543	Acinetobacter sp. LCT-H3	11	0
544	Odoribacter splanchnicus CAG: 14	11	0
545	Synergistes jonesii	11	0
546	Olsenella profusa	11	6
547	Synergistes sp. 3_1_syn1	11	0
548	Bilophila sp. 4_1_30	11	78
549	Clostridium sp. CAG: 798	11	61
550	Bacteroides sp. 2_1_33B	11	0
551	Prevotella sp. 885	11	146
552	Intestinibacter bartlettii	11	13
553	Enterorhabdus mucosicola	10	11
554	Bacteroides cellulosilyticus CAG: 158	10	30
555	Enterococcus sp. 3H8_DIV0648	10	0
556	Clostridium sp. CAG: 269	10	115
557	Candida parapsilosis	10	0
558	Clostridium nexile CAG: 348	10	74
559	Weissella sp. DD23	10	0
560	Actinomyces dentalis	9	0
561	uncultured crAssphage	9	9
562	Tissierellia bacterium SS-A11	9	0
563	Clostridium sp. ASBs410	9	0
564	Roseburia sp. CAG: 471	9	119
565	Paeniclostridium sordellii	9	0
566	Collinsella stercoris	9	0
567	Bacteroides coprophilus	9	8
568	Bacteroides sp. 3_1_33FAA	9	17
569	Enterococcus gilvus	9	0
570	Acidaminococcus sp. CAG: 542	8	0
571	Alistipes sp. CAG: 29	8	30
572	Prevotella sp. CAG: 617	8	8
573	Leuconostoc lactis	8	0
574	Collinsella sp. An2	8	0
575	Actinomyces sp. oral taxon 175	8	0
576	Clostridiales bacterium VE202-21	8	0
577	Listeria monocytogenes	8	0
578	Clostridium sp. 7_2_43FAA	8	0
579	Paraclostridium bifermentans	8	0
580	Enterococcus pallens	8	0
581	[Desulfotomaculum] guttoideum	7	0
582	Anaerococcus prevotii	7	0
583	Actinomyces viscosus	7	0
584	Bacteroides finegoldii	7	33
585	Clostridium celatum	7	0
586	Bacteroides stercoris CAG: 120	7	0
587	Enterococcus saccharolyticus	7	0
588	Enterococcus malodoratus	7	0
589	Clostridium sp. CAG: 470	7	10
590	Actinomyces odontolyticus	7	0
591	Peptoniphilus duerdenii	7	0
592	Actinomyces sp. ICM58	7	0
593	Ruminococcus sp. 37_24	7	0
594	Alistipes putredinis CAG: 67	7	9
595	Fusobacterium mortiferum	7	0
596	Collinsella phocaeensis	7	0
597	Dialister succinatiphilus	7	196
598	Enterococcus sp. kppr-6	6	0
599	Eubacterium callanderi	6	0
600	Sutterella wadsworthensis CAG: 135	6	18
601	Clostridiales bacterium 36_14	6	52
602	Prevotella lascolaii	6	11
603	Collinsella intestinalis	6	0
604	Lachnospiraceae bacterium 5_1_63FAA	6	33
605	Actinomyces sp. ICM39	6	0
606	Acinetobacter sp. CIP 101934	6	0
607	Acinetobacter lwoffii	5	0
608	Peptoniphilus sp. BV3AC2	5	0
609	Bifidobacterium bifidum CAG: 234	5	0
610	Bifidobacterium pseudocatenulatum CAG: 263	5	0
611	Lactobacillus rhamnosus	5	0
612	Prevotella sp. CAG: 732	5	65
613	Megamonas funiformis CAG: 377	5	0
614	Megamonas hypermegale	4	124
615	Eubacterium sp. CAG76_36_ 125	4	30
616	Bifidobacterium adolescentis CAG: 119	4	18
617	Roseburia sp. CAG: 197	0	47
618	Bacteroides sp. CAG: 98	0	41
619	Parasutterella excrementihominis CAG: 233	0	48
620	Clostridium sp. CAG: 122	0	98
621	Firmicutes bacterium CAG: 313	0	124
622	Clostridiales bacterium KLE1615	0	301
623	Elusimicrobium sp. An273	0	124
624	Bifidobacterium dentium	0	5
625	Clostridia bacterium UC5.1-1D1	0	8
626	Tyzzerella sp. Marseille-P3062	0	35
627	Acidaminococcus intestini	0	7
628	Prevotella sp. CAG: 386	0	64
629	uncultured Lachnospira sp.	0	248
630	Clostridium sp. M62/1	0	10
631	Sellimonas intestinalis	0	23
632	Clostridium sp. CAG: 780	0	114
633	Clostridium sp. AT4	0	26
634	Roseburia sp. CAG: 380	0	16
635	Ruminococcus sp. CAG: 330	0	23
636	Clostridium sp. CAG: 575	0	4
637	Clostridium sp. CAG: 62	0	74
638	Lachnospiraceae bacterium 8_1_57FAA	0	11
639	Eubacterium sp. CAG: 603	0	22
640	Ruminococcaceae bacterium cv2	0	15
641	Akkermansia sp. CAG: 344	0	58
642	Clostridium sp. 44_14	0	54
643	Clostridium sp. CAG: 628	0	107
644	Ruminococcus sp. CAG: 624	0	32
645	Roseburia sp. CAG: 303	0	451
646	Lactobacillus rogosae	0	33
647	Roseburia sp. CAG: 309	0	25
648	Acholeplasma sp. CAG: 878	0	115
649	Shigella sonnei	0	35
650	Megasphaera elsdenii CAG: 570	0	7
651	Fusobacterium sp. CAG: 439	0	8
652	Bifidobacterium pseudolongum	0	9
653	Bacteroides sp. CAG: 770	0	38
654	Bacteroides sp. 14(A)	0	11
655	Anaerovorax odorimutans	0	15
656	Bifidobacterium merycicum	0	7
657	Ruminococcus callidus	0	268
658	Eubacterium sp. CAG: 252	0	27
659	Clostridium sp. CAG: 253	0	42
660	Clostridium sp. ATCC BAA-442	0	20
661	Coprobacillus sp. 28_7	0	21
662	Clostridium sp. SCN 57-10	0	40
663	Ruminococcus sp. CAG: 403	0	7
664	Clostridium sp. 42_12	0	14
665	Firmicutes bacterium CAG: 65_45_313	0	108
666	Lachnospiraceae bacterium CAG: 25	0	8
667	Sutterella parvirubra	0	15
668	Eubacterium sp. 45_250	0	17
669	Firmicutes bacterium CAG: 272_52_7	0	26
670	Clostridium sp. 29_15	0	18
671	Veillonella dispar	0	94
672	Bacteroides sp. CAG: 530	0	145
673	Flavonifractor sp. An82	0	15
674	Firmicutes bacterium CAG: 449	0	81
675	Eubacterium ramulus	0	27
676	Clostridium sp. CAG: 75	0	26
677	Shigella flexneri	0	10
678	Coprococcus comes CAG: 19	0	9
679	Firmicutes bacterium CAG: 341	0	52
680	Candidatus Gastranaerophilales bacterium HUM_1	0	102
681	Clostridium sp. CAG: 813	0	49
682	Proteobacteria bacterium CAG: 495	0	31
683	Coprobacillus sp. CAG: 698	0	130
684	Prevotella stercorea	0	117
685	Gemmiger sp. An50	0	16
686	Clostridium sp. 26_21	0	12
687	Clostridium sp. CAG: 217	0	20
688	Butyrivibrio crossotus	0	11
689	Coprococcus sp. CAG: 782	0	11
690	Prevotella sp. P3-122	0	18
691	Blautia sp. CAG: 52	0	31
692	uncultured organism	0	7
693	Roseburia sp. 499	0	46
694	Clostridium sp. CAG: 277	0	170
695	Mitsuokella multacida	0	126
696	Azospirillum sp. 51_20	0	8
697	Ruminococcus sp. DSM 100440	0	37
698	Clostridium sp. CAG: 62_40_43	0	30
699	Butyrivibrio crossotus CAG: 259	0	10
700	Azospirillum sp. CAG: 239	0	82
701	Prevotella sp. CAG: 520	0	540
702	Lachnospiraceae bacterium TF01-11	0	111
703	Burkholderiales bacterium 1_1_47	0	118
704	Bacteroides massiliensis	0	134
705	Eubacterium sp. CAG: 248	0	294
706	Clostridiales bacterium VE202-14	0	17
707	Eubacterium sp. 36_13	0	36
708	Veillonella atypica	0	41
709	Sutterella sp. 54_7	0	5
710	Dakarella massiliensis	0	64
711	Clostridium ventriculi	0	119
712	Sutterella sp. CAG: 351	0	44
713	Bacteroides acidifaciens	0	9
714	Lachnospiraceae bacterium KHCPX20	0	7
715	Roseburia sp. CAG: 10041_57	0	38
716	Veillonella sp. DORA_A_3_16_22	0	33
717	Selenomonas ruminantium	0	6
718	Emergencia timonensis	0	14
719	Roseburia sp. CAG: 45	0	62
720	Azospirillum sp. 47_25	0	8
721	Fournierella massiliensis	0	23
722	Tenericutes bacterium HGW-Tenericutes-4	0	16
723	Blastocystis sp. subtype 1	0	33
724	Prevotella bryantii	0	8
725	Roseburia sp. 831b	0	46
726	Bacteroides sp. CAG: 754	0	25
727	Roseburia sp. 40_7	0	11
728	Roseburia sp. CAG: 100	0	70
729	Bacteroides congonensis	0	14
730	Clostridium sp. CAG: 12237_41	0	36
731	Lachnospiraceae bacterium 10-1	0	20
732	Eubacterium sp. CAG: 38	0	452
733	Azospirillum sp. CAG: 260	0	16
734	Bacteroides ovatus CAG: 22	0	36
735	Firmicutes bacterium CAG 194_44_15	0	7
736	Veillonella parvula	0	14
737	Clostridium sp. CAG: 265	0	41
738	Coprococcus sp. ART55/1	0	9
739	Parasutterella excrementihominis	0	63
740	Roseburia intestinalis CAG: 13	0	190
741	Roseburia sp. CAG: 50	0	13
742	uncultured Roseburia sp.	0	36
743	Akkermansia glycaniphila	0	18
744	Mycoplasma sp. CAG: 611	0	61
745	Eggerthella sp. CAG: 298	0	43
746	Clostridium sp. CAG: 632	0	226
747	Prevotella ruminicola	0	7
748	Drancourtella massiliensis	0	18
749	Lachnoclostridium sp. An14	0	19
750	Eubacterium sp. CAG: 115	0	14
751	Bacteroides sp. CAG: 1076	0	4
752	Coprococcus sp. CAG: 131	0	26
753	Veillonella sp. oral taxon 158	0	12
754	Phascolarctobacterium sp. CAG: 266	0	14
755	Lachnoclostridium edouardi	0	11
756	Prevotella stercorea CAG: 629	0	24
757	Alloprevotella tannerae	0	7
758	Olsenella sp. oral taxon 807	0	8

TABLE 9
PostIntervention Control vs PostIntervention Treatment Seed Average Values
		Post				Post
	Baseline	Intervention			Baseline	Intervention
	Control	Control		Increase/	Treatment	Treatment		Increase/
IDs	Average	Average	Difference	Decrease	Average	Average	Difference	Decrease
Carbohydrates				Decrease¶				Decrease¶
C , Vitamins,				Increase				Decrease¶
Prosthetic Groups,
Pigments
Amino Acids and				Decrease¶				Decrease¶
Derivatives
Protein Metabolism				Decrease¶				Decrease¶
Metabolism				Increase				Decrease¶
Cell Wall and Capsule				Decrease¶				Decrease¶
Fatty Acids, Lipids,				Decrease¶				Decrease¶
and
and				Decrease¶				Decrease¶
Metabolism				Decrease¶				Decrease¶
Respiration				Decrease¶				Decrease¶
Stress Response				Decrease¶				Decrease¶
Metabo  damage and				Decrease¶				Decrease¶
repair or mitigation
				Decrease¶				Decrease¶
				Decrease¶				Decrease¶
Phosphorus Metabolism				Decrease¶				Decrease¶
Regulation and				Decrease¶				Decrease¶
Cell Signaling
Cell Division and				Decrease¶				Decrease¶
Cell Cycle
acquisition and				Increase				Decrease¶
metabolism
Potassium metabolism				Decrease¶				Decrease¶
Sulfur Metabolism				Decrease¶				Decrease¶
Virulence, Disease				Decrease¶				Decrease¶
and Defense
Phages, Prophages,				Decrease¶				Decrease¶
Transposable elements,
Plasmids
Metabolism of Aromatic								Decrease¶
Compounds
M  and Che				Increase				Decrease¶
Thiamin				Increase				Decrease¶
Nitrogen Metabolism				Decrease¶				Decrease¶
Predictions based on				Decrease¶				Decrease¶
plant-prokaryote
comparative analysis
Mito  electron				Decrease¶				Decrease¶
transport system
in plants
and				Decrease¶				Decrease¶
lation
sugars				Decrease¶				Decrease¶
Secondary Metabolism				Decrease¶				Decrease¶
Plant Gluc				Decrease¶				Decrease¶
Transcriptional				Decrease¶				Decrease¶
regulation
Phages, Prophages,				Decrease¶				Decrease¶
Transposable elements
Plant cell walls and				Decrease¶				Decrease¶
surfaces
Central metabolism				Increase
Autotrophy				Decrease¶				Decrease¶
A  Sensor and				Decrease¶				Decrease¶
transport module
Polyamines								Decrease¶
Stress Response								Decrease¶
and Stationary Phase
Response
				Decrease¶				Decrease¶
electron
transport system
indicates data missing or illegible when filed

Discussion:

In this study, following earlier reports of clinical improvement in terms of sleep (Raghavan et al., 2021^a), behavioural pattern (Raghavan et al., 2021^b), plasma αSyn (Raghavan et al., 2021a) and serum melatonin increase (Raghavan et al., 2021^b), gut dysbiosis has been shown to have a strong correlation with the severity of symptoms in ASD (Grimaldi et al., 2018). We evaluated and compared the gut microbiota of the subjects who were supplemented with AFO-202-derived 1,3-1,6 beta glucan with those who did not take the supplement.

Several studies have reported the differences in the gut microbiota between children with ASD and neurotypical children. Reduced number of bifidobacterial and increased Clostridium spp., Desulfovibrio spp., Sutterella spp., and/or Veillonellacea was reported by Souza et al (2012). Tomova et al (2015) reported a change in Bacteroidetes/Firmicutes ratio and an increase in bifidobacterial numbers after probiotic administration.

An exclusion diet and a 6-week prebiotic intervention demonstrated lower abundance of Bifidobacterium spp. and Veillonellaceae family and higher abundance of Faecalibacterium prausnitzii and Bacteroides spp. (Grimaldi et al., 2018). Faecalibacterium, Ruminococcus, and Bifidobacterium were relatively less abundant, whereas Caloramator, Sarcina, Sutterella ceae, and Enterobacteriaceae were more abundant in children with ASD (De Angelis et al., 2013). In addition, lower abundances of the genera Prevotella, Coprococcus, and unclassified Veillonellaceae have been reported (Kang et al., 2013). Among these bacteria, increased Bacteroidaceae, Prevotellaceae, and Ruminococcaceae and decreased Prevotella copri, Faecalibacterium prausnitzii, and Haemophilus parainfluenzae have been reported (Kang et al., 2018; Oh et al., 2020).

In the present study, in line with these reports, the shift of the gut microbiome was towards a beneficial spectrum in Group 2 (Nichi Glucan) because there was a decrease in Enterobacter, Lactobacillus, Escherichia coli, Akkermansia muciniphila CAG:154, Blautia spp., Coprobacillus sp., several clostridium spp., and Clostridium bolteae CAG:59, with an increase in the abundance of Bacteroides, Prevotella, Faecalibacterium prausnitzii, and Prevotella copri. Desulfovibrio Bacteria which have been reported to be associated with PD (Murros et al., 2021) decreased in the Gr. 2.

In particular, Enterobacteria and E. coli significantly decreased in Group 2 compared to Group 1 after the intervention. Gram-negative enteric bacteria such as the Enterobacter and E. coli secrete the amyloid curli that constitutes 85% of the extracellular matrix of enteric biofilms. The curli has similarities and associations with pathological and immunomodulatory human amyloids such as amyloid-3 implicated in AD, αSyn involved in ASD and PD, and serum amyloid A associated with neuroinflammation (Miller et al., 2021). Curli causes misfolding (Al-Mazidi et al., 2021) and accumulation of the neuronal protein αSyn in the form of insoluble amyloid aggregations, leading to inflammation and neuronal dysfunction that is central to pathogenesis of Lewy-body-associated synucleinopathies, including PD and AD.

Curli-producing bacteria also increase the production and aggregation of the amyloid protein αSyn, which has been shown to propagate in a prion-like fashion from the gut to the brain via the vagus nerve and/or spinal cord, thus culminating in the neurological disorders such as ASD (Al-Mazidi et al., 2021). In this study, the significant decrease in Enterobacter and E-coli will thus be of benefit in these synculeopathies. Before the start of this study, the objective to study αSyn was to understand the effects of the beta glucan supplementation on Synaptic imbalance in presynaptic terminals, observed in ASD.

The study results showed that plasma levels of αSyn increased in Group 2 compared with Group 1 along with improvement in Childhood Autism Rating Scale score and sleep pattern which to our knowledge is the first of its kind intervention producing an observable change in the plasma synuclein levels (Al-Mazidi et al., 2021).

In a study by Ding et al., it was reported that 14 functional properties displayed differences between the ASD and healthy control groups. Four functions, including galactose metabolism, glycosyltransferase activity, glutathione metabolism, and antifolate resistance, were enriched in the ASD group. In another study by Lindefeldt et al, the relative abundance of 26 metabolic pathways was diminished after 3 months on a ketogenic diet in children with epilepsy and 3 became more relative abundant.

The group with most pathways changed was carbohydrate metabolism, showing reduction of fructooligosaccharides (FOS) and raffinose utilization, sucrose utilization, glycogen metabolism, lacto-N-biose I and galacto-N-biose metabolic pathway. The SEED average findings of the present study also reflect this beneficial outcome (FIG. 21 and Table 9)

The study of the gut microbiome has offered further new insights wherein Enterobacter increasing curli protein and αSyn deposition in the enteric nervous system having been controlled by the beta glucan food supplement, the increase in plasma αSyn levels point out to the disintegration of the amyloid deposits leading to these αSyn entering the blood stream. Indeed, natural killer (NK) cells have been shown to act as efficient scavengers of abnormal α-Syn aggregates (Earls et al., 2020), and the AFO-202 beta glucan has a proven capability to increase and activate NK cells (Ikewaki et al., 2007), which could be another probable mechanism contributing to the increased αSyn levels in the plasma, apart from positive clinical outcomes in these children with ASD.

This result highlights NK cell's potential as a promising therapeutic strategy for prophylaxis and prevention of brain disorders, and they are likely to be used for such αSyn accumulation and propagation, after relevant research on their specific pathways and variations in their capability. The NK cells have been proven to clear the amyloid deposits peripherally though not macrophages (Raghavan et al., 2021^c). In the central nervous system, such a role is played by the microglia (Bartels et al., 2020). βeta-glucans also rejuvenate microglia (Luna et al., 2015) that have been shown to scavenge amyloid deposits in the brain and CNS (Morato Torres et al., 2020), thus proving to be a wholesome therapeutic strategy for neurodevelopmental and neurodegenerative diseases.

Altered α-Syn protein misfolding spreading to anatomically connected regions in a prion-like manner and mediating neurodegenerative diseases such as PD (Terajima et al., 2020) and the increased risk of children with ASD in developing PD at a later stage (Swirski et al., 2014) suggests further research into these converging pathogenic pathways of neurodevelopmental and neurodegenerative diseases is needed as well as suggests that this safety-proven food supplement is a preventive strategy in subjects with ASD against PD.

Other than research into normal and abnormal α-syn being warranted, studying the implications of soluble and insoluble α-syn (Boziki et al., 2020) is important because the proportion of insoluble α-syn that was phosphorylated at Ser129 was reported to be significantly higher in brain tissue from PD patients. In addition, cell lines such as the SH-SYHY neuroblastoma (Boziki et al., 2020) will reveal the correlation of the various α-syn with the severity of symptoms and pathogenesis in these neurodegenerative diseases, apart from helping to develop novel disease-modifying strategies employing such simple nutritional supplementation.

The microbiota reconstituted in a beneficial manner in the present study with AFO-202 beta glucan must be further progressed into research to study the effects of other variants of A. pullulans beta glucan that have been shown to be anti-inflammatory. Such research could lead to mechanistic insight into the molecular pathways from the local immune responses in the gut leading to systemic inflammation and, eventually, to organ-specific autoimmunity of the CS in neuroinflammatory conditions such as MS.

Conclusion:

Favourable reconstitution of the gut microbiota after consumption of AFO-202 beta glucan in children with ASD has been demonstrated in this study, apart from the clinical improvement already reported. The decrease in Enterobacteria demonstrates the potential of this beta-glucan supplementation for neurodevelopmental conditions such as ASD as well as neurodegenerative disorders such as PD and AD, with converging pathways of amyloid accumulations and propagation, warranting larger clinical studies and research to recommend this as a routine food supplement or an adjunct to existing therapies for prevention and management of both neurodevelopmental and neurodegenerative diseases.

List of Abbreviations

• • ASD—autism spectrum disorder
  • WGM—Whole genome metagenome
  • αSyn—α-synuclein
  • MS—multiple sclerosis
  • AD—Alzheimer's disease
  • PD—Parkinson's disease

Improving Behavioural Pattern and Alpha-Synuclein Levels

Abstract:

Autism spectrum disorders (ASDs) are a wide range of disabilities in which the neurosynaptic biomarkers and mechanisms remain elusive. As there are no definite interventional modalities available to improve the behavioural pattern, remedial therapies are the only option and have varying outcomes. Based on our earlier study on the improvement of melatonin in ASD children when supplemented with a biological response modifier beta-glucan food supplement, we have evaluated the childhood autism rating scale (CARS) and alpha-synuclein levels in this randomized, parallel-group, multiple-arm clinical trial. Six subjects with ASD (n=6) Gr. 1 underwent conventional treatment comprising remedial behavioural therapies and L-Carnosine 500 mg per day, and 12 subjects (n=12) Gr. 2 underwent supplementation with the Nichi Glucan food supplement 0.5 g twice daily along with the conventional treatment.

There was a significant decrease in the CARS score in all of the children of the Nichi Glucan Gr.2 compared to the control (p-value=0.034517), by an average of 3 points in the improvement of autism's signs and symptoms, whereas the improvement was very mild or nil in Gr.1. Plasma levels of alpha-synuclein were significantly higher in Gr. 2 (Nichi Glucan) than in the control group Gr. 1 (p-value=0.091701). Improvement of the behavioural pattern CARS score and a correlating alpha-synuclein level, followed by a safe beta-glucan food supplement, warrants further research on other parameters, such as gut-microbiota evaluation, and relevant neuronal biomarkers which is likely to cast light on novel solutions.

Trial Registration Number:

• • Clinical Trials Registry of India (CTRI/2020/10/028322)

Lay Summary:

Behavioural pattern in children with Autism Spectrum Disorder has been observed to improve following consumption of Beta 1,3-1,6 Glucan food supplement. The CARS score has also shown improved, compared to the control group in this pilot clinical study along with increase of a neuronal marker Alpha-Synuclein which is usually lower in affected children compared to normal age matched controls.

Methods:

This study was approved by the institutional ethics committee of Kenmax Medical Service Private Limited, Madurai, India and was registered as a randomized, parallel-group, and multiple-arm clinical trial in the Clinical Trials Registry of India (CTRI/2020/10/028322). The caregiver of all the subjects gave their informed consent for inclusion before participation in the study. The study was conducted in accordance with the Declaration of Helsinki.

Study Design:

The subjects enrolled in the study had received a diagnosis of ASD by a developmental paediatrician and were verified by a psychologist using a clinical interview for a behavioural pattern that incorporated CARS.

Eighteen subjects (n=18) with ASD in total were enrolled in this prospective, open-label, pilot clinical trial comprising of two arms. The CONSORT flow diagram is presented as FIG. 14.

Arm 1 or Gr. 1: Control: Six subjects with ASD (n=6) underwent conventional treatment comprising remedial behavioural therapies and L-Carnosine 500 mg per day.

Arm 2 or Gr. 2: Treatment arm: 12 subjects (n=12) underwent supplementation with Nichi Glucan (Aureobasidium pullulans strain AFO-202 (also referred to as FO-68 [(accession number) FERM BP-19327]) derived Beta 1,3-1,6 Glucan) food supplement along with conventional treatment. Each subject consumed two sachets (0.5 g each) of Nichi Glucan daily—one sachet with a meal twice daily—for a period of 90 days.

Inclusion Criteria:

• • i. Age: 3 to 18 years;
  • ii. Gender: Both male and female;
  • iii. ASD criteria as per CARS score; and,
  • iv. Parents/caretakers willing to provide consent for their children to actively participate in the study.

Exclusion Criteria:

• • i. Subjects aged more than 18 years old;
  • ii. Any child with acute general illness or who has been on any antibiotic, anti-inflammatory, or antioxidant treatment in the two weeks prior to enrolment in the study;
  • iii. Hyperallergic to any of the investigational products; and,
  • iv. Subjects with long-standing infections.

Outcome Measures:

• • i. Childhood autism rating scale (CARS):
  • The CARS was monitored at baseline and after 90 days between the Gr.1 (control) and Gr.2 (Nichi Glucan). The CARS score was calculated based on a cumulative score obtained on the CARS scale, wherein a score below 30 indicates absence of sufficient signs and symptoms indicative of autism, a score between 30 and 36 indicates mild-to-moderately severe autism, and a score from 37 to 60 is correlated with severe autism (Ramaekers et al., 2019). The psychologist who performed the assessment and the parents were blind to the participant's treatment status; hence, this is a double-blind study.
  • ii. Evaluation of plasma alpha-synuclein:
  • Human alpha-synuclein (α-syn) levels in plasma were measured in peripheral blood at baseline and after the study's completion at 90 days. The measurement was performed using the human α-synuclein (α-syn) ELISA kit (KINESISDx, USA) as per the manufacturer's instructions.

Data Analysis:

All data were analysed using Excel software statistics package analysis software (Microsoft Office Excel(R)); Student's paired t-tests were also calculated using this package; and p-values<0.05 were considered significant.

Results:

During enrolment, six subjects with ASD (n=6) could be enrolled in the control group (Gr. 1), whereas in the treatment group (Gr. 2), one of them dropped out before the start of the study. During the study, four subjects were lost to follow-up: two in Gr. 1 (one dropped out due to social problems in the family, and the other relocated to another city) and two in Gr. 2 (one dropped out due to social problems in the family, and the other relocated to another city). A total of 13 subjects (four in Gr. 1 and nine in Gr. 2) completed the study. One female subject was in both Gr. 1 and Gr. 2. The rest were male.

Adverse Effects:

Only one child exhibited possible mild adverse effects related to increased bowel movements in Gr. 2 for one week after supplementation with Nichi Glucan, which settled on its own. No adverse effects were found in any of the other children.

Score on CARS Scale:

Among the children in the control group (Gr.1), all four were in the category of severe autism, and their score at baseline ranged from 37 to 52 (mean=42.75±5.76). Among the nine children in Gr.2, two were in the mild-to-moderate category of autism (mean=33.5±2.5), whereas the remaining seven were in the category of severe autism (mean=43.71±4.80).

After the intervention, the mean CARS score in the four children of the control group was 42.5±5.4, while in Gr.2 (Nichi Glucan), the mean of the CARS score in the two children with mild-to-moderate autism was 32.5±0.5. In the remaining seven children, the CARS score after Nichi Glucan intervention had a mean of 40.1±5.96. Thus, there was a significant decrease in the CARS score in all of the children in the Nichi Glucan Gr.2 group compared to the control (p-value=0.034517), with an average of 3 points in the improvement of autism's signs and symptoms, whereas the improvement was very mild or nil in Gr.1 (FIG. 26).

Among the various parameters assessed on the CARS, there was visible subjective improvement in the emotional response, including reduction in irritability and anger (88%), sleep improvement (88%), speech characteristics with improvement in finger pointing and monosyllables in 77%, and improved responses to the caregiver in 77% of the children in Nichi Glucan Gr. 2, but these improvements were very mild or nil in Gr.1.

Plasma levels of alpha-synuclein ranged between 0.12 and 20.41 ng/dl (mean=9.73 ng/dl) in the control group and between 0.45 and 41.12 ng/dl (mean=9.39 ng/dl) in the treatment group at baseline. After the intervention, plasma levels of alpha-synuclein increased, with a mean increase in levels of 26.72 ng/dl in the treatment (Nichi Glucan) Gr.2 group compared to the control group Gr. 1 (mean increase=10.56 ng/dl) (p-value=0.091701) (FIG. 27).

Discussion:

In this study of 13 subjects, the behavioural pattern evaluated by the CARS score improved in all nine subjects of Gr.2 (Nichi Glucan) (FIG. 14), especially on the emotional aspects and sleep-related parameters, and the alpha-synuclein levels increased significantly in these nine subjects compared to the control (FIG. 26). Alpha-synuclein plays a key role in the synaptic functions of neurons by regulating CADPS2 mRNA expression. There are reports that the neural overconnectivity and synapse alteration associated with the pathogenesis of ASD may actually owe their aetiology to alpha-synuclein dysregulation (Kadak et al., 2015; Sriwimol et al., 2018; Obergasteiger et al., 2014).

Further, alpha-synuclein has recently been considered one of the important biomarkers for the diagnosis of autism and ASD, wherein the levels are low compared to age-matched controls (Kadak et al., 2015; Sriwimol et al., 2018; Siddique et al. 2020). In regard to neurodegenerative diseases such as PD, the reports have been varied, with some reporting lower than normal levels and others higher. In a correlating hypothesis of the plasma alpha-synuclein level, between autism and neurodegenerative diseases, it has been proposed that alpha-synuclein aggregation in the neural synapse may lead to lower plasma levels (Sriwimol et al., 2018).

Whether the increase in alpha-synuclein levels in plasma in the ASD patients after Nichi Glucan supplementation is due to regulation/prevention of alpha-synuclein's aggregation in the neural synapse must be investigated because an earlier study on beta-glucan from yeast showed reduction in alpha-synuclein expression on the brain substantia nigra in Parkinson's rat model (Masruroh et al., 2017). However, no single mechanism, intervention, or therapy has proven its ability to regulate alpha-synuclein levels, especially in children with ASD. In our study, which is the first of its kind, the plasma alpha-synuclein levels showed significant increase after Nichi Glucan supplementation, and the levels were in line with those that were reported for children without ASD (Kadak et al., 2015; Sriwimol et al., 2018).

Studies on children with ASD have indicated there is an underlying neuroinflammatory process occurring in different regions of the brain involved in microglial activation, thus resulting in a loss of connections or underconnectivity of neurons and leading to behavioural manifestations (Shah et al., 2009). MCP-1, IL-6, IL-10, and TNF-α have been shown to be expressed in higher levels in children with autism (Shah et al., 2009). Beta-glucan has been proven to reduce the expression of inflammatory and proinflammatory markers, including II-6 and TNF-α (Ikewaki et al., 2007), apart from having a neuroprotective effect by attenuating inflammatory cytokine production through microglia (Alp et al., 2012). This mechanism of counteracting ASD inflammation by Nichi Glucan supplementation deserves further research.

In another study, beta-glucan reduced induced microglia activation and its phagocytosis of synaptic puncta and upregulation of proinflammatory cytokine (TNF-α, IL-1β, and IL-6) mRNA expression apart from promoting Tau signalling and improving cognition and brain function via the gut-brain axis (Shi et al., 2020). The mechanism by which the beta-glucan promoted behavioural improvement in the present study and correlated with the regulation of alpha-synuclein levels needs further in-depth research, not only for ASD but also for neurodegenerative diseases such as AD, PD, and so on, especially with regard to its effects on the gut-microbial ecosystem. The evolving data on the gut-brain axis and gut microbiota indicate there are two major approaches to balancing gut microbiota: probiotic and prebiotic.

Probiotic approaches, such as nutritional probiotics, faecal transplantation, and so on, involve direct administration of the beneficial microorganisms that have to colonise the gut (Peng et al., 2020). However, the gut environment must be conducive for such probiotic supplementation. This is where prebiotic approaches come in, such as Nichi Glucan, which help in regulating the gut-microbial ecosystem and preventing chronic inflammatory status Peng et al., 2020); this must be validated by future studies in terms of the effects of Nichi Glucan and gut microbiota in their relevance to ASD.

The limitation of the study is the limited number of participants, the unequal distribution of genders, and the number of participants between the groups. However, this is only a pilot study, and larger randomized, multi-centric clinical trials are warranted. Nevertheless, the study is significant as it has identified a simple nutritional supplemental intervention based on a naturally derived beta-glucan, the Nichi Glucan, which could stimulate endogenous alpha-synuclein secretion, promote better synaptic regulation, and improve the behaviour symptoms of children with autism. However, the results suggest that the benefits will be considerable when evaluated in terms of social and emotional well-being and alleviation of caregiver stress, which is extremely significant.

Conclusion:

Patients with ASD showed improvement in behavioural symptoms and improved levels of plasma alpha-synuclein; thus, this pilot clinical study of nutritional supplementation with an AFO-202 strain of black yeast Aureobasidium pullulans produced the biological response modifier beta-glucan (Nichi Glucan). Evaluation as per the CARS score has also shown significant beneficial effects. Although further validations need to be performed, the study definitely confirms the potential of Nichi Glucan as a simple but effective food supplement to be considered as a routine in children with ASD. Further research on the mechanisms of its action in improving alpha-synuclein levels and balancing the immune system in the context of managing chronic inflammation and gut-microbiota regulation as a prebiotic is likely to improve understanding of other diseases caused by neuroinflammation such as PD and AD.

Comparison of Different Beta Glucans with AFO-202Alpha-Synuclein Suppression Data from F26S Study

Methods

Neuroblastoma cell line (SHSY-5Y Tet-On: SCC291) (MERCK) was suspended in 10% FCS-DMEM/F12 medium and seeded into 96-well microplates to achieve a cell count of 5×104 cells/well. After 24 hours of incubation, the cells were washed with 10% FCS-DMEM/F12 medium and new 10% FCS-DMEM/F12 medium was added.

Then, the different beta glucans (Product 1: Micelle Glucan(R) (gel or liquid type) purchased from RL-JP Co., Japan; Product. 2: Beta-glucan NEW EX (gel or liquid type) purchased from Aureo BIS, Japan; Product 3: Yeast Glucan (capsule, inside powder?) purchased from Shell Life Japan Co., Japan) were added to the medium, and the cells were cultured for 1 day. After incubation, the wells were washed three times with PBS and fixed in 0.25% glutaraldehyde-PBS for 1 hour at room temperature. After fixation, the wells were washed three times with PBS-0.05% Tween (PBS-T). After washing the wells with PBS-T, α-synuclein polyclonal antibody (proteintech Co. 10842-1-AP; x1,000 dilution) was added to the wells and incubated at room temperature for 1 h. Then, 2% BSA-PBS-T was added and left for 1 h (to block non-specific reactions).

After 1 hour, the wells were washed with PBS-T and 50 μL of biotin-labeled anti-rabbit IgG antibody (Cosmo Bio) diluted 5,000-fold was added to the wells and the reaction was carried out for 40 minutes at room temperature. After washing the wells, 50 μL of 10,000-fold diluted peroxidase-labeled streptavidin (Cosmo Bio) was added and the reaction was carried out for 20 minutes at room temperature. After washing the wells again, 50 μL of TMB (Cosmo Bio) was added to the wells, and the reaction was stopped with 0.5 M-HCl for 10 minutes.

After that, the absorbance (OD value) was measured with a microplate reader (450 nm) (Tosoh). Data were expressed as ΩOD value (sample OD value−blank OD value). The expression rate was calculated based on the control (None).

Results:

Results are found in Table 10.

TABLE 10
Expression of α-synuclein on the neuroblastoma cell line
(SHSY-5Y Tet-On: SCC291) treated with several beta-glucans (BGs)
	δOD: 450 nm	Expression %	Suppression %
Treatment	Mean ± SD	vs. None	vs. None
None	0.776 ± 0.0211	100.0	0.0
P.1: Micelle BG	0.733 ± 0.1047	94.46	5.54
50 μg/mL
P.2:  BG	0.709 ± 0.0075	91.41	8.59
50 μg/mL
P.3:  BG	0.745 ± 0.0111	96.05	3.96
50 μg/mL
AFO-202	0.630 ± 0.0644	81.19	18.81
50 μg/mL
indicates data missing or illegible when filed

Decrease in α-synuclein expression was highest in AFO-202 beta glucan. Since these cell lines produced α-synuclein are considered to be abnormal/misfolded and capable of aggregation, their decrease in expression is considered to be a suppression of production of abnormal α-synuclein and hence an advantage.

Improving Sleep Pattern and Serum Melatonin

Introduction:

Sleep problems are reported in 50 to 80% of children with Autism and Autism Spectrum disorders (ASD) [C1]. In adolescents and older children with ASD, sleep problems are higher including delayed sleep onset, shorter sleep duration and daytime sleepiness whereas in younger children bedtime resistance, sleep anxiety, parasomnias and night waking are predominant [C2]. Problems in sleep exacerbate the other features of autism such as tantrums, aggression, self-injury, inattention, hyperactivity, social interactions and repetitive behaviours, adding to the parental stress and the entire family's well-being [C1, C3].

Melatonin, a neurohormone secreted by the pineal gland which regulates circadian rhythms including sleep patterns has been shown to be released at lower levels in individuals with autism and has been shown to have a positive effect on sleep in autism by acting on relieving Anxiety, improving sensory processing, possess anti-nociceptive effects on pain, and also gastro-intestinal dysfunction or gut dysbiosis [C3]. A significant proportion of children with ASD have chronic gastrointestinal problems such as diarrhea and/or constipation, irritable bowel syndrome etc. These GIT symptoms have been related cortisol response to stress and gut dysbiosis induced chronic inflammation in ASD [C2] which in turn has associations with altered melatonin levels in autism [C2]. Thus, melatonin supplementation [C2,C4,C5] is one of the main pharmacological approaches under consideration for ASD.

Clinical studies of supplemental melatonin in ASD children have shown to improve sleep latency and quality [C2,C4,C5] in varying degrees [C3]. It is also to be noted that melatonin, though the side effects have been reported to be minimal, it has been found to be effective mostly in short term treatment of sleep disorders and the positive effects have waned during follow up (6-12 months) in specific clinical studies [C6]. Beta (β)-glucans which are naturally occurring compounds have been shown to have a wide range of biological response modifying beneficial effects in metabolism, anti-cancer as well as in reducing the stress and mental disorders by acting on the immune system related pathways [C7]. An animal study has earlier shown that melatonin levels were upregulated in the blood serum of rats in the presence of rice bran (RB) and Beta (β)-glucan present in a mushroom Sarcodon aspratus (S)'s extracts [C7,C8]. We and other research teams have earlier reported the beneficial effects of Nichi Glucan, a black yeast (Aureobasidium pullulans) AFO-202 derived 1,3-,16 beta glucan in metabolic disorders [C9,C10], cancer [C11,C12] in human clinical studies and as a suggested vaccine adjuvant for COVID-19 [C13]. Herein we undertook to study the effects of Nichi Glucan on sleep pattern and serum melatonin levels of ASD children in this pilot clinical study.

Example 4

Materials and Methods:

Thirteen children with ASD, four in the control group (Gr.1) and nine in the treatment group (Gr.2) age range 2.5 to 13 years were included in the study. The subjects of Gr.2 consumed 1 gram of Nichi glucan (Aureobasidium pullulans strain AFO-202 (also referred to as FO-68 [(accession number) FERM BP-19327]) derived Beta 1,3-1,6 Glucan) as food supplement along with conventional therapies while Gr. 1 underwent conventional therapies alone for a duration of 90 days. The serum melatonin levels were evaluated before and after the study along with assessment of the subjective parameters in sleep pattern by means of a questionnaire to the caregiver in both the groups.

Results:

In the Nichi Glucan supplementation group (Gr. 2), the serum melatonin increased on an average from 238.85 ng/dl pre-intervention to 394.72 ng/dl post-intervention which was greater than the control group (Gr.1). All the children in the Nichi Glucan group (Gr.2) showed improvement in sleep pattern and quality.

Conclusion:

Aureobasidium pullulans derived Beta 1,3-1,6 Glucan after 90-days consumption has shown visible improvement in sleep quality, pattern and serum melatonin levels in this first of its kind report in the literature which warrants a larger multicentric study for validation and in-depth research on the mechanisms to recommend this as a routine supplementation in kids with ASD to improve their quality of sleep.

Example 5

Materials and Methods:

This study was approved by our Institutional ethics committee of Kenmax Medical Service Private Limited, Madurai, India and registered in the Clinical trial registry of India (CTRI/2020/10/028322).

Study Design:

The subjects enrolled in the study had clinical diagnosis of ASD by a developmental paediatrician using standard assessment verified using a clinical interview that incorporated CARS (Childhood Autism Rating Scale).

Eighteen subjects (n=18) with ASD in total were enrolled in this prospective open label pilot clinical trial comprising of two arms,

Arm 1 or Group (Gr.) 1: Control: Six subjects with ASD (n=6) underwent conventional treatment which comprised of remedial behavioural therapies and L-Carnosine 500 mg per day.

Arm 2 or Group (Gr.) 2: Treatment arm: Twelve subjects (n=12) underwent supplementation with Nichi Glucan (Aureobasidium pullulans strain AFO-202 (also referred to as FO-68 [(accession number) FERM BP-19327]) derived Beta 1,3-1,6 Glucan) food supplement along with conventional treatment. The subjects consumed 2 sachets (0.5 g each) of Nichi Glucan, one sachet with a meal twice daily for a period of 90 days.

Inclusion Criteria:

• • i. Age: 3 to 18 years;
  • ii. 2. Gender: Both male and female;
  • iii. ASD criteria as per CARS (Childhood Autism Rating Scale) score; and,
  • iv. Parents willing to consent for their children for actively participating in the study.

Exclusion Criteria:

• • i. Subjects aged more than 18 years old;
  • ii. Any child with acute general illness or is on any antibiotic, anti-inflammatory, or antioxidant treatment in the two weeks prior to enrolment in the study;
  • iii. Hyperallergic to any of the investigational products; and,
  • iv. Subjects with long standing infections

Outcome Measures:

• • i. Sleep pattern assessment by questionnaire:
  • The Parent or caregiver completed a survey questionnaire, the Children's Sleep Habits Questionnaire-Abbreviated (CSHQ-A) was used in this research to assess the sleep problems which consisted of 22 questions (NICHD SECCYD-Wisconsin), with adaptations to suit the local cultural and social conditions.
  • ii. Evaluation of serum melatonin:
  • Melatonin levels in serum were measured in peripheral blood collected at daytime (and evaluation was performed using Human Melatonin ELISA Kit (BT-LAB-Bioassay Technology Laboratory kit, China)

Data Analysis:

All data were analysed using Excel software statistics package analysis software (Microsoft Office Excel(R)); Student's paired t-tests were also calculated using this package; P-values<0.05 were considered significant.

Results:

During enrolment, six subjects with ASD (n=6) could be enrolled in the control Gr.1 while in treatment group (Gr. 2), one of them dropped out even before start of the study. During the study, three subjects were lost to follow-up, one in Gr.1 (subject relocated to another city) and 2 in Gr. 2 (one due to social problems in the family and other relocated to another city). Totally 13 subjects (4 in Gr.1 and 9 in Gr.2) completed the study. There was one female subject in both Gr.1 and Gr. 2. The rest were male.

Improvement in Sleep Pattern:

On the Children's Sleep Habits related Questionnaire (CSHQ), there was significant reduction in the total score especially in terms of decrease in bedtime resistance and time of onset of sleep in the Gr.2 compared to Gr.1 (Table 11). The total sleep score ranged from 66 to 67 in Gr.1 (Mean=66.25±0.5) in the Gr.1 Control group while it ranged from 62 to 75 in Gr.2 at baseline (Mean=72±5.02) in Gr.2 (Nichi Glucan) at baseline. At the end of the study the total sleep score ranged from 58 to 66 in Gr.1 (Mean=64±4) in the Gr.1 Control group while it ranged from 51 to 70 in Gr.2 (Mean=64.22±7.47) in Gr.2 (Nichi Glucan). The reduction in sleep score after intervention indicating improvement in sleep behaviour was statistically significant in Gr.2 (p value=0.009879) indicating a significant improvement in the sleep patterns of the subject in the Nichi Glucan arm while the difference in sleep score did not show any statistically significant improvement in the control arm (p value=0.153494). The total sleep score also decreased well in the Nichi Glucan group compared to the control (FIG. 28).

TABLE 11
Results of Children's Sleep Habits related Questionnaire (CSHQ), with significant
reduction in the total score indicating improvement in bedtime resistance and
time of onset of sleep in Nichi Glucan Gr. 2 compared to Control, Gr. 1
	Gr. 1 (Mean values)	Gr. 2 (Mean values)
Parameters	Baseline	End of Study	Baseline	End of Study
Bedtime resistance	28	25.75	28.5556	23.2222
Time of Onset of Sleep	20.25	20.25	21.8889	19.4444
Duration of Sleep	6	6	6.44444	5.55556
Night waking	6	6	6	6
Day-time sleepiness	6	6	9.11111	10

Serum Melatonin Levels:

In the control group (Gr.1), the serum Melatonin increased on an average from 110.585 to only 114.11 post-intervention (FIG. 29A) while in the Nichi Glucan supplementation group (Gr.2), the serum Melatonin increased on an average from 238.85 ng/dl pre-intervention to 394.72 ng/dl post-intervention (FIG. 29B). The fold increase in Nichi Glucan group Gr. 2 was 2.29 compared to 1 in Gr.1 (FIG. 29C) though higher in Gr.2 was not statistically significant (p-value=0.065786)

Adverse Effects:

Only one child exhibited possible mild adverse effects related to increased bowel movements in Gr. 2 for one week after supplementation with Nichi Glucan which settled on its own. There were no adverse effects in any of the other children.

Discussion:

In this open-label clinical trial of supplementation with Nichi Glucan, we found that majority of the children in the Nichi Glucan group (Gr.2), 8 out of 9 subjects (88%) had an improvement in sleep pattern and quality of sleep observed by decrease in sleep score after Nichi Glucan supplementation. The serum melatonin increased to a greater extent in Gr. 2 compared to Gr.1. The sleep score significantly decreased in Gr. 2 compared to gr.1 (FIG. 28).

There were only minimal adverse effects. This is the first of its kind study, in which a nutritional supplement that is not a pharmacological drug has been able to improve sleep pattern with evidence in laboratory evaluation of corresponding serum melatonin and in children with ASD.

Sleep difficulties are a major problem in children with ASD with 53% having been reported to have difficulty in sleep onset (53%), 40% restless sleep, 34% night-time awakening and 32% difficulty in arousal from sleep [C14]. Lack of good sleep also affects emotional and functioning ability in turn leading to impairment in academic and social functioning and maintaining relationships in these children. Therefore, ensuring good quality sleep becomes an essential part of therapy for ASD. Among pharmacological interventions, melatonin [C2,C4,C5], trazodone, benzodiazepines, and SSRI antidepressants represent the most commonly used medications in the paediatric population [C15]. Melatonin supplementation remains the treatment of choice, given the side effects of other interventions and clinical trials having showed positive outcome of its supplementation [C15]. Nevertheless, there are reports that melatonin is more effective as short term rather than long term though those studies have mostly been in individuals without ASD [C6].

A nutritional supplement which can be simple, easy to administer and has minimal or no adverse effects will be an ideal alternative to melatonin. In the current study, Nichi Glucan which has been in consumption as a food supplement for several decades [C16] with proven benefits in metabolic disorders, cancer etc. [C9-12] has been shown to be a promising strategy based on the current study's results in terms of improvement in quality of sleep and increase in daytime serum melatonin levels.

It has been postulated that low melatonin levels in ASD children could have its etiologic origin in melatonin deficiency in mothers of these children exerting its effects during neurodevelopment in embryo [C17]. Another study has reported the clear correlation between gut microbiome profiles of children with ASD and their mothers suggesting the importance for assessing the microbiome during the early stage in mothers during pregnancy and planning of personalized treatment and prevention of ASD via microbiota modulation [C17]. Beta glucan has also been shown to reduce the underlying chronic inflammation due to gut dysbiosis and helping to modulate towards a healthy microbiome, which will be further advantageous in ASD as chronic inflammation has been shown to be associated with severity of ASD symptoms [C18], Thus, with the current study showing that beta glucans can enhance melatonin and sleep quality in children with ASD, the ability of Beta glucans to modulate gut microbiota and reverse gut dysbiosis as the possible mechanism behind the increase in levels of melatonin [C6,C19,C20], thereby improving sleep, needs further research.

This is only a pilot study and the limitation with the very less ample number is planned to be overcome by additional large-scale studies apart from studying the possible beneficial effects of Nichi Glucan on the behavioural aspects and other symptoms in patients with ASD.

Conclusion:

Patients with ASD have shown improvement in quality of sleep and improved levels of serum melatonin, in this open label pilot clinical study of nutritional supplementation with an AFO-202 strain of black yeast Aureobasidium pullulans produced 1,3-1,6 beta Glucan (Nichi-Glucan). The efficacy of Nichi Glucan in terms of behavioural improvement and other parameters observed in this pilot study in children with ASD, when confirmed in a larger study with long-term follow-up, it is worth recommending it as a supplementary food in such children. Further in-depth evaluation of the mechanisms and their correlation with other neurological parameters is recommended, which may throw light on novel solutions and drug candidates from such findings.

Melatonin and Gut Microbiome Correlation

AFO-202 Study

Methods

The study involved 18 subjects with ASD who were randomly allocated: six subjects in the control group (Group 1) underwent conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day, and 12 subjects (Group 2) underwent supplementation with Nichi Glucan 0.5 g twice daily along with the conventional treatment for 90 days. The subjects' stool samples were collected at baseline and after the intervention.

Whole genome metagenome (WGM) sequencing was performed.

Results

The results are shown in FIGS. 31-34.

Inference:

All the species, R. Hominis, R. intestinalis, R. inulinivorans and R. faecis increased greatly post-intervention in AFO-202 treatment group. R. inulinivorans and R. faecis decreased in the control group. The increase in melatonin and improved sleep reported in the study (doi: 10.21203/rs.3.rs-701988/v1) can be attributed to the increase in abundance of Roseburia.

F5s gut Microbiome in Autism and Epilepsy

Seed Average of Gut Microbiome

What is SEED?:

In 2004, the SEED (http://pubseed.theseed.org/) was created to provide consistent and accurate genome annotations across thousands of genomes and as a platform for discovering and developing de novo annotations. The SEED is a constantly updated integration of genomic data with a genome database, web front end, API and server scripts. It is used by many scientists for predicting gene functions and discovering new pathways

Methods:

Eighteen subjects with ASD were enrolled in this prospective, open-label, pilot clinical trial comprised of two arms. Arm 1 or Group 1 (control group): Six subjects with ASD underwent conventional treatment comprising remedial behavioural therapies and L-carnosine 500 mg per day. Arm 2 or Group 2 (Nichi Glucan group): 12 subjects underwent supplementation with Nichi Glucan food supplement along with conventional treatment (remedial behavioural therapies and L-carnosine 500 mg per day). Each subject consumed two sachets (0.5 g each) of Nichi Glucan daily—one sachet with a meal twice daily—for 90 days.

Faecal samples were collected at baseline and 90 days after the intervention using a sterile faecal collection kit and the samples were kept at −20° C. until they were transferred to the laboratory and processed. Samples for DNA extraction were stored at −80° C. until needed for analysis.

The samples were then taken for whole genome metagenome analysis. Initially, the reads were filtered for human DNA contamination. The filtered reads were then aligned to bacterial, fungal, viral and archea genomes. De novo assembly was carried out using the pre-processed reads to obtain the scaffolds. These scaffolds were then used for gene prediction. The abundances in terms of SEED annotations were analysed.

Results

The results are shown in FIG. 35 and Table 9.

Interpretation

There is several fold decrease in all the gene annotations (metabolites and metabolic functions) in the AFO-202 Nichi Glucan treatment group including Carbohydrates, Fatty acids, lipids, virulence, metabolite damage, nitrogen metabolism, mitochondrial electron transport system etc.

Inference:

• • 1. Most of the metabolic pathways and related functional genes are enriched or elevated in Autism and epilepsy;
  • 2. A ketogenic diet which is advocated for autism and epilepsy has shown decrease in these pathways by SEED analysis in other studies; and,
  • 3. Therefore, the several fold decrease in the SEED relative average data in AFO-202 group in the present study shows the benefits of this beta glucan in decreasing the metabolic pathways of the gut microbiota which is responsible for the positive clinical outcome reported in the studyF5S Study—Alpha-Synuclein-Support Data from F26S Study:

Methods

Neuroblastoma cell line (SHSY-5Y Tet-On: SCC291) (MERCK) was suspended in 10% FCS-DMEM/F12 medium and seeded into 96-well microplates to achieve a cell count of 5×104 cells/well. After 24 hours of incubation, the cells were washed with 10% FCS-DMEM/F12 medium and new 10% FCS-DMEM/F12 medium was added.

Then, β-glucan AFO-202 (50 μg/mL) and PMA (500 ng/mL) (Sigma) were added to the medium, and the cells were cultured for 1 to 3 days. After incubation, the wells were washed three times with PBS and fixed in 0.25% glutaraldehyde-PBS for 1 hour at room temperature. After fixation, the wells were washed three times with PBS-0.05% Tween (PBS-T). After washing the wells with PBS-T, 50 μL of 500-fold diluted α-synuclein polyclonal rabbit antibody (proteintech Co. 10842-1-AP) was added to the wells and incubated at room temperature for 1 h. Then, 2% BSA-PBS-T was added and left for 1 h (to block non-specific reactions).

After 1 hour, the wells were washed with PBS-T and 50 μL of biotin-labeled anti-rabbit IgG antibody (Cosmo Bio) diluted 5,000-fold was added to the wells and the reaction was carried out for 40 minutes at room temperature. After washing the wells, 50 μL of 10,000-fold diluted peroxidase-labeled streptavidin (Cosmo Bio) was added and the reaction was carried out for 20 minutes at room temperature. After washing the wells again, 50 μL of TMB (Cosmo Bio) was added to the wells, and the reaction was stopped with 0.5 M-HCl for 10 minutes.

After that, the absorbance (OD value) was measured with a microplate reader (450 nm) (Tosoh). Data were expressed as ΩOD value (sample OD value−blank OD value). The expression rate was calculated based on the control (None).

Results

The results are shown in FIGS. 36A-B and Table 12 below.

TABLE 12
Expression of α-synuclein on the neuroblastoma cell line
(SHSY-5Y Tet-On: SCC291) stimulated beta-glucans(BGs) or PMA
				α-synuclein
				expression (%)
	Stimulation	Concentration	δOD value	vs. None
	None	0.281	100.0
	BG-AF202	50	μg/mL	0.198	70.5
	PMA	500	ng/mL	0.166	50.1

The neuroblastoma cell line (SHSY-5Y Tet-On: SCC291) was stimulated with BGs or PMA for 3 days. An α-synuclein polyclonal antibody (proteintech Co. 10842-1-AP) was used in this experiment (glutaraldehyde-fixed cellular ELISA).

AFO-202 Beta Glucan Decreases α-Synuclein Expression

Interpretation-I

Alpha synuclein expression is decreased by AFO-202 in cell lines. Since these cell lines produced ASN are abnormal/misfolded and capable of aggregation, their decrease in expression is considered to be a suppression of production of abnormal ASN and hence an advantage.

Interpretation-II

Beta Glucans having been able to control ROS and mitochondrial Stress and hence the above suppression of abnormal αSyn could be attributed due to that mechanism.

Interpretation-III

It is the abnormal ASN causing aggregates which can show transmission from cell to cell and prone to propagation like prions through gut brain axis and therefore AFO-202 making their production lesser at cellular level is helping to address the issue at the root cause itself.

Interpretation-IV

Since AFO-202 can regulate dyslipidemia and because alpha-synuclein binding with oxidized lipid metabolites can lead to mitochondrial dysfunction, leading to neuronal disorders, AFO-202 (i) decreasing misfolded alpha-synuclein production and (ii) regulating lipids has an advantage.

Interpretation-V

The increase in plasma levels of Alpha-Synuclein in the autism children (http://dx.doi.org/10.1136/bmjno-2021-000203) can be attributed to the clearing of the deposits by NK cells activated by AFO-202 beta glucan.

Interpretation-VI

Capacity of beta glucans to activate microglia will be of advantage in clearing the aggregates in the CNS therefore attributing to the behaviour and sleep pattern improvement of AFO-202 in the autism study (http://dx.doi.org/10.1136/bmjno-2021-000203)

Modifications and Other Embodiments

Various modifications and variations of the described glucan products, compositions and methods as well as the concept of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed is not intended to be limited to such specific embodiments. Various modifications of the described modes for carrying out the invention which are obvious to those skilled in the chemical, biological, medical, environmental, cosmetic or food arts or related fields are intended to be within the scope of the following claims.

REFERENCES

• A1. Miller A L, Bessho S, Grando K, Tükel Ç. Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Front Immunol. 2021 Feb. 26; 12:638867.
• A2. Kang D W, Park J G, Ilhan Z E, Wallstrom G, Labaer J, Adams J B, Krajmalnik-Brown R. Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLoS One. 2013 Jul. 3; 8(7):e68322.
• A3. Liu F, Li J, Wu F, Zheng H, Peng Q, Zhou H. Altered composition and function of intestinal microbiota in autism spectrum disorders: a systematic review. Transl Psychiatry. 2019 Jan. 29; 9(1):43.
• A4. Shahi S K, Freedman S N, Murra A C, Zarei K, Sompallae R, Gibson-Corley K N, Karandikar N J, Murray J A, Mangalam A K. Prevotella histicola, A Human Gut Commensal, Is as Potent as COPAXONE(R)(R) in an Animal Model of Multiple Sclerosis. Front Immunol. 2019 Mar. 22; 10:462
• Al-Mazidi, S., & Al-Ayadhi, L. Y (2021). Plasma Levels of Alpha and Gamma Synucleins in Autism Spectrum Disorder: An Indicator of Severity. Medical principles and practice: international journal of the Kuwait University, Health Science Centre, 30(2), 160-167.
• Bartels, T., De Schepper, S., & Hong, S. (2020). Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. Science (New York, N.Y.), 370(6512), 66-69.
• Boziki, M. K., Kesidou, E., Theotokis, P., Mentis, A. A., Karafoulidou, E., Melnikov, M., Sviridova, A., Rogovski, V., Boyko, A., & Grigoriadis, N. (2020). Microbiome in Multiple Sclerosis; Where Are We, What We Know and Do Not Know. Brain sciences, 10(4), 234.
• Ding, X., Xu, Y, Zhang, X., Zhang, L., Duan, G., Song, C., Li, Z., Yang, Y, Wang, Y, Wang, X., & Zhu, C. (2020). Gut microbiota changes in patients with autism spectrum disorders. Journal of psychiatric research, 129, 149-159.
• DeAngelis, M., Piccolo, M., Vannini, L., Siragusa, S., De Giacomo, A., Serrazzanetti, D. I., Cristofori, F., Guerzoni, M. E., Gobbetti, M., & Francavilla, R. (2013). Fecal microbiota and metabolome of children with autism and pervasive developmental disorder not otherwise specified. PloS one, 8(10), e76993.
• Dedeepiya, V. D., Sivaraman, G., Venkatesh, A. P., Preethy, S., & Abraham, S. J. (2012). Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India. Case reports in medicine, 2012, 895370.
• Dilsizoglu Senol, A., Samarani, M., Syan, S., Guardia, C. M., Nonaka, T., Liv, N., Latour-Lambert, P., Hasegawa, M., Klumperman, J., Bonifacino, J. S., & Zurzolo, C. (2021). α-Synuclein fibrils subvert lysosome structure and function for the propagation of protein misfolding between cells through tunneling nanotubes. PLoS biology, 19(7), e3001287.
• Earls, R. H., Menees, K. B., Chung, J., Gutekunst, C. A., Lee, H. J., Hazim, M. G., Rada, B., Wood, L. B., & Lee, J. K. (2020). NK cells clear α-synuclein and the depletion of NK cells exacerbates synuclein pathology in a mouse model of α-synucleinopathy. Proceedings of the National Academy of Sciences of the United States of America, 117(3), 1762-1771.
• Ganesh, J. S., Rao, Y. Y., Ravikumar, R., Jayakrishnan, G. A., Iwasaki, M., Preethy, S., & Abraham, S. J. (2014). Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin—a case report. Journal of dietary supplements, 11(1), 1-6.
• Grimaldi, R., Gibson, G. R., Vulevic, J., Giallourou, N., Castro-Mejia, J. L., Hansen, L. H., Leigh Gibson, E., Nielsen, D. S., & Costabile, A. (2018). A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome, 6(1), 133.
• ^aIkewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya V D, Rajmohan M, Vaddi S, Senthilkumar R, Preethy S, Abraham S J K. Beneficial effects of the AFO-202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on non-esterified fatty acid levels in obese diabetic KKAy mice: A comparative study.bioRxiv 2021.07.22.453362; doi: 10.1101/2021.07.22.453362
• ^bIkewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya V D, Vaddi S, Senthilkumar R, Levy G A, Abraham S J K. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM-animal model of non-alcoholic steatohepatitis.bioRxiv 2021.07.08.451700; doi: 10.1101/2021.07.08.451700
• ^cIkewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya V D, Senthilkumar R, Preethy S, Abraham S J K. Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study. medRxiv 2021.08.05.21261640. doi: 10.1101/2021.08.05.21261640
• Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3-1,6 glucan), currently available commercially as a health food supplement. Microbiol Immunol. 2007; 51:861-73.
• Kang, D. W., Adams, J. B., Coleman, D. M., Pollard, E. L., Maldonado, J., McDonough-Means, S., Caporaso, J. G., & Krajmalnik-Brown, R. (2019). Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Scientific reports, 9(1), 5821.
• Kang, D. W., Park, J. G., Ilhan, Z. E., Wallstrom, G., Labaer, J., Adams, J. B., & Krajmalnik-Brown, R. (2013). Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PloS one, 8(7), e68322.
• Kang, D. W., Ilhan, Z. E., Isern, N. G., Hoyt, D. W., Howsmon, D. P., Shaffer, M., Lozupone, C. A., Hahn, J., Adams, J. B., & Krajmalnik-Brown, R. (2018). Differences in fecal microbial metabolites and microbiota of children with autism spectrum disorders. Anaerobe, 49, 121-131.
• Lindefeldt, M., Eng, A., Darban, H., Bjerkner, A., Zetterström, C. K., Allander, T., Andersson, B., Borenstein, E., Dahlin, M., & Prast-Nielsen, S. (2019). The ketogenic diet influences taxonomic and functional composition of the gut microbiota in children with severe epilepsy. NPJ biofilms and microbiomes, 5(1), 5.
• Luna, E., & Luk, K. C. (2015). Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. FEBS letters, 589(24 Pt A), 3749-3759.
• Miller, A. L., Bessho, S., Grando, K., & Tükel, Ç. (2021). Microbiome or Infections: Amyloid-Containing Biofilms as a Trigger for Complex Human Diseases. Frontiers in immunology, 12, 638867.
• Morato Torres, C. A., Wassouf, Z., Zafar, F., Sastre, D., Outeiro, T. F., & Schüle, B. (2020). The Role of Alpha-Synuclein and Other Parkinson's Genes in Neurodevelopmental and Neurodegenerative Disorders. International journal of molecular sciences, 21(16), 5724.
• Murros, K. E., Huynh, V. A., Takala, T. M., & Saris, P. (2021). Desulfovibrio Bacteria Are Associated With Parkinson's Disease. Frontiers in cellular and infection microbiology, 11, 652617.
• Oh, D., & Cheon, K. A. (2020). Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview. Soa—ch'ongsonyon chongsin uihak=Journal of child & adolescent psychiatry, 31(3), 131-145.
• Raghavan, K., Dedeepiya, V. D., Suryaprakash, V., Rao, K. S., Ikewaki, N., Sonoda, T., Levy, G. A., Iwasaki, M., Senthilkumar, R., Preethy, S., & Abraham, S. J. (2022). Beneficial effects of novel Aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomedicine & pharmacotherapy=Biomedecine & pharmacotherapie, 145, 112243.
• ^aRaghavan, K., Dedeepiya, V. D., Ikewaki, N., Sonoda, T., Iwasaki., M., Preethy. S., Abraham, S. J. K. Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study. BMJ Neurology Open (In print). Preprint in MedRxiv: https://doi.org/10.1101/2021.06.28.21259619
• ^bRaghavan, K., Dedeepiya, V. D. Kandaswamy, R., Balamurugan. M., Ikewaki, N., Sonoda, T., Kurosawa, G., Iwasaki, M., Preethy, S., Abraham, S. J. K. (2021). Improvement of sleep patterns and serum melatonin levels in children with autism spectrum disorders after consumption of beta-1,3/1,6-glucan in a pilot clinical study. Research Square rs.3.rs-701988/v1; doi: 10.21203/rs.3.rs-701988/v1
• ^cRaghavan, K., Kandaswamy, R. S., Ikewaki, N., Iwasaki, M., & Abraham, S. (2021). Potentials to alleviate coagulopathy and enhance microglial function of beta (β)-glucans, making them worth a clinical study for COVID-19's neurological sequalae. Journal of the neurological sciences, 427, 117554.
• Sampson, T. R., Challis, C., Jain, N., Moiseyenko, A., Ladinsky, M. S., Shastri, G. G., Thron, T., Needham, B. D., Horvath, I., Debelius, J. W., Janssen, S., Knight, R., Wittung-Stafshede, P., Gradinaru, V., Chapman, M., & Mazmanian, S. K. (2020). A gut bacterial amyloid promotes α-synuclein aggregation and motor impairment in mice. eLife, 9, e53111.
• Santocchi, E., Guiducci, L., Prosperi, M., Calderoni, S., Gaggini, M., Apicella, F., Tancredi, R., Billeci, L., Mastromarino, P., Grossi, E., Gastaldelli, A., Morales, M. A., & Muratori, F. (2020). Effects of Probiotic Supplementation on Gastrointestinal, Sensory and Core Symptoms in Autism Spectrum Disorders: A Randomized Controlled Trial. Frontiers in psychiatry, 11, 550593.
• Swirski, M., Miners, J. S., de Silva, R., Lashley, T., Ling, H., Holton, J., Revesz, T., & Love, S. (2014). Evaluating the relationship between amyloid-3 and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimer's research & therapy, 6(5-8), 77.
• Souza, N. C., Mendonca, J. N., Portari, G. V., Jordao Junior, A. A., Marchini, J. S., & Chiarello, P. G. (2012). Intestinal permeability and nutritional status in developmental disorders. Alternative therapies in health and medicine, 18(2), 19-24.
• Tomova A, Husarova V, Lakatosova S, Bakos J, Vlkova B, Babinska K, Ostatnikova D. Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav. 2015; 138:179-87.
• Werner, T., Horvath, I., & Wittung-Stafshede, P. (2020). Crosstalk Between Alpha-Synuclein and Other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson's Disease. Journal of Parkinson's disease, 10(3), 819-830.
• Shen R L, Dang X Y, Dong J L, Hu X Z. Effects of oat β-glucan and barley β-glucan on fecal characteristics, intestinal microflora, and intestinal bacterial metabolites in rats. J Agric Food Chem. 2012 Nov. 14; 60(45):11301-8.
• Turunen K, Tsouvelakidou E, Nomikos T, Mountzouris K C, Karamanolis D, Triantafillidis J, Kyriacou A. Impact of beta-glucan on the faecal microbiota of polypectomized patients: a pilot study. Anaerobe. 2011 December; 17(6):403-6
• Zhen W, Liu Y, Shao Y, Ma Y, Wu Y, Guo F, Abbas W, Guo Y, Wang Z. Yeast β-Glucan Altered Intestinal Microbiome and Metabolome in Older Hens. Front Microbiol. 2021 Dec. 17; 12:766878.
• 1. Al-Mazidi, S., & Al-Ayadhi, L. Y. (2021). Plasma Levels of Alpha and Gamma Synucleins in Autism Spectrum Disorder: An Indicator of Severity. Medical principles and practice: international journal of the Kuwait University, Health Science Centre, 30(2), 160-167. https://doi.org/i0.1159/000513935
• 2. Alp, H., Varol, S., Celik, M. M., Altas, M., Evliyaoglu, O., Tokgoz, O., Tanriverdi, M. H., & Uzar, E. (2012). Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced by streptozosin. Experimental diabetes research, 2012, 230342. https://doi.org/10.1155/2012/230342
• 3. Centers for Disease Control and Prevention. What is Autism Spectrum Disorder? Retrieved from https://www.cdc.gov/ncbddd/autism/facts.html
• 4. Dedeepiya, V. D., Sivaraman, G., Venkatesh, A. P., Preethy, S., & Abraham, S. J. (2012).
• 5. Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India. Case reports in medicine, 2012, 895370. https://doi.org/10.1155/2012/895370
• 6. Ganesh, J. S., Rao, Y. Y., Ravikumar, R., Jayakrishnan, G. A., Iwasaki, M., Preethy, S., & Abraham, S. J. (2014). Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin—a case report. Journal of dietary supplements, 11(1), 1-6. https://doi.org/10.3109/19390211.2013.859211
• 7. Ikewaki, N., Fujii, N., Onaka, T., Ikewaki, S., & Inoko, H. (2007). Immunological actions of Sophy beta-glucan (beta-1,3-1,6 glucan), currently available commercially as a healthfood supplement. Microbiology and immunology, 51(9), 861-873. https://doi.org/10.1111/j.1348-0421.2007.tb03982.x
• 8. Ikewaki, N., Iwasaki, M., Kurosawa, G., Rao, K. S., Lakey-Beitia, J., Preethy, S., & Abraham, S. J. (2021). β-glucans: wide-spectrum immune-balancing food-supplement-based enteric (p3-WIFE) vaccine adjuvant approach to COVID-19. Human vaccines & immunotherapeutics, 1-6. Advance online publication. https://doi.org/10.1080/21645515.2021.1880210
• 9. Kadak, M. T., Cetin, I., Tarakcioglu, M. C., Ozer, O. F., Kacar, S., & Çimen, B. (2015). Low Serum Level α-Synuclein and Tau Protein in Autism Spectrum Disorder Compared to Controls. Neuropediatrics, 46(6), 410-415. https://doi.org/10.1055/s-0035-1565273
• 10. Karhu, E., Zukerman, R., Eshraghi, R. S., Mittal, J., Deth, R. C., Castejon, A. M., Trivedi, M., Mittal, R., & Eshraghi, A. A. (2020). Nutritional interventions for autism spectrum disorder. Nutrition reviews, 78(7), 515-531. https://doi.org/10.1093/nutrit/nuz092
• 11. Obergasteiger, J., Überbacher, C., Pramstaller, P. P., Hicks, A. A., Corti, C., & Volta, M. (2017). CADPS2 gene expression is oppositely regulated by LRRK2 and alpha-synuclein. Biochemical and biophysical research communications, 490(3), 876-881. https://doi.org/10.1016/j.bbrc.2017.06.134
• 12. Peng, M., Tabashsum, Z., Anderson, M., Truong, A., Houser, A. K., Padilla, J., Akmel, A., Bhatti, J., Rahaman, S. O., & Biswas, D. (2020). Effectiveness of probiotics, prebiotics, and prebiotic-like components in common functional foods. Comprehensive reviews in food science and food safety, 19(4), 1908-1933. https://doi.org/10.1111/1541-4337.12565
• 13. Rahayu, M., Kurniawan, S. N., Husna, M., Hermawan, H. O. (2016). The effect of beta glucan of Saccharomyces cerevisae on the decrease of alpha synuclein expression in the brain substantia nigra of parkinson's wistar strain rats (Rattus novergicus) model induced with rotenone. Malang Neurology Journal 2(1). ISSN 2442-5001. Retrieved from https://mnj.ub.ac.id/index.php/mnj/article/view/32
• 12. Ramaekers, V. T., Sequeira, J. M., DiDuca, M., Vrancken, G., Thomas, A., Philippe, C., Peters, M., Jadot, A., & Quadros, E. V. (2019). Improving Outcome in Infantile Autism with Folate Receptor Autoimmunity and Nutritional Derangements: A Self-Controlled Trial. Autism research and treatment, 2019, 7486431. https://doi.org/10.1155/2019/7486431
• 13. Shah, V. B., Williams, D. L., & Keshvara, L. (2009). beta-Glucan attenuates TLR2- and TLR4-mediated cytokine production by microglia. Neuroscience letters, 458(3), 111-115. https://doi.org/10.1016/j.neulet.2009.04.039
• 14. Shi, H., Yu, Y., Lin, D., Zheng, P., Zhang, P., Hu, M., Wang, Q., Pan, W., Yang, X., Hu, T., Li, Q., Tang, R., Zhou, F., Zheng, K., & Huang, X. F. (2020). β-glucan attenuates cognitive impairment via the gut-brain axis in diet-induced obese mice. Microbiome, 8(1), 143. https://doi.org/10.1186/s40168-020-00920-y
• 15. Siddique, A., Khan, H. F., Ali, S., Abdullah, A., Munir, H., & Ariff, M. (2020). Estimation of Alpha-Synuclein Monomer and Oligomer Levels in the Saliva of the Children With Autism Spectrum Disorder: A Possibility for an Early Diagnosis. Cureus, 12(8), e9936. https://doi.org/10.7759/cureus.9936
• 16. Srikantha, P., & Mohajeri, M. H. (2019). The Possible Role of the Microbiota-Gut-Brain-Axis in Autism Spectrum Disorder. International journal of molecular sciences, 20(9), 2115. https://doi.org/10.3390/ijms20092115
• 17. Sriwimol, W., & Limprasert, P. (2018). Significant Changes in Plasma Alpha-Synuclein and Beta-Synuclein Levels in Male Children with Autism Spectrum Disorder. BioMed research international, 2018, 4503871. https://doi.org/10.1155/2018/4503871
• 18. Xu, M., Mo, X., Huang, H., Chen, X., Liu, H., Peng, Z., Chen, L., Rong, S., Yang, W., Xu, S., & Liu, L. (2020). Yeast β-glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in Aβ1-42-induced AD-like mice. International journal of biological macromolecules, 161, 258-270. https://doi.org/10.1016/j.ijbiomac.2020.05.180
• 19. Vargas, K. J., Schrod, N., Davis, T., Fernandez-Busnadiego, R., Taguchi, Y V., Laugks, U., Lucic, V., & Chandra, S. S. (2017). Synucleins Have Multiple Effects on Presynaptic Architecture. Cell reports, 18(1), 161-173. https://doi.org/10.1016/j.celrep.2016.12.023
• C1. Goldman S E, Richdale A L, Clemons T, Malow B A. Parental sleep concerns in autism spectrum disorders: variations from childhood to adolescence. J Autism Dev Disord. 2012 April; 42(4):531-8.
• C2. Malow B, Adkins K W, McGrew S G, Wang L, Goldman S E, Fawkes D, Burnette C. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012 August; 42(8):1729-37
• C3. Gagnon K, Godbout R. Melatonin and Comorbidities in Children with Autism Spectrum Disorder. Curr Dev Disord Rep. 2018; 5(3):197-206.
• C4. Maras A, Schroder C M, Malow B A, Findling R L, Breddy J, Nir T, Shahmoon S, Zisapel N, Gringras P. Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol. 2018 December; 28(10):699-710.
• C5. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012 December; 21(6):700-9. doi: 10.1111/j.1365-2869.2012.01021.x.
• C6. Russcher M, Koch B C, Nagtegaal J E, van Ittersum F J, Pasker-de Jong P C, Hagen E C, van Dorp W T, Gabreëls B, Wildbergh T X, van der Westerlaken M M, Gaillard C A, Ter Wee P M. Long-term effects of melatonin on quality of life and sleep in haemodialysis patients (Melody study): a randomized controlled trial. Br J Clin Pharmacol. 2013 November; 76(5):668-79. doi: 10.1111/bcp.12093.
• C7. Costa H F B, Chemical and biological characterization of an aqueous Sambucus nigra L. flower extract 2019.
• C8. Dutta S D, Patel D K, Ganguly K, Lim K T. Effects of GABA/β-glucan supplements on melatonin and serotonin content extracted from natural resources. PLoS One. 2021 Mar. 5; 16(3):e0247890. doi: 10.1371/journal.pone.0247890.
• C9. Dedeepiya V D, Sivaraman G, Venkatesh A P, et al. Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India. Case Rep Med 2012 (2012):895370.
• C10. Ganesh J S, Rao Y Y, Ravikumar R, Jayakrishnan G A, Iwasaki M, Preethy S, Abraham S J. Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin—a case report. J Diet Suppl (2014)11:1-6.
• C11. Mizobuchi S, Taniwaki C, Watanabe Y, Sasaguri S. Antitumor effects of combined therapy with intraperitoneal CDDP and oral Sofy β-glucan. Abstract presented at the 63rd General Meeting of the Japanese Society of Gastroenterology, Japan (2008).
• C12. Mio M. Effect of oral intake of black yeast beta-glucan on NK activity in the elderly and patients with cancer. Abstract presented at 29th Annual Meeting of the Japanese Society of Venous and Enteral Nutrition Pacifico Yokohama, Japan (2014).
• C13. Katoh S, Rao K S, Suryaprakash V, Horiguchi A, Kushibiki T, Ojima K, Iwasaki M, Takeda M, Senthilkumar R, Rajmohan M, Karthick R, Preethy S, Abraham S. β-Glucans: Wide-spectrum Immune-balancing Food-supplement-based Enteric (β-WIFE) Vaccine Adjuvant Approach to COVID-19. Human Vaccines & Immunotherapeutics (2021)
• C14. Parvataneni T, Srinivas S, Shah K, Patel R S. Perspective on Melatonin Use for Sleep Problems in Autism and Attention-Deficit Hyperactivity Disorder: A Systematic Review of Randomized Clinical Trials. Cureus. 2020 May 28; 12(5):e8335. doi: 10.7759/cureus.8335.
• C15. Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3-1,6 glucan), currently available commercially as a health food supplement. Microbiol Immunol. 2007; 51(9):861-73. doi: 10.1111/j.1348-0421.2007.tb03982.x.
• C16. Braam W, Ehrhart F, Maas APHM, Smits M G, Curfs L. Low maternal melatonin level increases autism spectrum disorder risk in children. Res Dev Disabil. 2018 November; 82:79-89. doi: 10.1016/j.ridd.2018.02.017.
• C17. Li N, Yang J, Zhang J, Liang C, Wang Y, Chen B, Zhao C, Wang J, Zhang G, Zhao D, Liu Y, Zhang L, Yang J, Li G, Gai Z, Zhang L, Zhao G. Correlation of Gut Microbiome Between ASD Children and Mothers and Potential Biomarkers for Risk Assessment. Genomics Proteomics Bioinformatics. 2019 February; 17(1):26-38. doi: 10.1016/j.gpb.2019.01.002. Epub 2019 Apr. 23. PMID: 31026579; PMCID: PMC6520911.
• C18. Innate Immunity and Neuroinflammation in Neuropsychiatric Conditions Including Autism Spectrum Disorders: Role of Innate Immune Memory. Harumi Jyonouchi DOI: 10.5772/intechopen.87167
• C19. Cheng W Y, Lam K L, Pik-Shan Kong A, Chi-Keung Cheung P. Prebiotic supplementation (beta-glucan and inulin) attenuates circadian misalignment induced by shifted light-dark cycle in mice by modulating circadian gene expression. Food Res Int. 2020 November; 137:109437. doi: 10.1016/j.foodres.2020.109437.
• C20. Shi H, Yu Y, Lin D, Zheng P, Zhang P, Hu M, Wang Q, Pan W, Yang X, Hu T, Li Q, Tang R, Zhou F, Zheng K, Huang X F. β-glucan attenuates cognitive impairment via the gut-brain axis in diet-induced obese mice. Microbiome. 2020 Oct. 2; 8(1):143. doi: 10.1186/s40168-020-00920-y.
• D1. Valdes A M, Walter J, Segal E, Spector T D. Role of the gut microbiota in nutrition and health. BMJ. 2018 Jun. 13; 361:k2179.
• D2. Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. Pharmacol Ther. 2016 February; 158:52-62.
• D3. Shreiner A B, Kao J Y, Young V B. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015 January; 31(1):69-75. doi: 10.1097/MOG.0000000000000139. PMID: 25394236; PMCID: PMC4290017.
• D4. Zierer J, Jackson M A, Kastenmüller G, Mangino M, Long T, Telenti A, Mohney R P, Small K S, Bell J T, Steves C J, Valdes A M, Spector T D, Menni C. The fecal metabolome as a functional readout of the gut microbiome. Nat Genet. 2018 June; 50(6):790-795.
• D5. Dedeepiya V, Sivaraman G, Venkatesh A, Preethy S, Abraham S. Potential Effects of Nichi Glucan as a Food Supplement for Diabetes Mellitus and Hyperlipidemia; Preliminary Findings from the Study on Three Patients from India. Case Reports in Medicine 2012 (2012), Article ID 895370
• D6. Ganesh J S, Rao Y Y, Ravikumar R, Jayakrishnan A G, Iwasaki M, Preethy S, Abraham S. Beneficial effects of Black yeast derived 1-3, 1-6 beta glucan-Nichi Glucan in a dyslipidemic individual of Indian origin—A case report. J Diet Suppl. 2014; 11(1):1-6.
• D7. Raghavan K, Dedeepiya V D, Ikewaki N, Sonoda T, Iwasaki M, Preethy S, Abraham S J K. Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomized, parallel-group pilot clinical study. BMJ Neurology Open (In print)
• D8. Raghavan K, Dedeepiya V D, Kandaswamy R, Balamurugan M, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Preethy S, Abraham S J K. Improvement of sleep patterns and serum melatonin levels in children with autism spectrum disorders after consumption of beta-1,3/1,6-glucan in a pilot clinical study. Research Square rs.3.rs-701988/v1; doi: 10.21203/rs.3.rs-701988/v1
• D9. Raghavan K, Dedeepiya V D, Srinivasan S, Pushkala S, Subramanian S, Ikewaki N, Iwasaki M, Senthilkumar R, Preethy S, Abraham S. Disease-modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in young boys with Duchenne muscular dystrophy: Results of an open-label, prospective, randomized, comparative clinical study. medRxiv 2021.12.13.21267706
• D10. Ikewaki N, Kurosawa G, Iwasaki M, Preethy S, Dedeepiya V D, Vaddi S, Senthilkumar R, Levy G A, Abraham S J K. Hepatoprotective effects of Aureobasidium pullulans derived Beta 1,3-1,6 biological response modifier glucans in a STAM-animal model of non-alcoholic steatohepatitis.bioRxiv 2021.07.08.451700; doi: 10.1101/2021.07.08.451700
• D11. Pushkala S, Seshayyan S, Theranirajan E, Sudhakar D, Raghavan K, Dedeepiya V D, Ikewaki N, Iwasaki M, Preethy S, Abraham S. Efficient control of IL-6, CRP and Ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial. medRxiv 2021.12.14.21267778; doi: 10.1101/2021.12.14.21267778
• D12. Raghavan K, Dedeepiya V D, Suryaprakash V, Rao K S, Ikewaki N, Sonoda T, Levy G A, Iwasaki M, Senthilkumar R, Preethy S, Abraham S J K. Beneficial Effects of novel Aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-Dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study. Biomedicine and Pharmacotherapy 2021. sciencedirect. https://doi.org/10.1016/j.biopha.2021.112243
• D13. Raghavan K, Dedeepiya V D, Yamamoto N, Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Kandaswamy R, Senthilkumar R, Preethy S, Abraham S J K. Beneficial reconstitution of gut microbiota and control of alpha-synuclein and curli-amyloids-producing enterobacteria, by beta 1,3-1,6 glucans in a clinical pilot study of autism and potentials in neurodegenerative diseases. medRxiv 2021.10.26.21265505; doi: 10.1101/2021.10.26.21265505
• D14. Bashir K M I, Choi J S. Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future. Int J Mol Sci. 2017 Sep. 5; 18(9):1906.
• D15. Ikewaki N, Fujii N, Onaka T, Ikewaki S, Inoko H. Immunological actions of Sophy beta-glucan (beta-1,3-1,6 glucan), currently available commercially as a health food supplement. Microbiol Immunol. 2007; 51(9):861-73.
• D16. Ikewaki N, Onaka T, Ikeue Y, Nagataki M, Kurosawa G, Dedeepiya V D, Rajmohan M, Vaddi S, Senthilkumar R, Preethy S, Abraham S J K. Beneficial effects of the AFO-202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on non-esterified fatty acid levels in obese diabetic KKAy mice: A comparative study.bioRxiv 2021.07.22.453362; doi: 10.1101/2021.07.22.453362
• D17. Ikewaki N, Sonoda T, Kurosawa G, Iwasaki M, Dedeepiya V D, Senthilkumar R, Preethy S, Abraham S J K. Immune and metabolic beneficial effects of Beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: An exploratory study. medRxiv 2021.08.05.21261640; doi: 10.1101/2021.08.05.21261640
• D18. STAM Model. https://www.smccro-lab.com/service/service_disease_area/stam.html
• D19. Nakashima A, Sugimoto R, Suzuki K, Shirakata Y, Hashiguchi T, Yoshida C, Nakano Y Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis. Food Sci Nutr. 2018; 7(1):139-147
• D20. Dantzer R. Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa. Physiol Rev. 2018 Jan. 1; 98(1):477-504.
• D21. KolodziejczykAA, Zheng D, Shibolet O, Elinav E. The role of the microbiome in NAFLD and NASH. EMBO Mol Med. 2019 February; 11(2):e9302. doi: 10.15252/emmm.201809302. PMID: 30591521; PMCID: PMC6365925.
• D22. Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci. 2020 Jul. 23; 21(15):5214. doi: 10.3390/ijms21155214. PMID: 32717871; PMCID: PMC7432372.
• D23. Kang D W, Adams J B, Vargason T, Santiago M, Hahn J, Krajmalnik-Brown R. Distinct Fecal and Plasma Metabolites in Children with Autism Spectrum Disorders and Their Modulation after Microbiota Transfer Therapy. mSphere. 2020 Oct. 21; 5(5):e00314-20. doi: 10.1128/mSphere. 00314-20. PMID: 33087514; PMCID: PMC7580952.
• D24. Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppo V, Simola N, Morelli M, Santoru M L, Atzori L, Melis M, Cossu G, Manzin A. Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease. mSystems. 2020 Sep. 15; 5(5):e00561-20. doi: 10.1128/mSystems. 00561-20. PMID: 32934117; PMCID: PMC7498685.
• D25. Gibson C M, Childs-Kean L M, Naziruddin Z, Howell C K. The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation. Transpl Infect Dis. 2021 February; 23(1):e13397.

Claims

1. A composition for improving gut microbiota, comprising a beta-glucan produced by Aureobasidium pullulans APO-202 (FERM BP-I9327).

2. The composition according to claim 1, wherein the improvement of gut microbiota comprises a decrease of Akkermansia muciniphila with an increase of beneficial bacteria including Roseburia in a gut.

3. The composition according to claim 1, wherein the composition is for prophylactic, ameliorating and/or curative treatment of autism spectrum disorders (ASD), multiple sclerosis (MS), Alzheimer's disease (AD), Parkinson's disease (PD) and/or epilepsy.

4. The composition according to claim 1, wherein the composition is for improving behavioural pattern and alpha-synuclein levels.

5. The composition according to claim 1, wherein the composition is for improving sleep pattern and serum melatonin.

6. The composition according to claim 5, wherein the improvement is in a child with autism spectrum disorder.

7. The composition according to claim 1, wherein the composition is a pharmaceutical composition.

8. The composition according to claim 1, wherein the composition is a food composition.

9. A method of improving gut microbiota in a subject, comprising administering a beta-glucan produced by Aureobasidium pullulans AFO-202 (FERM BP-19327) to the subject in need thereof.